Original Article
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
N Engl J Med 2002; 346:235-242January 24, 2002
- Abstract
Background
The standard treatment for patients with diffuse large-B-cell lymphoma is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Rituximab, a chimeric monoclonal antibody against the CD20 B-cell antigen, has therapeutic activity in diffuse large-B-cell lymphoma. We conducted a randomized trial to compare CHOP chemotherapy plus rituximab with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Methods
Previously untreated patients with diffuse large-B-cell lymphoma, 60 to 80 years old, were randomly assigned to receive either eight cycles of CHOP every three weeks (197 patients) or eight cycles of CHOP plus rituximab given on day 1 of each cycle (202 patients).
Results
The rate of complete response was significantly higher in the group that received CHOP plus rituximab than in the group that received CHOP alone (76 percent vs. 63 percent, P=0.005). With a median follow-up of two years, event-free and overall survival times were significantly higher in the CHOP-plus-rituximab group (P<0.001 and P=0.007, respectively). The addition of rituximab to standard CHOP chemotherapy significantly reduced the risk of treatment failure and death (risk ratios, 0.58 [95 percent confidence interval, 0.44 to 0.77] and 0.64 [0.45 to 0.89], respectively). Clinically relevant toxicity was not significantly greater with CHOP plus rituximab.
Conclusions
The addition of rituximab to the CHOP regimen increases the complete-response rate and prolongs event-free and overall survival in elderly patients with diffuse large-B-cell lymphoma, without a clinically significant increase in toxicity.
Media in This Article
Figure 2
Overall Survival among 399 Patients Assigned to Chemotherapy with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) or with CHOP plus Rituximab.Figure 1
Event-free Survival among 399 Patients Assigned to Chemotherapy with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) or with CHOP plus Rituximab.Article Activity
- Article
The most frequent type of non-Hodgkin's lymphoma, diffuse large-B-cell lymphoma, accounts for approximately 40 percent of new cases of lymphoma.1 More than half of patients with diffuse large-B-cell lymphoma are over 60 years of age,2-4 and the treatment of these elderly patients is a difficult challenge. The CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone) is the standard of care for younger and elderly patients with diffuse large-B-cell lymphoma,5 but it induces complete responses in only 40 to 50 percent of elderly patients, with three-year event-free and overall survival rates of 30 percent and 35 to 40 percent, respectively.6 Attempts to increase the efficacy of CHOP by adding other cytotoxic drugs have not succeeded, probably because these additional drugs cannot be administered unless the doses of cyclophosphamide and doxorubicin are reduced below those given in the CHOP regimen.5,7 Intensified chemotherapy regimens may improve the outcome in young patients with a poor prognosis,8 but they are not well tolerated by elderly patients. Indeed, CHOP itself may be too toxic for elderly patients.9,10 More easily tolerated regimens have been designed for elderly patients, but although they cause fewer side effects, they are less effective and no more beneficial than CHOP.6,11
Rituximab, a chimeric anti-CD20 IgG1 monoclonal antibody, is effective when given as a single agent in the treatment of relapsed or refractory indolent lymphomas and has activity in relapsed or refractory diffuse large-B-cell lymphoma.12-15 CD20 is a cell-surface protein that occurs almost exclusively on mature B cells. The chimeric antibody is a human IgG1 in which the CD20-binding region was derived by genetic engineering from a mouse monoclonal antibody. On the basis of phase 2 studies in which rituximab in combination with CHOP had a good safety profile and induced responses in over 90 percent of patients with indolent or aggressive lymphoma,16,17 the Groupe d'Etude des Lymphomes de l'Adulte (GELA) undertook a study to compare CHOP plus rituximab with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Methods
Patients
Patients were eligible if they were 60 to 80 years of age and had untreated diffuse large-B-cell lymphoma that had been diagnosed according to the Revised European–American Lymphoma classification18 or the World Health Organization classification.19 Patients were required to have stage II, III, or IV disease and a performance status of 0 to 2 (good to fair) according to the criteria of the Eastern Clinical Oncology Group. Patients were not eligible if they had T-cell lymphoma, a history of indolent lymphoma, central nervous system involvement, active cancer, or any serious active concomitant disease or if, in the opinion of the investigator, their general status did not permit the administration of eight courses of CHOP. Patients were also excluded if they had a cardiac contraindication to doxorubicin therapy (e.g., abnormal contractility on echocardiography) or a neurologic contraindication to vincristine (e.g., peripheral neuropathy). Finally, patients with a positive serologic test for the human immunodeficiency virus or unresolved hepatitis B virus infection were also excluded.
This study complied with all provisions of the Declaration of Helsinki and its current amendments and was conducted in accordance with Good Clinical Practice guidelines.20 All patients gave written informed consent. The protocol and informed-consent forms were approved by the local and national institutional review boards in each participating center and country. Study oversight was provided by an independent data and safety monitoring committee. The study investigators are listed in the Appendix.
Randomization
Eligible patients were randomly assigned by the study coordinating center to treatment with CHOP or CHOP plus rituximab. They were stratified according to center and age-adjusted International Prognostic Index scores (0 or 1 vs. 2 or 3, with a higher score indicating a higher risk of death), which are based on disease stage, performance status, and the lactate dehydrogenase level.2 A panel of at least three hematopathologists conducted a central pathology review, without knowledge of the patients' outcome, to confirm the diagnosis of CD20-positive diffuse large-B-cell lymphoma.
Treatment
Patients treated with CHOP received the combination of 750 mg of cyclophosphamide per square meter of body-surface area on day 1; 50 mg of doxorubicin per square meter on day 1; 1.4 mg of vincristine per square meter, up to a maximal dose of 2 mg, on day 1; and 40 mg of prednisone per square meter per day for five days. They were treated every three weeks for eight cycles of CHOP. Patients treated with CHOP plus rituximab also received rituximab, at a dose of 375 mg per square meter, on day 1 of each of the eight cycles of CHOP. The rituximab infusion was interrupted in the event of fever, chills, edema, congestion of the head and neck mucosa, hypotension, or any other serious adverse event and was resumed when such an event was no longer occurring. No radiation therapy was scheduled or recommended at the end of treatment.
Patients who had grade 4 (severe) neutropenia or febrile neutropenia after any cycle of chemotherapy were given granulocyte colony-stimulating factor. If grade 4 neutropenia persisted during the next cycle, the doses of cyclophosphamide and doxorubicin were decreased by 50 percent. For patients with grade 3 (moderate) or 4 thrombocytopenia, the doses of cyclophosphamide and doxorubicin were decreased by 50 percent. If the neutrophil count was lower than 1500 per cubic millimeter or the platelet count was lower than 100,000 per cubic millimeter before a scheduled cycle, the cycle was delayed for up to two weeks, and then treatment was stopped. The doses of rituximab were not modified, but rituximab was discontinued when CHOP was stopped. Treatment was stopped if lymphoma progressed or the patient declined to continue or at the discretion of the investigator in cases of intercurrent illness or adverse events.
Response to Treatment and Adverse Events
Tumor responses were assessed after eight cycles of chemotherapy or at the end of treatment and were classified as complete response, unconfirmed complete response, partial response, stable disease, or progressive disease according to the International Workshop criteria.21 Complete response was defined as the disappearance of all lesions and of radiologic or biologic abnormalities observed at diagnosis and the absence of new lesions. An unconfirmed complete response was defined as a complete response with the persistence of some radiologic abnormalities, which had to have regressed in size by at least 75 percent. Partial response was defined as the regression of all measurable lesions by more than 50 percent, the disappearance of nonmeasurable lesions, and the absence of new lesions. Stable disease was defined as a regression of any measurable lesion by 50 percent or less or no change for the nonmeasurable lesions, but without growth of existing lesions or the appearance of new lesions. Progressive disease was defined as the appearance of a new lesion, any growth of the initial lesion by more than 25 percent, or growth of any measurable lesion that had regressed during treatment by more than 50 percent from its smallest dimensions.
All adverse events reported by the patient or observed by the investigator were collected from the case-report form in predefined categories. An adverse event was defined as any adverse change from the patient's base-line condition, whether it was considered related to treatment or not. Each event was graded according to the National Cancer Institute Common Toxicity Criteria grading system.22 All grade 3 and 4 events plus grade 2 infection were recorded in detail. Grade 1 and 2 adverse events were not extensively described.
Statistical Analysis
The sample size was calculated on the basis of the primary end point of event-free survival, and the number of patients required was based on the assumption of an exponential distribution of events. On the basis of the results of previous studies with CHOP in elderly patients, a conservative three-year event-free survival of 30 percent was assumed for the CHOP regimen.23,24 To detect a change from 30 percent to 45 percent with the addition of rituximab, we calculated that 400 patients, recruited over three years and followed for a minimum of one year, would be required to provide the study with 80 percent power at an overall 5 percent significance level (two-sided, with an alpha level of 0.05). A single interim analysis of the primary efficacy outcome was planned; it included the 328 patients who underwent randomization before January 1, 2000.25
Event-free and overall survival was analyzed by the log-rank test, and the results were expressed as Kaplan–Meier plots. A multivariate Cox regression analysis was performed to assess the effect of pretreatment prognostic factors (specifically, age, sex, number of extranodal sites, presence or absence of bone marrow involvement, beta2-microglobulin level, serum albumin level, presence or absence of bulky disease, B symptoms [weight loss, fever, and night sweats]), and age-adjusted International Prognostic Index scores) on event-free and overall survival. Estimates of the treatment effect, after adjustment for these prognostic factors, are expressed as risk ratios for event-free and overall survival (CHOP plus rituximab as compared with CHOP), with 95 percent confidence intervals. Analyses of efficacy and safety included all randomized patients and followed the intention-to-treat principle. All P values are two-tailed. Statistical analyses were performed with SAS software (SAS Institute, Cary, N.C.) by the investigators at the GELA statistical office, without restrictions or outside control by the sponsor. The investigators had complete access to all study data.
Results
This study was conducted at 86 centers in France, Belgium, and Switzerland. A total of 399 patients were enrolled between July 1998 and March 2000, and 398 patients (202 in the CHOP-plus-rituximab group and 196 in the CHOP group) received at least one dose of protocol-specified treatment (1 patient was enrolled but died before treatment was administered).
Base-Line Characteristics
The median age of the patients was 69 years. There was no significant difference between the two groups in any clinical or pathological characteristic (Table 1Table 1
Characteristics of the 399 Patients.). Prognosis was poor, which is consistent with the prognosis in elderly patients with aggressive lymphoma. Central pathological review was completed for 97 percent of patients; the results confirmed a diagnosis of diffuse large-B-cell lymphoma in 90 percent of those who could be assessed in the CHOP-plus-rituximab group and 85 percent in the CHOP group.Treatment
The eight scheduled courses of chemotherapy were given to 72 percent of patients treated with CHOP and 80 percent of patients treated with CHOP plus rituximab. This difference was due to the number of patients who withdrew from the CHOP group because of disease progression: 23, as compared with 7 of those treated with CHOP plus rituximab. In each treatment cycle, more than 90 percent of the patients received at least 90 percent of the planned doses of doxorubicin and cyclophosphamide, with no significant difference between treatment groups in dose intensity for either drug in any cycle. In the CHOP-plus-rituximab group, more than 95 percent of the patients received the planned dose of rituximab.
Efficacy
With a median follow-up of 24 months, 86 events (progression, relapse, or death) were observed in the CHOP-plus-rituximab group and 120 in the CHOP group (in 43 percent and 61 percent of patients, respectively) (Table 2Table 2
Results of the Intention-to-Treat Analysis of End Points. and Figure 1Figure 1Event-free Survival among 399 Patients Assigned to Chemotherapy with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) or with CHOP plus Rituximab.). Event-free survival was significantly longer for patients treated with CHOP plus rituximab than for those treated with CHOP alone (P<0.001). According to the Cox analysis, the regimen of CHOP plus rituximab reduced the risk of events by 42 percent, as compared with the risk with CHOP alone (Table 2). The difference in event-free survival between the treatment groups was attributable to the higher number of patients in the CHOP group who had disease progression during treatment or with relapse. There was a significant benefit of CHOP plus rituximab over CHOP alone, both among patients with relatively low risk disease, indicated by a score of 0 or 1 on the International Prognostic Index (P<0.001), and those with high-risk disease, indicated by a score of 2 or 3 on the International Prognostic Index (P<0.03). Patients younger than 70 years and those 70 years or older, as well as the patients with diffuse large-B-cell lymphoma, had the same benefit from the combination of CHOP plus rituximab (data not shown).A complete response or unconfirmed complete response was achieved in 76 percent of the patients treated with CHOP plus rituximab, as compared with 63 percent of those treated with CHOP alone (P=0.005) (Table 3Table 3
Response to Treatment with CHOP or CHOP plus Rituximab.). Disease progression during treatment was reported for 22 percent of patients in the CHOP group and 9 percent in the CHOP-plus-rituximab group. Prolongation of disease-free survival (complete remission) and progression-free survival in the CHOP-plus-rituximab group was of the same magnitude as the prolongation of event-free survival (data not shown). Survival was significantly longer for patients treated with CHOP plus rituximab than for those treated with CHOP alone (P=0.007): at two years, 70 percent of patients treated with CHOP plus rituximab were alive, as compared with 57 percent of those treated with CHOP alone (Table 2 and Figure 2Figure 2Overall Survival among 399 Patients Assigned to Chemotherapy with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) or with CHOP plus Rituximab.).Base-line prognostic factors were analyzed by multivariate Cox regression analysis. A high concentration (more than 3 mg per liter) of beta2-microglobulin was identified as a negative prognostic factor in terms of both event-free and overall survival (risk ratio, 1.58 [95 percent confidence interval, 1.14 to 2.21] for death, disease progression, or another event and 1.82 [1.22 to 2.72] for death from any cause, respectively). The presence of more than one extranodal site of disease was another significant negative prognostic factor in terms of overall survival (risk ratio for death from any cause, 1.46). After adjustment for these prognostic factors, the risk ratio associated with treatment with CHOP plus rituximab, as compared with CHOP alone, was 0.55 (95 percent confidence interval, 0.41 to 0.75) for death, disease progression, or another event and 0.53 (0.37 to 0.77) for death from any cause, as compared with the unadjusted values of 0.58 (0.44 to 0.77) and 0.64 (0.45 to 0.89), respectively.
Adverse Effects
Table 4Table 4
Nonhematologic Adverse Events Observed in Patients Treated with CHOP plus Rituximab or CHOP Alone. presents all reported adverse events in each group. The grade 3 and 4 adverse events were consistent with the expected toxic effects of CHOP chemotherapy and occurred with similar frequency in both groups. Infection was one of the most frequent grade 3 or 4 adverse events in both groups. The difference in the incidence of cardiac events during treatment (47 percent for CHOP plus rituximab, as compared with 35 percent for CHOP) (Table 4) was due to a higher incidence of grade 1 events in the CHOP-plus-rituximab group than in the CHOP group (24 percent vs. 13 percent). This difference was consistent with the mild-to-moderate infusion-related events described in phase 2 studies of rituximab.12-14,26 The incidence of grade 3 or 4 cardiac toxicity was the same in both groups (8 percent), with more reports of supraventricular arrhythmias and tachycardias in the CHOP-plus-rituximab group. Grade 3 or 4 cardiac failure or left ventricular dysfunction occurred in 18 patients in the CHOP-plus-rituximab group and 19 patients in the CHOP group.Grade 3 or 4 adverse events related to the infusion of rituximab were observed in 19 patients in the CHOP-plus-rituximab group (9 percent); the most frequent of these were respiratory symptoms (with or without bronchospasm), chills, fever, and hypotension. In all cases, the symptoms disappeared after the infusion was slowed or stopped, and no patient died as a result of such an adverse event. All patients were able to receive further cycles of CHOP plus rituximab without recurrence of grade 3 or 4 infusion-related reactions.
Thirty-four patients (13 in the CHOP group and 21 in the CHOP-plus-rituximab group) died from causes not attributable to lymphoma; 23 died during the treatment period from infection (16 patients), cachexia (4 patients), or cardiovascular events (3 patients), without any significant difference between the groups. The remaining 11 patients (2 in the CHOP group and 9 in the CHOP-plus-rituximab group) died from infection (4 patients), cachexia (2 patients), cardiac disease (2 patients), suicide (1), another type of cancer (1), or gastrointestinal hemorrhage (1) while in a complete remission after completing therapy.
The median nadir of the neutrophil count after each cycle of chemotherapy was similar in both groups. After the first cycle, neutrophil counts fell to 400 per cubic millimeter in both groups. Thereafter, the median was slightly higher in the CHOP group than in the CHOP-plus-rituximab group. Neutropenia was not associated with an increase in episodes of infection during treatment, as shown in Table 4. The percentages of patients who required treatment with granulocyte colony-stimulating factor increased to a similar degree in each treatment group, to 37 percent for the fourth cycle and 43 percent for the eighth cycle. There were a few more cases of herpes zoster after treatment in patients receiving CHOP plus rituximab than in those receiving CHOP (nine vs. two, P=0.40). During treatment, 19 percent of patients receiving CHOP and 14 percent of those receiving CHOP plus rituximab had grade 3 or 4 anemia. The median nadir platelet counts remained above 130,000 per cubic millimeter in both treatment groups for all eight cycles.
Discussion
This randomized trial compared the efficacy and safety of rituximab in combination with CHOP chemotherapy with that of CHOP chemotherapy alone in elderly patients with diffuse large-B-cell lymphoma. We found higher response rates and improved event-free and overall survival among patients treated with the combination of rituximab and CHOP. The longer survival in the CHOP-plus-rituximab group was due to a lower rate of disease progression during therapy and fewer relapses among patients who had a complete response. Treatment with CHOP plus rituximab was well tolerated, and the incidence of severe or serious adverse events was no different from that in the CHOP group.
The event-free survival among elderly patients with diffuse large-B-cell lymphoma was only 12 to 18 months in previous randomized studies of chemotherapy.6,9,24 We chose CHOP for use in this study because it is as effective as, and less toxic than, other, more recently developed chemotherapeutic regimens5,27,28; it is also considered to be standard therapy for elderly patients with diffuse large-B-cell lymphoma.6,11,29 The results with CHOP alone in our trial were similar to those previously reported in elderly patients.6,9-11,23,29 For this reason, we believe that the better results with CHOP plus rituximab are not attributable to an unusually poor outcome among patients in the CHOP group.
In a study comparing a regimen of doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (ACVB) with CHOP in elderly patients, we found that ACVB was associated with longer event-free survival because patients who received ACVB had a lower incidence of relapses.23 However, the rate of death due to toxic effects of the therapy was higher with ACVB than with CHOP, particularly in patients over 65 years of age, and for this reason, treatment with ACVB was not associated with prolonged survival.
In conclusion, the addition of rituximab to CHOP chemotherapy, given for eight cycles to elderly patients with newly diagnosed diffuse large-B-cell lymphoma, significantly increases the rate of complete response, decreases the rates of treatment failure and relapse, and improves event-free and overall survival as compared with standard CHOP alone. These gains were achieved without a significant increase in clinically significant toxic effects.
Supported by grants from Hoffmann–LaRoche.
Drs. Coiffier, Salles, Reyes, and Gisselbrecht have served as consultants to Roche, Genentech, or IDEC, the manufacturers of rituximab; have been members of speakers' bureaus sponsored by Roche, Genentech, or IDEC; or have done both for Roche, Genentech, or IDEC, as well as for other companies involved in the manufacture of antilymphoma drugs or other monoclonal antibodies.
Source Information
From the Hospices Civils de Lyon and the Université Claude Bernard, Lyons (B.C., G.S.); Hôpital Henri-Mondor, Paris (E.L., P.G., F.R.); Assistance Publique–Hôpitaux de Paris, Hôpital Saint-Louis, Paris (J.B., C.G.); Hôpital de Hautepierre, Strasbourg (R.H.); the Centre Becquerel, Rouen (H.T.); the Institut Paoli-Calmette, Marseilles (R.B.); and the Centre Hospitalier de Lens (P.M.) — all in France; and the Université Catholique de Louvain, Brussels, Belgium (E.N.). Pierre Lederlin, Ph.D., Centre Hospitalier Universitaire de Brabois, Nancy, France, was also an author.
Address reprint requests to Dr. Coiffier at the Service d'Hématologie, Centre Hospitalier Lyon-Sud, 69495 Pierre Bénite CEDEX, France, or at bertrand.coiffier@chu-lyon.fr.
Appendix
The following persons and institutions participated in this GELA study: External advisory committee — E. Montserrat (chairman, Spain), M. Björkholm (Sweden), M. Buyse (Belgium), F. Cavalli (Switzerland), and M. Pfreundschuh (Germany); Pathological review committee — J. Brière, P. Gaulard, J. Bosq, J.F. Emile, B. Fabiani, and T. Petrella; Statistics — E. Lepage and N. Nio; Pharmacist — I. Madelaine; GELA clincial research — R. Chvetzoff; study centers (all in France, unless otherwise specified) — Centre Hospitalier Lyon-Sud, Pierre-Bénite — B. Coiffier and G. Salles; Hôpital de Hautepierre, Strasbourg — R. Herbrecht; Centre Becquerel, Rouen — H. Tilly; Centre Jean Bernard, Le Mans — P. Solal-Celigny; Institut Paoli Calmette, Marseilles — R. Bouabdallah; Centre Hospitalier Universitaire de Brabois, Nancy — P. Lederlin; Centre Léon Bérard, Lyons — C. Sebban; Institut Gustave Roussy, Villejuif — J.N. Munck and C. Fermé; Centre Hospitalier de Lens, Lens — P. Morel; Hôpital Henri Mondor, Creteil — F. Reyes and C. Haioun; Centre Hospitalier de Chambéry, Chambéry — M. Blanc; Hôpital Bon Secours, Metz — B. Christian; Centre Hospitalier Universitaire de Lille, Lille — B. Quesnel; Academisch Ziekenhuis Sint-Jan, Bruges, Belgium — A. van Hoof; Hôpital Saint-Louis, Paris — C. Gisselbrecht; Hôpital Purpan, Toulouse — M. Attal; Centre Hospitalier Universitaire Dupuytren, Limoges — D. Bordessoule; Hôpital Jean Bernard, Poitiers — V. Delwail; Université Catholique de Louvain, Ivoir, Belgium — A. Bosly; Centre Hospitalier Universitaire Clemenceau, Caen — M. Macro; Centre François Magendie, Pessac — G. Marit; Hôpital Pitié Salpétrière, Paris — J. Gabarre; Hôpital André Mignot, Le Chesnay — S. Castaigne; Centre Hospitalier Universitaire de Nîmes, Nîmes — E. Jourdan; Centre Hospitalier de la Durance, Avignon — E. Lepeu; Hôpital Pasteur, Colmar — B. Audhuy; Centre Antoine Lacassagne, Nice — A. Thyss; Clinique Pasteur, Evreux — N. Albin; Centre Médical Foch, Suresnes — E. Baumelou; Hôtel Dieu, Paris — A. Delmer; Centre Hospitalier de Brive, Brive — S. Lefort; Centre Hospitalier de Bourg en Bresse, Bourg en Bresse — H. Orfeuvre; Hôpital V. Prouvo, Roubaix — I. Plantier; Hôpital Bicêtre, Le Kremlin-Bicêtre — G. Tertian; Hôpital Necker, Paris — B. Varet; Hôpital Beclere, Clamart — F. Boué; Centre Hospitalier Universitaire de Dijon, Dijon — O. Casasnovas and D. Caillot; Université Catholique de Louvain, Brussels, Belgium — E. Van Den Neste; Institut Curie, Paris — D. Decaudin; Centre Hospitalier Universitaire Saint-Louis–Lariboisière, Paris — P. Brice, H. Dombret, J.P. Fermand, and J.M. Zini; Centre Hospitalier Universitaire de Liège, Liège, Belgium — G. Fillet; Fondation Drevon, Dijon — M. Flesch; Centre Hospitalier R. Dubos, Pontoise — Y. Kerneis; Centre Hospitalier d'Annecy, Annecy — C. Martin; Hôpital de Valence, Valence — P.Y. Péaud; Centre Hospitalier de Blois, Blois — P. Rodon; Centre Hospitalier Saint-Vincent, Lille — C. Rose; Hôtel Dieu, Clermont-Ferrand — P. Travade; Clinique Saint-Jean, Lyons — B. Velay; Hôpital de Bayonne, Bayonne — F. Bauduer; Centre Hospitalier de Libourne, Libourne — K. Bouabdallah; Hôpital Emile Muller, Mulhouse — J.C. Eisenmann; Hôpital Marc Jacquet, Melun — C. Kulekci; Centre Hospitalier Bois de l'Abbaye, Seraing, Belgium — S. Lampertz; Hôpital Inter Armées Percy, Clamart — G. Nedellec; Centre François Baclesse, Caen — A.M. Peny; Centre Hospitalier Victor Dupouy, Argenteuil — V. Pulik; Hôpital de Chalon, Chalon — B. Salles; Centre Hospitalier de Perpignan, Perpignan — X. Vallantin; Centre Hospitalier Robert Ballanger, Aulnay sous Bois — P. Agranat; Centre Hospitalier Universitaire de Nice, Nice — J.P. Cassuto; Centre Hospitalier Hutois, Huy, Belgium — J. Collignon; Centre Hospitalier de la Citadelle, Liège, Belgium — B. de Prijck; Hôpital Jolimont, Haine Saint Paul, Belgium — A. Delannoy; Centre Hospitalier Gilles de Corbeil, Corbeil Essonnes — A. Devidas; Hôpital La Fontonne, Antibes — J.F. Dor; Hôpital Cochin, Paris — F. Dreyfus; Clinique Saint Jean, Brussels, Belgium — C. Dubois; Clinique de Chaumont, Chaumont — G. Dupont; Centre Val d'Aurelle, Montpellier — M. Fabbro; Hôpital J. Monod, Le Havre — C. Fruchart; Clinique les Fougères, Dieppe — J.P. Gaillard; Centre Hospitalier Universitaire de Rennes, Rennes — B. Grosbois; Centre René Huguenin, Saint-Cloud — M. Janvier; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland — N. Ketterer; Centre Hospitalier du Val de Sambre, Sambreville, Belgium — C. Leroy; Clinique Saint Pierre, Ottignies, Belgium — M. Maerevoet; Hôpital des Canaux, Macon — F. Marechal; Hôpital Saint Joseph, Gilly, Belgium — P. Mineur; Hôpital Saint Joseph, Arlon, Belgium — P. Pierre; Centre Hospitalier Universitaire Nord, Marseilles — G. Sebahoun; Centre Hospitalier de Meaux, Meaux — C. Soussain; and Hôpital Nord, Amiens — C. Traulle.
- References
References
1
Coiffier B. Non-Hodgkin's lymphomas. In: Cavalli F, Hansen HH, Kaye SB, eds. Textbook of medical oncology. London: Martin Dunitz, 1997:265-87.
2
The International Non-Hodgkin's Lymphoma Prognostic Factors Project
Full Text | Web of Science | Medline3
The Non-Hodgkin's Lymphoma Classification Project
CrossRef | Web of Science | Medline4
The Non-Hodgkin's Lymphoma Classification Project
Web of Science | Medline5
Fisher RI ,Gaynor ER ,Dahlberg S , et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-1006
Full Text | Web of Science | Medline6
Sonneveld P ,de Ridder M ,van der Lelie H , et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995;13:2530-2539
Web of Science | Medline7
Dixon DO ,Neilan B ,Jones SE , et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 1986;4:295-305
Web of Science | Medline8
Haioun C ,Lepage E ,Gisselbrecht C , et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol -- a Groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol 2000;18:3025-3030
Web of Science | Medline9
Coiffier B . What treatment for elderly patients with aggressive lymphoma? Ann Oncol 1994;5:873-875
Web of Science | Medline10
Zinzani PL ,Storti S ,Zaccaria A , et al. Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood 1999;94:33-38
Web of Science | Medline11
Meyer RM ,Browman GP ,Samosh ML , et al. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 1995;13:2386-2393
Web of Science | Medline12
Maloney DG ,Grillo-Lopez AJ ,White CA , et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-2195
Web of Science | Medline13
McLaughlin P ,Grillo-Lopez AJ ,Link BK , et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833
Web of Science | Medline14
Coiffier B ,Haioun C ,Ketterer N , et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927-1932
Web of Science | Medline15
Foran JM ,Rohatiner AZS ,Cunningham D , et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000;18:317-324[Erratum, J Clin Oncol 2000;18:2006.]
Web of Science | Medline16
Czuczman MS ,Grillo-Lopez AJ ,White CA , et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268-276
Web of Science | Medline17
Vose JM ,Link BK ,Grossbard ML , et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001;19:389-397
Web of Science | Medline18
Harris NL ,Jaffe ES ,Stein H , et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392
Web of Science | Medline19
Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer, 2001.
20
Good clinical practice for trials on medicinal products in the European community. Good Clin Pract J 1994;1:Suppl-Suppl
21
Cheson BD ,Horning SJ ,Coiffier B , et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999;17:1244-1244[Erratum, J Clin Oncol 2000;18:2351.]
Web of Science | Medline22
Cancer Therapy Evaluation Program. Common toxicity criteria, version 2.0. Bethesda, Md.: National Cancer Institute, March 1998.
23
Tilly H ,Lepage E ,Coiffier B , et al. A randomized comparison of ACVBP and CHOP in the treatment of advanced aggressive non-Hodgkin's lymphoma: the LNH93-5 study. Blood 2000;96:832a-832a abstract.
Web of Science24
Bastion YB ,Blay JY ,Divine M , et al. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival -- a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol 1997;15:2945-2953
Web of Science | Medline25
Coiffier B ,Lepage E ,Herbrecht R , et al. MabThera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): interim results of a randomized GELA trial. Blood 2000;96:223a-223a abstract.
Web of Science26
Maloney DG ,Liles TM ,Czerwinski DK , et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457-2466
Web of Science | Medline27
Gordon LI ,Harrington D ,Andersen J , et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992;327:1342-1349
Full Text | Web of Science | Medline28
Jerkeman M ,Anderson H ,Cavallin-Stahl E , et al. CHOP versus MACOP-B in aggressive lymphoma -- a Nordic Lymphoma Group randomised trial. Ann Oncol 1999;10:1079-1086
CrossRef | Web of Science | Medline29
Tirelli U ,Errante D ,Van Glabbeke M , et al. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 1998;16:27-34
Web of Science | Medline
- Citing Articles (1168)
Citing Articles
1
Murali Janakiram, Venu K. Thirukonda, Matthew Sullivan, Adam M. Petrich. (2012) Emerging Therapeutic Targets in Diffuse Large B-Cell Lymphoma. Current Treatment Options in Oncology
CrossRef2
Alexandre Chan, Terence Rong De Ng, Kevin Yi-Lwern Yap. (2012) Clinically–relevant anticancer-antidepressant drug interactions. Expert Opinion on Drug Metabolism & Toxicology 8:2, 173-199
CrossRef3
Anthony Mato, Tatyana Feldman, Joshua Richter, David S. Siegel, Andre Goy. (2012) Liquid Tumors in the Elderly. Clinics in Geriatric Medicine 28:1, 115-152
CrossRef4
Naoe Goto, Hisashi Tsurumi, Masao Takemura, Nobuhiro Kanemura, Senji Kasahara, Takeshi Hara, Ichiro Yasuda, Masahito Shimizu, Toshiki Yamada, Michio Sawada, Takeshi Takahashi, Tetsuya Yamada, Mitsuru Seishima, Hisataka Moriwaki, Tsuyoshi Takami. (2012) Serum soluble CD27 level is associated with outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Leukemia & Lymphoma1-21
CrossRef5
Scott F Huntington, Mahsa S Talbott, John P Greer, David S Morgan, Nishitha Reddy. (2012) Toxicities and Outcomes among Septuagenarians and Octogenarians with Diffuse Large B cell Lymphoma Treated with Rituximab-CHOP Therapy. Leukemia & Lymphoma1-21
CrossRef6
Yuhko Suzuki, Tsutomu Yoshida, Guoqin Wang, Tomiteru Togano, Shunsuke Miyamoto, Koji Miyazaki, Keiichi Iwabuchi, Meijin Nakayama, Ryouichi Horie, Nozomi Niitsu, Yuichi Sato, Naoya Nakamura. (2012) Association of CD20 levels with clinicopathological parameters and its prognostic significance for patients with DLBCL. Annals of Hematology
CrossRef7
Ho-Jin Shin, Joo Seop Chung, Moo-Kon Song, Seon-Kyeong Kim, Sangmin Choe, Goon-Jae Cho. (2012) Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma. Cancer Chemotherapy and Pharmacology
CrossRef8
J. A. Rodrigo, L. K. Hicks, M. C. Cheung, K. W. Song, H. Ezzat, C. S. Leger, J. Boro, J. S. G. Montaner, M. Harris, H. A. Leitch. (2012) HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era. Advances in Hematology 2012, 1-9
CrossRef9
Eiji Tanaka, Yukitomo Urata. (2012) Risk of hepatitis B reactivation in patients treated with tumor necrosis factor-α inhibitors. Hepatology Researchno-no
CrossRef10
Anne W Beaven, David Rizzieri. (2012) Clinical evidence for the role of pixantrone in the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma. Clinical Investigation 2:1, 49-58
CrossRef11
Mark A. Rosenthal, Samar Issa. 2012. Primary central nervous system lymphoma. , 779-806.
CrossRef12
Emilia Hardak, Ilana Oren, Eldad J. Dann, Mordechai Yigla, Tal Faibish, Jacob M. Rowe, Irit Avivi. (2012) The Increased Risk for Pneumocystis Pneumonia in Patients Receiving Rituximab-CHOP-14 Can Be Prevented by the Administration of Trimethoprim/Sulfamethoxazole: A Single-Center Experience. Acta Haematologica 127:2, 110-114
CrossRef13
Man Fai Law, Sze Fai Yip, Wai Lun Poon, Hay Nun Chan, Ho Kei Lai, Chun Yin Ha, Celia S. S. Ng, Yiu Ming Yeung. (2012) Intrapleural rituximab for the treatment of malignant pleural effusion due to B-cell lymphomas. Leukemia & Lymphoma 53:1, 156-157
CrossRef14
Akiko Meguro, Katsutoshi Ozaki, Kazuya Sato, Iekuni Oh, Shinichiro Fujiwara, Rie Hosonuma, Miyuki Sasazaki, Yuji Kikuchi, Yuji Hirata, Chihiro Yamamoto, Mitsuyo Uesawa, Hiroyuki Kobayashi, Haruko Matsu, Hiroshi Okabe, Eisuke Uehara, Akinori Nishikawa, Raine Tatara, Kaoru Hatano, Chizuru Yamamoto, Tomohiro Matsuyama, Masaki Toshima, Masuzu Ueda, Ken Ohmine, Takahiro Suzuki, Masaki Mori, Tadashi Nagai, Kazuo Muroi, Keiya Ozawa. (2012) Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older. Leukemia & Lymphoma 53:1, 43-49
CrossRef15
Tamar Tadmor, Aaron Polliack. (2012) Rituximab in space: intrapleural and other novel routes of administration for lymphomas and lymphoid leukemias. Leukemia & Lymphoma 53:1, 5-7
CrossRef16
D. MOKART, A. ETIENNE, B. ESTERNI, J.-P. BRUN, L. CHOW-CHINE, A. SANNINI, M. FAUCHER, J.-L. BLACHE. (2012) Critically ill cancer patients in the intensive care unit: short-term outcome and 1-year mortality. Acta Anaesthesiologica Scandinavican/a-n/a
CrossRef17
Paul A. Fields, David C. Linch. (2012) Treatment of the elderly patient with diffuse large B cell lymphoma. British Journal of Haematologyno-no
CrossRef18
Belinda A. Campbell, Joseph M. Connors, Randy D. Gascoyne, W. James Morris, Tom Pickles, Laurie H. Sehn. (2012) Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy. Cancern/a-n/a
CrossRef19
Avichai Shimoni, Irit Avivi, Jacob M. Rowe, Moshe Yeshurun, Itai Levi, Reuven Or, Paulina Patachenko, Abraham Avigdor, Tzila Zwas, Arnon Nagler. (2012) A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancern/a-n/a
CrossRef20
Marco Gunnellini, Rita Emili, Stefano Coaccioli, Anna Marina Liberati. (2012) The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-Cell Lymphoma. Advances in Hematology 2012, 1-10
CrossRef21
Rodney R. Miles, Staci Arnold, Mitchell S. Cairo. (2012) Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia. British Journal of Haematologyn/a-n/a
CrossRef22
Nicolas Mounier, Natacha Heutte, Catherine Thieblemont, Josette Briere, Philippe Gaulard, Pierre Feugier, Hervé Ghesquieres, Eric Van Den Neste, Daniela Robu, Herve Tilly, Reda Bouabdallah, Violaine Safar, Bertrand Coiffier. (2012) Ten-Year Relative Survival and Causes of Death in Elderly Patients Treated With R-CHOP or CHOP in the GELA LNH-985 Trial. Clinical Lymphoma Myeloma and Leukemia
CrossRef23
Brigita Gregoric, Vesna Zadnik, Barbara Jezersek Novakovic. (2012) The diffuse large B-cell lymphoma - where do we stand now in everyday clinical practice. Radiology and Oncology 1:-1, 1-8
CrossRef24
Stefan W. Krause, Michael Gerken, Reinhard Andreesen, Ferdinand Hofstädter, Monika Klinkhammer-Schalke. (2011) Treatment of B cell lymphoma with chemotherapy plus rituximab: a survival benefit can be demonstrated in the routine data of a regional cancer registry. Annals of Hematology
CrossRef25
Naoe Goto, Hisashi Tsurumi, Hideko Goto, Yoriko Ino Shimomura, Senji Kasahara, Takeshi Hara, Ichiro Yasuda, Masahito Shimizu, Nobuo Murakami, Takeshi Yoshikawa, Kenji Fukuno, Takeshi Takahashi, Yusuke Kito, Tsuyoshi Takami, Hisataka Moriwaki. (2011) Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens. Annals of Hematology
CrossRef26
Xiaoyang Li, Zhao Liu, Junning Cao, Xiaonan Hong, Jianmin Wang, Fangyuan Chen, Chun Wang, Shanhua Zou, Junmin Li, Zhixiang Shen. (2011) Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group. Annals of Hematology
CrossRef27
A. V. Hadjinicolaou, M. K. Nisar, H. Parfrey, E. R. Chilvers, A. J. K. Ostor. (2011) Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology
CrossRef28
K. Tsukasaki, K. Tobinai, T. Hotta, M. Shimoyama. (2011) Lymphoma Study Group of JCOG. Japanese Journal of Clinical Oncology
CrossRef29
David Telio, Kim Fernandes, Clement Ma, Richard Tsang, Armand Keating, Michael Crump, John Kuruvilla. (2011) Salvage Chemotherapy and Autologous Stem Cell Transplantation in Primary Refractory DLBCL: Outcomes and Prognostic Factors. Leukemia & Lymphoma1-19
CrossRef30
Veronica Goffredo, Angelo Paradiso, Girolamo Ranieri, Cosmo Damiano Gadaleta. (2011) Yttrium-90 (90Y) in the principal radionuclide therapies: An efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999–2009). Critical Reviews in Oncology/Hematology 80:3, 393-410
CrossRef31
Jean Klastersky, Andrea Gombos, Aspasia Georgala, Ahmad Awada. (2011) Prevention of neutropenia-related events in elderly patients with hematological cancer. Aging Health 7:6, 829-842
CrossRef32
Yun Fan, Chong Luo, Lvhong Luo, Zhiyu Huang, Haifeng Yu. (2011) Retrospective analysis of hepatitis B virus reactivation after rituximab combination chemotherapy in patients with B-cell lymphoma. The Chinese-German Journal of Clinical Oncology 10:12, 721-725
CrossRef33
Hiroto KANEKO, Kazuho SHIMURA, Shigeo HORIIKE, Junya KURODA, Yosuke MATSUMOTO, Shohei YOKOTA, Koichi NISHIDA, Yasuo OHKAWARA, Masafumi TANIWAKI. (2011) Cytogenetic analysis of de novo CD5-positive diffuse large B-cell lymphoma. Asia-Pacific Journal of Clinical Oncology 7:4, 346-350
CrossRef34
Norifumi Tsukamoto, Hiroshi Handa, Akihiko Yokohama, Takeki Mitsui, Takayuki Saitoh, Hiromi Koiso, Hideki Uchiumi, Takumi Hoshino, Masamitsu Karasawa, Hirokazu Murakami, Masaru Kojima, Yoshihisa Nojima. (2011) Long-term follow-up of EBV-positive lymphoproliferative disorders in a patient with systemic lupus erythematosus. Medical Molecular Morphology 44:4, 237-241
CrossRef35
Ling-Ping Chen, Shyh-Jer Lin, Ming-Sun Yu. (2011) Impact of cutoff age in predicting clinical outcomes of elderly diffuse large B cell lymphoma receiving rituximab or not: A hospital-based study. Journal of Clinical Gerontology and Geriatrics
CrossRef36
Juan José Alonso, Araceli Cánovas, José Guillermo Barreiro, Ciriaco Aguirre. (2011) Infectious complications of chemotherapy in clinically aggressive mature B and T cell lymphomas. European Journal of Internal Medicine
CrossRef37
M. Mansour Ceesay, Estella Matutes, Graham P. Taylor, Paul Fields, Jamie Cavenagh, Sylwia Simpson, Aloysius Ho, Stephen Devereux, Ghulam J. Mufti, Antonio Pagliuca. (2011) Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL). Leukemia Research
CrossRef38
D. Hoelzer. (2011) Novel Antibody-Based Therapies For Acute Lymphoblastic Leukemia. Hematology 2011:1, 243-249
CrossRef39
N. Emami-Shahri, T. Hagemann. (2011) Resistance--the true face of biological defiance. Rheumatology
CrossRef40
Moo-Kon Song, Joo-Seop Chung, Ho-Jin Shin, Sang-Min Lee, Su-Ee Lee, Ho-Sup Lee, Gyeong-Won Lee, Seong-Jang Kim, Seok-Mo Lee, Dong-Seop Chung. (2011) Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Annals of Hematology
CrossRef41
Salvatore Di Maio, Dinesh Ramanathan, Rabindranath Garcia-Lopez, Michael Herbas Rocha, Francisco Ponce Guerrero, Manuel Ferriera, Laligam N. Sekhar. (2011) Evolution and Future of Skull Base Surgery: The Paradigm of Skull Base Meningiomas. World Neurosurgery
CrossRef42
Ling Cai, Michael C. Stauder, Yu-Jing Zhang, Philip Poortmans, Ye-Xiong Li, Nicolaos Constantinou, Juliette Thariat, Sidney P. Kadish, Tan Dat Nguyen, Youlia M. Kirova, Pirus Ghadjar, Damien C. Weber, Victoria Tuset Bertran, Mahmut Ozsahin, René-Olivier Mirimanoff. (2011) Early-Stage Primary Bone Lymphoma: A Retrospective, Multicenter Rare Cancer Network (RCN) Study. International Journal of Radiation Oncology*Biology*Physics
CrossRef43
Christian Récher, Bertrand Coiffier, Corinne Haioun, Thierry Jo Molina, Christophe Fermé, Olivier Casasnovas, Catherine Thiéblemont, André Bosly, Guy Laurent, Franck Morschhauser, Hervé Ghesquières, Fabrice Jardin, Serge Bologna, Christophe Fruchart, Bernadette Corront, Jean Gabarre, Christophe Bonnet, Maud Janvier, Danielle Canioni, Jean-Philippe Jais, Gilles Salles, Hervé Tilly. (2011) Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. The Lancet 378:9806, 1858-1867
CrossRef44
Marcus Smith, Harsh Golwala, Hany Magharyous, Timothy Trotter, Ravindranauth Sawh, Pedro Lozano. (2011) Right Atrial B-Cell Lymphoma in a Patient with Ocular Melanoma. Journal of Cardiac Surgery 26:6, 625-628
CrossRef45
Yung-Cheng Su, Lee-Yung Shih, Chung-Chi Huang. (2011) Rituximab-induced Acute Eosinophilic Pneumonia with Diffuse Alveolar Damage: A Case Report. Journal of Experimental & Clinical Medicine
CrossRef46
Naoki Hosen, Hiroyoshi Ichihara, Atsuko Mugitani, Yasutaka Aoyama, Yuki Fukuda, Satoshi Kishida, Yoshikazu Matsuoka, Hiroko Nakajima, Manabu Kawakami, Tamotsu Yamagami, Shigeo Fuji, Hiroya Tamaki, Takafumi Nakao, Sumiyuki Nishida, Akihiro Tsuboi, Shinsuke Iida, Masayuki Hino, Yoshihiro Oka, Yusuke Oji, Haruo Sugiyama. (2011) CD48 as a novel molecular target for antibody therapy in multiple myeloma. British Journal of Haematologyno-no
CrossRef47
Chadi Nabhan, Sonali M. Smith, Irene Helenowski, Erika Ramsdale, Benjamin Parsons, Reem Karmali, Josephine Feliciano, Britt Hanson, Scott Smith, June McKoy, Annette Larsen, Andrew Hantel, Stephanie Gregory, Andrew M. Evens. (2011) Analysis of very elderly (≥80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome. British Journal of Haematologyno-no
CrossRef48
Min Kyoung Kim, Cheolwon Suh, Hyun Sook Chi, Hee Soon Cho, Young Kyung Bae, Kyung Hee Lee, Gyeong-Won Lee, In-Suk Kim, Hyeon-Seok Eom, Sun-Young Kong, Sung Hwa Bae, Hun Mo Ryoo, Im-Hee Shin, Yeung-Chul Mun, Hwasoon Chung, Myung Soo Hyun. (2011) VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma. Cancer Scienceno-no
CrossRef49
Moo-Kon Song, Joo-Seop Chung, Ho-Jin Shin, Joon-Ho Moon, Jeong-Ok Lee, Ho-Sup Lee, Sang-Min Lee, Gyeong-Won Lee, Su-Ee Lee, Seong-Jang Kim. (2011) Prognostic value of metabolic tumor volume by PET/CT in primary gastrointestinal diffuse large B cell lymphoma. Cancer Scienceno-no
CrossRef50
Naoto Tomita, Masahiro Yokoyama, Wataru Yamamoto, Reina Watanabe, Yutaka Shimazu, Yasufumi Masaki, Saburo Tsunoda, Chizuko Hashimoto, Kayoko Murayama, Takahiro Yano, Rumiko Okamoto, Ako Kikuchi, Kazuo Tamura, Kazuya Sato, Kazutaka Sunami, Hirohiko Shibayama, Rishu Takimoto, Rika Ohshima, Yoshihiro Hatta, Yukiyoshi Moriuchi, Tomohiro Kinoshita, Masahide Yamamoto, Ayumi Numata, Yoshiaki Ishigatsubo, Kengo Takeuchi. (2011) Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Scienceno-no
CrossRef51
Makiko Ban-Hoefen, Jennifer L. Kelly, Steven H. Bernstein, Jane Liesveld, Louis Constine, Michael Becker, Laurie Milner, Gordon Phillips, Jonathan W. Friedberg. (2011) High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era. Leukemia & Lymphoma1-20
CrossRef52
Benigno C. Valdez, David Murray, Yago Nieto, Yang Li, Guiyun Wang, Richard E. Champlin, Borje S. Andersson. (2011) Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and SAHA in lymphoma cell lines. Leukemia & Lymphoma1-21
CrossRef53
Jesse Popov, Anita I Kapanen, Christopher Turner, Rebecca Ng, Catherine Tucker, Gigi Chiu, Richard Klasa, Marcel B Bally, Ghania Chikh. (2011) Multivalent rituximab lipid nanoparticles as improved lymphoma therapies: indirect mechanisms of action and in vivo activity. Nanomedicine1-17
CrossRef54
I. W. Flinn. (2011) CD37: the comeback kid. Blood 118:15, 4007-4008
CrossRef55
Takashi Ishida, Ryuzo Ueda. (2011) Antibody therapy for Adult T-cell leukemia–lymphoma. International Journal of Hematology
CrossRef56
Joanna Grabska, Constantin A Dasanu. (2011) Autoimmune phenomena in untreated and treated marginal zone lymphoma. Expert Opinion on Pharmacotherapy 12:15, 2369-2379
CrossRef57
Nicola Renzo, Antonella Montanini, Donato Mannina, Alessandra Dondi, Stefania Muci, Salvatrice Mancuso, M. Rosaria Paolis, Caterina Plati, Caterina Stelitano, Catia Patti, Attilio Olivieri, Eliana Liardo, Gabriele Buda, Renato Cantaffa, Massimo Federico. (2011) Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL). Supportive Care in Cancer 19:10, 1505-1510
CrossRef58
John L. Reagan, Alan Rosmarin, James N. Butera, Ahmed Nadeem, Fred J. Schiffman, William M. Sikov, Eric Winer, Anthony E. Mega. (2011) Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL. Cancer Chemotherapy and Pharmacology 68:4, 1075-1080
CrossRef59
Yu-Chung Huang, Chia-Jen Liu, Chun-Yu Liu, Jih-Tung Pai, Ying-Chung Hong, Hao-Wei Teng, Liang-Tsai Hsiao, Ta-Chung Chao, Jyh-Pyng Gau, Jin-Hwang Liu, Hui-Chi Hsu, Tzeon-Jye Chiou, Po-Min Chen, Yuan-Bin Yu, Cheng-Hwai Tzeng. (2011) Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma. Annals of Hematology 90:10, 1145-1151
CrossRef60
Esa Jantunen, Anna Sureda. (2011) The Evolving Role of Stem Cell Transplants in Lymphomas. Biology of Blood and Marrow Transplantation
CrossRef61
R. Alvarez, J. Dupuis, A. Plonquet, C. Christov, C. Copie-Bergman, F. Hemery, I. Gaillard, T. El Gnaoui, F. Kuhnowski, M. Bedoui, K. Belhadj, P. Brugieres, C. Haioun. (2011) Clinical relevance of flow cytometric immunophenotyping of the cerebrospinal fluid in patients with diffuse large B-cell lymphoma. Annals of Oncology
CrossRef62
S. A. M. van de Schans, A. N. M. Wymenga, D. J. van Spronsen, H. C. Schouten, J. W. W. Coebergh, M. L. G. Janssen-Heijnen. (2011) Two sides of the medallion: poor treatment tolerance but better survival by standard chemotherapy in elderly patients with advanced-stage diffuse large B-cell lymphoma. Annals of Oncology
CrossRef63
M. Christina Cox, Vincenzo Ambrogi, Valerio Lanni, Elena Cavalieri, Sabrina Pelliccia, Francesco Scopinaro, Bruno Monarca, Paolo Marchetti, M. Antonietta Aloe Spiriti. (2011) Use of interim [ 18 F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy. Leukemia & Lymphoma1-7
CrossRef64
Hye Jin Kang, Won Seog Kim, Seok Jin Kim, Je-Jung Lee, Deok-Hwan Yang, Jin Seok Kim, Se-Ryeon Lee, Gyeong-Won Lee, Hyo Jung Kim, Ho Young Kim, Sung Yong Oh, Hugh Chul Kim, Hyeon-Seok Eom, Jooseop Chung, Jinny Park, Cheolwon Suh, Baek-Yeol Ryoo. (2011) Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. Annals of Hematology
CrossRef65
T. Aung, B. Chapuy, D. Vogel, D. Wenzel, M. Oppermann, M. Lahmann, T. Weinhage, K. Menck, T. Hupfeld, R. Koch, L. Trumper, G. G. Wulf. (2011) Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. Proceedings of the National Academy of Sciences 108:37, 15336-15341
CrossRef66
Xue-chun Lu, Bo Yang, Rui-li Yu, Xiao-hua Chi, Shuai Tuo, Chao-wei Tuo, Hong-li Zhu, Yao Wang, Chao-guang Jiang, Xiao-bing Fu, Yang Yang, Yang Liu, Shan-qian Yao, Han-ren Dai, Li-li Cai, Bing-jun Li, Wei-dong Han. (2011) Clinical Study of Autologous Cytokine-Induced Killer Cells for the Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma. Cell Biochemistry and Biophysics
CrossRef67
G. Compaci, L. Obéric, L. Ysebaert, C. Borel, G. Laurent. (2011) AMA (Assistance des malades ambulatoires) : une procédure de télémédecine appliquée à la prise en charge des lymphomes agressifs. Oncologie
CrossRef68
R. Delarue. (2011) Neutropénie et risque infectieux sous rituximab. Oncologie
CrossRef69
M. Ahlgrimm, M. Pfreundschuh, M. Kreuz, E. Regitz, K.-D. Preuss, J. Bittenbring. (2011) Impact of Fc-gamma receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab. Blood
CrossRef70
Yin-long Yang, Ting-ting Ye, Zhu-yin Wang, Er-li Gao, Lei-ping Wang, Peng Li, Xue-min Chen, Xiao-hua Zhang. (2011) Complete remission of primary bilateral adrenal lymphoma achieved by Rituximab-CHOP chemotherapy. Central European Journal of Medicine
CrossRef71
F. Merli, S. Luminari, G. Rossi, C. Mammi, L. Marcheselli, A. Tucci, F. Ilariucci, A. Chiappella, M. Musso, A. Di Rocco, C. Stelitano, I. Alvarez, L. Baldini, P. Mazza, F. Salvi, A. Arcari, A. Fragasso, P.G. Gobbi, A.M. Liberati, M. Federico. (2011) R-CHOP vs R-miniCEOP for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma. Results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi (IIL).. Leukemia & Lymphoma1-22
CrossRef72
Disni Muringampurath-John, Christopher R. Flowers, Michael Toscano, Chen Zhengjia, Jonathan Kaufmann, Martha Arellano, Leon Bernal-Mizrachi, Leonard T Heffner, Mary-Jo Lechowicz, Morgan McLemore, Elliott Winton, David L Jaye, Sagar Lonial, Hanna Jean Khoury. (2011) Rituximab-HyperCVAD for aggressive Non-Hodgkin's Lymphoma. Leukemia & Lymphoma1-7
CrossRef73
Ana Mozos, Gaël Roué, Armando López-Guillermo, Pedro Jares, Elias Campo, Dolors Colomer, Antonio Martinez. (2011) The Expression of the Endoplasmic Reticulum Stress Sensor BiP/GRP78 Predicts Response to Chemotherapy and Determines the Efficacy of Proteasome Inhibitors in Diffuse Large B-Cell Lymphoma. The American Journal of Pathology
CrossRef74
Michael Pfreundschuh, Evelyn Kuhnt, Lorenz Trümper, Anders Österborg, Marek Trneny, Lois Shepherd, Devinder S Gill, Jan Walewski, Ruth Pettengell, Ulrich Jaeger, Pier-Luigi Zinzani, Ofer Shpilberg, Stein Kvaloy, Peter de Nully Brown, Rolf Stahel, Noel Milpied, Armando López-Guillermo, Viola Poeschel, Sandra Grass, Markus Loeffler, Niels Murawski. (2011) CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. The Lancet Oncology
CrossRef75
Naoe Goto, Hisashi Tsurumi, Senji Kasahara, Nobuhiro Kanemura, Takeshi Hara, Ichiro Yasuda, Masahito Shimizu, Nobuo Murakami, Michio Sawada, Toshiki Yamada, Masao Takemura, Mitsuru Seishima, Yusuke Kito, Tsuyoshi Takami, Hisataka Moriwaki. (2011) Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens. European Journal of Haematology 87:3, 217-227
CrossRef76
Fernando Cabanillas. (2011) Rituximab in DLBCL: 6 years on. The Lancet Oncology
CrossRef77
Kensei Tobinai, Tadahiko Igarashi, Kuniaki Itoh, Mitsutoshi Kurosawa, Hirokazu Nagai, Akira Hiraoka, Tomohiro Kinoshita, Naokuni Uike, Michinori Ogura, Shigeru Nawano, Shigeo Mori, Yasuo Ohashi, . (2011) Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: A multicenter phase II study. Cancer Science 102:9, 1698-1705
CrossRef78
M. Cortés Romera, C. Gámez Cenzano, A.P. Caresia Aróztegui, J. Martín-Comín, E. González-Barca, Y. Ricart Brulles, A. Palacios Abufón, J. Robles Barba, L. Rodríguez-Bel, S. Rossi Seoane, A. Fernández de Sevilla. (2011) Utilidad de la PET-TC en la valoración de la respuesta precoz al tratamiento en el linfoma B difuso de celula grande. Resultados preliminares. Revista Española de Medicina Nuclear
CrossRef79
Klaus Bienemann, Birgit Burkhardt, Simon Modlich, Ulrike Meyer, Anja Möricke, Kirsten Bienemann, Christine Mauz-Körholz, Gabriele Escherich, Martin Zimmermann, Dieter Körholz, Gritta Janka-Schaub, Martin Schrappe, Alfred Reiter, Arndt Borkhardt. (2011) Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (Ataxia teleangiectasia or Nijmegen-breakage syndrome): a retrospective survey. British Journal of Haematologyno-no
CrossRef80
A. Pallardy, P. Soubeyran, C. Bodet-Milin, H. Maisonneuve, S. Le Gouill, C. Rousseau, A. Faivre-Chauvet, A.-L. Cazeau, E. Garin, J.-L. Baulieu, A. Brion, J.-P. Vuillez, T. Lamy, D.-M. Goldenberg, F. Kraeber-Bodéré. (2011) Consolidation par 90Y-epratuzumab en fractionné dans le lymphome B diffus à grandes cellules : résultats préliminaires d’une étude de phase II. Médecine Nucléaire 35:9, 478-486
CrossRef81
N. Boujelbene, N. Ketterer, N. Boujelbene, K. Khanfir, S. Bhagwati, E. Herrmann, R. O. Mirimanoff, M. Ozsahin, A. Zouhair. (2011) Mise au point sur le lymphome testiculaire primaire. Oncologie 13:9, 598-604
CrossRef82
Dieter Hoelzer, Nicola Gökbuget. (2011) Chemoimmunotherapy in acute lymphoblastic leukemia. Blood Reviews
CrossRef83
Vinochani Pillay, Hui K. Gan, Andrew M. Scott. (2011) Antibodies in oncology. New Biotechnology 28:5, 518-529
CrossRef84
Michinori Ogura, Kiyoshi Ando, Masafumi Taniwaki, Takashi Watanabe, Toshiki Uchida, Ken Ohmachi, Yosuke Matsumoto, Kensei Tobinai, . (2011) Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin’s lymphoma6. Cancer Science 102:9, 1687-1692
CrossRef85
Liang Wang, Panpan Liu, Qirong Geng, Xiaoqin Chen, Yue Lv. (2011) Prognostic significance of neuron-specific enolase in patients with diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy. Leukemia & Lymphoma 52:9, 1697-1703
CrossRef86
Robert Kridel, Pierre-Yves Dietrich. (2011) Prevention of CNS relapse in diffuse large B-cell lymphoma. The Lancet Oncology
CrossRef87
R. Griffiths, J. Mikhael, M. Gleeson, M. Danese, M. Dreyling. (2011) Addition of rituximab to chemotherapy alone as first-line therapy improves over-all survival in elderly patients with mantle cell lymphoma. Blood
CrossRef88
S Hasselblom, M Stenson, O Werlenius, M Sender, C Lewerin, U Hansson, H Nilsson-Ehle, P-O Andersson. (2011) Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era. Leukemia & Lymphoma1-17
CrossRef89
Christian Johannes Schmitt, Sascha Dietrich, Antony Dick Ho, Mathias Witzens-Harig. (2011) Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors. Annals of Hematology
CrossRef90
Hisashi Tsurumi, Takeshi Hara, Naoe Goto, Jun-ichi Kitagawa, Nobuhiro Kanemura, Takeshi Yoshikawa, Senji Kasahara, Hideko Goto, Kenji Fukuno, Toshiki Yamada, Michio Sawada, Masahito Shimizu, Takeshi Takahashi, Tsuyoshi Takami, Hisataka Moriwaki. (2011) A phase II study of rituximab combined with THP-COP regimen as a first-line therapy for patients with indolent B-cell lymphoma. Leukemia & Lymphoma1-20
CrossRef91
M. P. Chao, C. Tang, R. K. Pachynski, R. Chin, R. Majeti, I. L. Weissman. (2011) Extra-nodal dissemination of non-Hodgkin's lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood
CrossRef92
Tsutomu Tanaka, Kazuyuki Shimada, Kazuhito Yamamoto, Yoshiki Hirooka, Yasumasa Niwa, Isamu Sugiura, Kunio Kitamura, Hiroshi Kosugi, Tomohiro Kinoshita, Hidemi Goto, Shigeo Nakamura. (2011) Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan. Annals of Hematology
CrossRef93
A. A. Alizadeh, A. J. Gentles, A. J. Alencar, C. L. Liu, H. E. Kohrt, R. Houot, M. J. Goldstein, S. Zhao, Y. Natkunam, R. H. Advani, R. D. Gascoyne, J. Briones, R. J. Tibshirani, J. H. Myklebust, S. K. Plevritis, I. S. Lossos, R. Levy. (2011) Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood 118:5, 1350-1358
CrossRef94
J. A. Barnes, A. S. LaCasce, Y. Feng, C. E. Toomey, D. Neuberg, J. S. Michaelson, E. P. Hochberg, J. S. Abramson. (2011) Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Annals of Oncology 22:8, 1859-1864
CrossRef95
E. Weidmann, A. Neumann, F. Fauth, A. Atmaca, S. E. Al-Batran, C. Pauligk, E. Jager. (2011) Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Annals of Oncology 22:8, 1839-1844
CrossRef96
M. Pirani, R. Marcheselli, L. Marcheselli, A. Bari, M. Federico, S. Sacchi. (2011) Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis. Annals of Oncology 22:8, 1845-1858
CrossRef97
Suguru Fukuhara, Takashi Watanabe, Wataru Munakata, Masakazu Mori, Dai Maruyama, Sung-Won Kim, Yukio Kobayashi, Hirokazu Taniguchi, Akiko M. Maeshima, Ryuji Tanosaki, Yoshihiro Matsuno, Kensei Tobinai. (2011) Bulky disease has an impact on outcomes in primary diffuse large B-cell lymphoma of the breast: a retrospective analysis at a single institution. European Journal of Haematologyno-no
CrossRef98
Cinzia Pellegrini, Letizia Gandolfi, Federica Quirini, Pietro Ruggieri, Vittorio Stefoni, Enrico Derenzini, Alessandro Broccoli, Lisa Argnani, Stefano Pileri, Mario Mercuri, Michele Baccarani, Pier Luigi Zinzani. (2011) Primary Bone Lymphoma: Evaluation of Chemoimmunotherapy as Front-line Treatment in 21 Patients. Clinical Lymphoma Myeloma and Leukemia 11:4, 321-325
CrossRef99
Gisèle Compaci, Loic Ysebaert, Lucie Obéric, Hélène Derumeaux, Guy Laurent. (2011) Effectiveness of telephone support during chemotherapy in patients with diffuse large B cell lymphoma: The Ambulatory Medical Assistance (AMA) experience. International Journal of Nursing Studies 48:8, 926-932
CrossRef100
Bo Yang, Xue-chun Lu, Rui-li Yu, Xiao-hua Chi, Yang Liu, Yao Wang, Han-ren Dai, Hong-li Zhu, Li-li Cai, Wei-dong Han. (2011) Repeated transfusions of autologous cytokine-induced killer cells for treatment of haematological malignancies in elderly patients: a pilot clinical trial. Hematological Oncologyn/a-n/a
CrossRef101
Élie Azoulay, Alexandre Demoule, Samir Jaber, Achille Kouatchet, Anne-Pascale Meert, Laurent Papazian, Laurent Brochard. (2011) Palliative noninvasive ventilation in patients with acute respiratory failure. Intensive Care Medicine 37:8, 1250-1257
CrossRef102
S. Montes-Moreno, N. Martinez, B. Sanchez-Espiridion, R. Diaz Uriarte, M. E. Rodriguez, A. Saez, C. Montalban, G. Gomez, D. G. Pisano, J. F. Garcia, E. Conde, E. Gonzalez-Barca, A. Lopez, M. Mollejo, C. Grande, M. A. Martinez, C. Dunphy, E. D. Hsi, G. B. Rocque, J. Chang, R. S. Go, C. Visco, Z. Xu-Monette, K. H. Young, M. A. Piris. (2011) miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. Blood 118:4, 1034-1040
CrossRef103
K.-H. Heider, K. Kiefer, T. Zenz, M. Volden, S. Stilgenbauer, E. Ostermann, A. Baum, H. Lamche, Z. Kupcu, A. Jacobi, S. Muller, U. Hirt, G. R. Adolf, E. Borges. (2011) A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high pro-apoptotic activity for treatment of B-cell malignancies. Blood
CrossRef104
M. Kalac, L. Scotto, E. Marchi, J. Amengual, V. E. Seshan, G. Bhagat, N. Ulahannan, V. V. Leshchenko, A. M. Temkin, S. Parekh, B. Tycko, O. A. O'Connor. (2011) HDAC inhibitors and decitabine are highly synergistic and associated with unique gene expression and epigenetic profiles in models of DLBCL. Blood
CrossRef105
Manuel Gotti, Valeria Fiaccadori, Ercole Brusamolino. (2011) Diffuse large B-cell lymphoma: update on therapy and prognosis. Clinical Investigation 1:7, 989-997
CrossRef106
S. Tebra, K. Mahjoubi, K. Chaouach, A. Laatiri, N. Bouaouina. (2011) À propos de quatre cas de lymphome malin non hodgkinien primitif du cavum. Cancer/Radiothérapie 15:4, 338-341
CrossRef107
T. E. Witzig, J. M. Vose, P. L. Zinzani, C. B. Reeder, R. Buckstein, J. A. Polikoff, R. Bouabdallah, C. Haioun, H. Tilly, P. Guo, D. Pietronigro, A. L. Ervin-Haynes, M. S. Czuczman. (2011) An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Annals of Oncology 22:7, 1622-1627
CrossRef108
W. M. Tai, J. Chung, P. L. Tang, Y. X. Koo, X. Hou, K. W. Tay, R. Quek, M. Tao, S. T. Lim. (2011) Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Annals of Hematology 90:7, 809-818
CrossRef109
Yabing Cao, Yongsheng Lan, Jianfei Qian, Yuhuan Zheng, Sungyoul Hong, Haiyan Li, Michael Wang, Larry W. Kwak, Dongyu Lin, Jing Yang, Qing Yi. (2011) Targeting cell surface β2-microglobulin by pentameric IgM antibodies. British Journal of Haematology 154:1, 111-121
CrossRef110
David Christie, Keith Dear, Thai Le, Michael Barton, Andrew Wirth, David Porter, Daniel Roos, Gary Pratt. (2011) Limited Chemotherapy and Shrinking Field Radiotherapy for Osteolymphoma (Primary Bone Lymphoma): Results From the Trans-Tasman Radiation Oncology Group 99.04 and Australasian Leukaemia and Lymphoma Group LY02 Prospective Trial. International Journal of Radiation Oncology*Biology*Physics 80:4, 1164-1170
CrossRef111
Yujin Kobayashi, Katsuhiro Miura, Atsuko Hojo, Yoshihiro Hatta, Toshitake Tanaka, Daisuke Kurita, Noriyoshi Iriyama, Sumiko Kobayashi, Jin Takeuchi. (2011) Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma. Journal of Cancer Research and Clinical Oncology 137:7, 1079-1084
CrossRef112
Matteo Dell'olio, Rosario Potito scalzulli, Grazia Sanpaolo, Michele Nobile, Francesco Saverio mantuano, Antonio La sala, Giovanni D'arena, Eustachio Miraglia, Anna Lucania, Lucia Mastrullo, Cascavilla Nicola. (2011) Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma. Leukemia & Lymphoma 52:7, 1222-1229
CrossRef113
Katsuhiro Miura, Kazuhiro Takei, Sumiko Kobayashi, Satomi Kiso, Yukio Hirabayashi, Atsuko Hojo, Hitomi Kodaira, Mai Yagi, Daisuke Kurita, Yujin Kobayashi, Toshitake Tanaka, Noriyoshi Iriyama, Yoshihiro Hatta, Yoshimasa Kura, Tetsuo Yamazaki, Umihiko Sawada, Jin Takeuchi. (2011) An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma. International Journal of Hematology 94:1, 90-96
CrossRef114
Natacha Heutte, Corinne Haioun, Pierre Feugier, Bertrand Coiffier, Herve Tilly, Christophe Ferme, Jean Gabarre, Franck Morschhauser, Christian Gisselbrecht, Nicolas Mounier. (2011) Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant. Leukemia & Lymphoma 52:7, 1239-1248
CrossRef115
T.T.W. van Herpt, S.A.M. van de Schans, H.R. Haak, D.J. van Spronsen, M.W. Dercksen, M.L.G. Janssen-Heijnen. (2011) Treatment and outcome in non-Hodgkin's lymphoma patients with and without prevalent diabetes mellitus in a population-based cancer registry. Journal of Geriatric Oncology
CrossRef116
G S Nowakowski, B LaPlant, T M Habermann, C E Rivera, W R Macon, D J Inwards, I N Micallef, P B Johnston, L F Porrata, S M Ansell, R R Klebig, C B Reeder, T E Witzig. (2011) Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia
CrossRef117
Amrita Krishnan, Joycelynne M. Palmer, Ni-Chun Tsai, Jennifer R. Simpson, Auayporn Nademanee, Andrew Raubitschek, Sandra H. Thomas, Stephen J. Forman. (2011) Matched-Cohort Analysis of Autologous Hematopoietic Cell Transplantation with Radioimmunotherapy versus Total Body Irradiation–Based Conditioning for Poor-Risk Diffuse Large Cell Lymphoma. Biology of Blood and Marrow Transplantation
CrossRef118
Junshik Hong, Sanghui Park, Jinny Park, Hyung Sun Kim, Kyung-Hee Kim, Jeong Yeal Ahn, Min Young Rim, Minkyu Jung, Sun Jin Sym, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee. (2011) Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy. Leukemia & Lymphoma1-9
CrossRef119
G. Salles, D. de Jong, W. Xie, A. Rosenwald, M. Chhanabhai, P. Gaulard, W. Klapper, M. Calaminici, B. Sander, C. Thorns, E. Campo, T. Molina, A. Lee, M. Pfreundschuh, S. Horning, A. Lister, L. H. Sehn, J. Raemaekers, A. Hagenbeek, R. D. Gascoyne, E. Weller. (2011) Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 117:26, 7070-7078
CrossRef120
Shuzo Hamamoto, Keiichi Tozawa, Hideki Nishio, Noriyasu Kawai, Kenjiro Kohri. (2011) Successful treatment of primary malignant lymphoma of the penis by organ-preserving rituximab-containing chemotherapy. International Journal of Clinical Oncology
CrossRef121
Reem Karmali, Melissa L. Larson, James E. Wooldridge, Stephanie A. Gregory, Teresa O'Brien, Jamile M. Shammo, Katherine Bueschel, Parameswaran Venugopal. (2011) Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma. Leukemia & Lymphoma1-8
CrossRef122
I. N. M. Micallef, M. J. Maurer, G. A. Wiseman, D. A. Nikcevich, P. J. Kurtin, M. W. Cannon, D. G. Perez, G. S. Soori, B. K. Link, T. M. Habermann, T. E. Witzig. (2011) Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. Blood
CrossRef123
Chun-Jen Liu, Pei-Jer Chen, Ding-Shinn Chen, Jia-Horng Kao. (2011) Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. Hepatology International
CrossRef124
Luigi Marcheselli, Raffaella Marcheselli, Alessia Bari, ElianaValentina Liardo, Fortunato Morabito, Luca Baldini, Maura Brugiatelli, Francesco Merli, Nicola Di Renzo, Stefano Sacchi. (2011) Radiation therapy improves treatment outcome in patients with diffuselarge B-cell lymphoma. Leukemia & Lymphoma1-6
CrossRef125
Antonella Brunello, Rachna Kapoor, Martine Extermann. (2011) Hyperglycemia During Chemotherapy for Hematologic and Solid Tumors Is Correlated With Increased Toxicity. American Journal of Clinical Oncology 34:3, 292-296
CrossRef126
Erika Ramsdale, Sonali Smith. (2011) Old versus frail: why it matters in lymphoma. Leukemia & Lymphoma 52:6, 938-940
CrossRef127
A. Alaoua, G. Gilbert, N. Ghannouchi, M. Houchlef, A. Letaief, F. Bahri. (2011) Primary bilateral adrenal lymphoma revealed by hemophagocytic syndrome. Annales d'Endocrinologie 72:3, 247-250
CrossRef128
Eva Gimeno, Miquel Gómez, Juan Ramón González, Josep Comín, Alberto Alvarez-Larrán, Blanca Sánchez-González, Lluis Molina, Eva Domingo-Domenech, Francesc Garcia-Pallarols, Carmen Pedro, Eugenia Abella, Carles Vilaplana, Silvia de Sanjosé, Carlos Besses, Antonio Salar. (2011) NT-proBNP: A cardiac biomarker to assess prognosis in non-Hodgkin lymphoma. Leukemia Research 35:6, 715-720
CrossRef129
T. Melchardt, S. W. Hofbauer, R. Greil, G. Hopfinger. (2011) Novel agents in diffuse large B-cell lymphoma: A short update including ASH 2010. memo - Magazine of European Medical Oncology 4:2, 120-123
CrossRef130
Yasufumi Masaki, Miyuki Miki, Yue Sun, Takuji Nakamura, Haruka Iwao, Akio Nakajima, Nozomu Kurose, Tomoyuki Sakai, Zhe-Xiong Jin, Toshioki Sawaki, Takafumi Kawanami, Yoshimasa Fujita, Masao Tanaka, Toshihiro Fukushima, Yuko Hirose, Hisanori Umehara. (2011) High-dose methotrexate with R-CHOP therapy for the treatment of patients with primary central nervous system lymphoma. International Journal of Hematology 93:6, 720-726
CrossRef131
Rami S. Komrokji, Najla H. Al Ali, M.S. Beg, Malek M. Safa, Dana Rollison, Mohamed Kharfan-Dabaja, Celeste Bello, Jennifer Cultrera, Lubomir Sokol, Javier Pinilla-Ibarz, Eduardo M. Sotomayor. (2011) Outcome of Diffuse Large B-Cell Lymphoma in the United States Has Improved Over Time but Racial Disparities Remain: Review of SEER Data. Clinical Lymphoma Myeloma and Leukemia 11:3, 257-260
CrossRef132
Abdo Haddad, Dale Shepard. (2011) Geriatric Oncology and Palliative Medicine. Seminars in Oncology 38:3, 362-366
CrossRef133
N. Kawano, N. Yokota-Ikeda, S. Kawano, S. Yoshida, K. Yamashita, K. Kodama, S. Uezono, Y. Shimao, F. Kawano, A. Ueda. (2011) Successful treatment of non-Hodgkin's lymphoma with rituximab and dose-adjusted CHOP therapy in a patient with concomitant end-stage renal disease requiring haemodialysis. NDT Plus 4:3, 186-189
CrossRef134
L. Lee, L. Wang, M. Crump. (2011) Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points. Annals of Oncology 22:6, 1392-1403
CrossRef135
Aya Kita, Takahito Nakahara, Kentaro Yamanaka, Kenji Nakano, Mari Nakata, Masamichi Mori, Naoki Kaneko, Hiroshi Koutoku, Nobuyuki Izumisawa, Masao Sasamata. (2011) Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma. Leukemia Research 35:6, 787-792
CrossRef136
Vinod Kumar, Keitaro Matsuo, Atsushi Takahashi, Naoya Hosono, Tatsuhiko Tsunoda, Naoyuki Kamatani, Sun-Young Kong, Hidewaki Nakagawa, Ri Cui, Chizu Tanikawa, Masao Seto, Yasuo Morishima, Michiaki Kubo, Yusuke Nakamura, Koichi Matsuda. (2011) Common variants on 14q32 and 13q12 are associated with DLBCL susceptibility. Journal of Human Genetics 56:6, 436-439
CrossRef137
Pareen J. Shenoy, Neha Malik, Ajay Nooka, Rajni Sinha, Kevin C. Ward, Otis W. Brawley, Joseph Lipscomb, Christopher R. Flowers. (2011) Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer 117:11, 2530-2540
CrossRef138
Jiří Pavlů, Holger W. Auner, Sarah Ellis, Richard M. Szydlo, Chrissy Giles, Alejandro Contento, Amin Rahemtulla, Jane F. Apperley, Kikkeri Naresh, Donald H. MacDonald, Edward J. Kanfer. (2011) LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centre. Hematological Oncology 29:2, 75-80
CrossRef139
Brian K. Link, John Brooks, Kara Wright, Xiaoyun Pan, Margaret Voelker, Elizabeth Chrischilles. (2011) Diffuse large B-cell lymphoma in the elderly: diffusion of treatment with rituximab and survival advances with and without anthracyclines. Leukemia & Lymphoma 52:6, 994-1002
CrossRef140
Nazik Rayman, King H. Lam, Bronno van der Holt, Clara Koss, Joost van Leeuwen, Leo M. Budel, Andries H. Mulder, Pieter Sonneveld, Ruud Delwel. (2011) The expression of the peripheral cannabinoid receptor CB2 has no effect on clinical outcome in diffuse large B-cell lymphomas. European Journal of Haematology 86:6, 466-476
CrossRef141
K. Ohmachi, K. Tobinai, Y. Kobayashi, K. Itoh, M. Nakata, T. Shibata, Y. Morishima, M. Ogura, T. Suzuki, R. Ueda, K. Aikawa, S. Nakamura, H. Fukuda, M. Shimoyama, T. Hotta, . (2011) Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809. Annals of Oncology 22:6, 1382-1391
CrossRef142
N. Shikama, M. Oguchi, K. Isobe, K. Nakamura, Y. Tamaki, M. Hasegawa, T. Kodaira, S. Sasaki, Y. Kagami, . (2011) A Long-term Follow-up Study of Prospective 80%-dose CHOP Followed by Involved-field Radiotherapy in Elderly Lymphoma Patients. Japanese Journal of Clinical Oncology 41:6, 764-769
CrossRef143
Helen Marr, Gail L Jones, Graham H Jackson, Wendy Osborne. (2011) Diagnosis and management of haematological malignancies in older people. Reviews in Clinical Gerontology1-15
CrossRef144
Xiao-Qin Chen, Jie-Wen Peng, Gui-Nan Lin, Mei Li, Zhong-Jun Xia. (2011) The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy. Medical Oncology
CrossRef145
G. Gutierrez-Garcia, T. Cardesa-Salzmann, F. Climent, E. Gonzalez-Barca, S. Mercadal, J. L. Mate, J. M. Sancho, L. Arenillas, S. Serrano, L. Escoda, S. Martinez, A. Valera, A. Martinez, P. Jares, M. Pinyol, A. Garcia-Herrera, A. Martinez-Trillos, E. Gine, N. Villamor, E. Campo, L. Colomo, A. Lopez-Guillermo, . (2011) Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood 117:18, 4836-4843
CrossRef146
Frédéric Peyrade, Fabrice Jardin, Catherine Thieblemont, Antoine Thyss, Jean-François Emile, Sylvie Castaigne, Bertrand Coiffier, Corinne Haioun, Serge Bologna, Olivier Fitoussi, Gérard Lepeu, Christophe Fruchart, Dominique Bordessoule, Michel Blanc, Richard Delarue, Maud Janvier, Bruno Salles, Marc André, Marion Fournier, Philippe Gaulard, Hervé Tilly. (2011) Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. The Lancet Oncology 12:5, 460-468
CrossRef147
Thomas M. Habermann. (2011) ASH 2010 meeting report-top 10 clinically oriented abstracts in lymphoma. American Journal of Hematology 86:5, 446-449
CrossRef148
Alfred Haidenberger*, Sabine Fromm-Haidenberger*, Alexander Vries, Bela-Andre Popper, Michael Steurer, Ira Skvortsova, Johanna Kantner, Eberhard Gunsilius, Peter Lukas. (2011) Feasibility and Toxicity of Concomitant Radio/Immunotherapy with MabThera (Rituximab®) for Patients with Non-Hodkin's Lymphoma. Strahlentherapie und Onkologie 187:5, 300-305
CrossRef149
Sam Mayes, Nick Brown, Tim M Illidge. (2011) New antibody drug treatments for lymphoma. Expert Opinion on Biological Therapy 11:5, 623-640
CrossRef150
Michael Mian, Gianluca Gaidano, Annarita Conconi, Richard Tsang, Mary K. Gospodarowicz, Alessandro Rambaldi, Andrea Rossi, Elena Oldani, Massimo Federico, Stefano Luminari, Monica Bellei, Enrico M. Pogliani, Fausto Rossini, Maria Elena Cabrera, Maurizio Martelli, Armando Lopez-Guillermo, Mario Busetto, Franco Cavalli, Emanuele Zucca, Sergio Cortelazzo. (2011) High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study. Leukemia & Lymphoma 52:5, 823-832
CrossRef151
Tamás Schneider, Erika Tóth, József Lővey, Zsuzsanna Molnár, Beáta Deák, Erika Várady, Judit Csomor, András Matolcsy, Zsolt Lengyel, Klára Petri, István Gaudi, András Rosta. (2011) A primer mediastinalis lymphomák standard R-CHOP immun-kemoterápiás kezelése. Orvosi Hetilap 152:19, 735-742
CrossRef152
Corinne Haioun, Antonio Salar, Ruth Pettengell, Hans Erik Johnsen, Ulrich Duehrsen, Francesca Gaia Rossi, Gregor Verhoef, Matthias Schwenkglenks, Ulrich Jaeger, Lisa Hamilton, Beatriz Pujol, Pieternella Johanna Lugtenburg. (2011) Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ± rituximab chemotherapy: results from an observational study. Leukemia & Lymphoma 52:5, 796-803
CrossRef153
Pier Luigi Zinzani, Cinzia Pellegrini, Letizia Gandolfi, Vittorio Stefoni, Federica Quirini, Enrico Derenzini, Alessandro Broccoli, Lisa Argnani, Stefano Pileri, Michele Baccarani. (2011) Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial. Clinical Lymphoma Myeloma and Leukemia
CrossRef154
David G. Crockett, David G. Wagner, Sten Holmäng, Sonny L. Johansson, Henry T. Lynch. (2011) Upper Urinary Tract Carcinoma in Lynch Syndrome Cases. The Journal of Urology 185:5, 1627-1630
CrossRef155
W. Alduaij, A. Ivanov, J. Honeychurch, E. J. Cheadle, S. Potluri, S. H. Lim, K. Shimada, C. H. T. Chan, A. Tutt, S. A. Beers, M. J. Glennie, M. S. Cragg, T. M. Illidge. (2011) Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 117:17, 4519-4529
CrossRef156
S. A. M. van de Schans, D. E. Issa, O. Visser, P. Nooijen, P. C. Huijgens, H. E. Karim-Kos, M. L. G. Janssen-Heijnen, J. W. W. Coebergh. (2011) Diverging trends in incidence and mortality, and improved survival of non-Hodgkin's lymphoma, in the Netherlands, 1989-2007. Annals of Oncology
CrossRef157
A. O. Gang, C. Strom, M. Pedersen, F. d'Amore, L. M. Pedersen, A. Bukh, B. B. Pedersen, M. B. Moeller, L. S. Mortensen, O. V. Gadeberg, S. Ingeberg, T. Mourits-Andersen, S. Pulczynski, P. d. N. Brown. (2011) R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. Annals of Oncology
CrossRef158
Soranobu Ninomiya, Takeshi Hara, Hisashi Tsurumi, Masato Hoshi, Nobuhiro Kanemura, Naoe Goto, Senji Kasahara, Masahito Shimizu, Hiroyasu Ito, Kuniaki Saito, Yoshinobu Hirose, Tetsuya Yamada, Takeshi Takahashi, Mitsuru Seishima, Tsuyoshi Takami, Hisataka Moriwaki. (2011) Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP. Annals of Hematology 90:4, 409-416
CrossRef159
Wai Meng Tai, Daniel Quah, Swee Peng Yap, Sze Huey Tan, Tiffany Tang, Kuang Wei Tay, Yu Xuan Koo, Miriam Tao, Richard Quek, Soon Thye Lim. (2011) Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factors in 41 consecutive Asian patients. Leukemia & Lymphoma 52:4, 604-612
CrossRef160
Peter Borchmann, Raoul Herbrecht, Martin Wilhelm, Franck Morschhauser, Georg Heß, Paul Cernohous, Susan A. Veals, Jack W. Singer, Andreas Engert. (2011) Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma. Leukemia & Lymphoma 52:4, 620-628
CrossRef161
Lorenzo M. Leoni. (2011) The Evolving Role of Bendamustine in Lymphoid Malignancy: Understanding the Drug and Its Mechanism of Action—Introduction. Seminars in Hematology 48, S1-S3
CrossRef162
Richard R. Furman, Michael L. Grossbard, Jeffrey L. Johnson, Andrew L. Pecora, Peter A. Cassileth, Sin-Ho Jung, Bruce A. Peterson, Lee M. Nadler, Arnold Freedman, Ruthee-Lu Bayer, Nancy L. Bartlett, David D. Hurd, Bruce D. Cheson, For The Cancer Leukemia Group B And. (2011) A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leukemia & Lymphoma 52:4, 587-596
CrossRef163
John F. DiJoseph, Maureen M. Dougher, Deborah Y. Evans, Bin-Bing Zhou, Nitin K. Damle. (2011) Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP. Cancer Chemotherapy and Pharmacology 67:4, 741-749
CrossRef164
Susan E Krown. (2011) Cancer in Resource-Limited Settings. JAIDS Journal of Acquired Immune Deficiency Syndromes 56:4, 297-299
CrossRef165
Moses H Bateganya, Jeffrey Stanaway, Paula E Brentlinger, Amalia S Magaret, Anna Wald, Jackson Orem, Corey Casper. (2011) Predictors of Survival After a Diagnosis of Non-Hodgkin Lymphoma in a Resource-Limited Setting: A Retrospective Study on the Impact of HIV Infection and Its Treatment. JAIDS Journal of Acquired Immune Deficiency Syndromes 56:4, 312-319
CrossRef166
Chadi Nabhan, Nancy Davis, Jacob D. Bitran, Angel Galvez, Walter Fried, Kathy Tolzien, Susan Foss, Wendy M. Dewey, Parameswaran Venugopal. (2011) Efficacy and safety of clofarabine in relapsed and/or refractory non-hodgkin lymphoma, including rituximab-refractory patients. Cancer 117:7, 1490-1497
CrossRef167
Senji Kasahara, Takeshi Hara, Hisashi Tsurumi, Naoe Goto, Jun-Ichi Kitagawa, Nobuhiro Kanemura, Takeshi Yoshikawa, Hideko Goto, Kenji Fukuno, Toshiki Yamada, Michio Sawada, Takeshi Takahashi, Tsuyoshi Takami, Hisataka Moriwaki. (2011) Phase II study of the tetrahydropyranyl adriamycin–cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma. Leukemia & Lymphoma 52:4, 629-634
CrossRef168
A. Gutiérrez, F. Mestre, G. Pérez-Manga, J. Rodríguez. (2011) Diffuse large B-cell lymphoma in the older. Critical Reviews in Oncology/Hematology 78:1, 59-72
CrossRef169
Vaishali Bagalkot, Mi Kyung YU, Sangyong Jon. 2011. Nanoparticles for Combined Cancer Imaging and Therapy. , 565-592.
CrossRef170
W. Alduaij, T. M. Illidge. (2011) The future of anti-CD20 monoclonal antibodies: are we making progress?. Blood 117:11, 2993-3001
CrossRef171
Martha Romero, Josette Brière, Cédric Bazelaire, Christophe Lebœuf, Li Wang, Philippe Ratajczak, David Sibon, Eric Kerviler, Catherine Thieblemont, Anne Janin. (2011) Aflibercept-mediated early angiogenic changes in aggressive B-cell lymphoma. Cancer Chemotherapy and Pharmacology
CrossRef172
Pier Luigi Zinzani, Letizia Gandolfi, Alessandro Broccoli, Lisa Argnani, Stefano Fanti, Cinzia Pellegrini, Vittorio Stefoni, Enrico Derenzini, Federica Quirini, Michele Baccarani. (2011) Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. Cancer 117:5, 1010-1018
CrossRef173
Antonino Musolino, Daniela Boggiani, Michele Panebianco, Giovanna Vasini, Stefania Salvagni, Vittorio Franciosi, Andrea Ardizzoni. (2011) Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma. Cancer 117:5, 964-973
CrossRef174
Jon Kobashigawa, Maria G. Crespo-Leiro, Stephan M. Ensminger, Hermann Reichenspurner, Annalisa Angelini, Gerald Berry, Margaret Burke, Lawrence Czer, Nicola Hiemann, Abdallah G. Kfoury, Donna Mancini, Paul Mohacsi, Jignesh Patel, Naveen Pereira, Jeffrey L. Platt, Elaine F. Reed, Nancy Reinsmoen, E. Rene Rodriguez, Marlene L. Rose, Stuart D. Russell, Randy Starling, Nicole Suciu-Foca, Jose Tallaj, David O. Taylor, Adrian Van Bakel, Lori West, Adriana Zeevi, Andreas Zuckermann. (2011) Report from a consensus conference on antibody-mediated rejection in heart transplantation. The Journal of Heart and Lung Transplantation 30:3, 252-269
CrossRef175
Ahmad S Halwani, Brian K Link. (2011) Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin’s lymphoma. Expert Review of Anticancer Therapy 11:3, 443-455
CrossRef176
Eva Gimeno, Blanca Sánchez-González, Alberto Álvarez-Larrán, Carmen Pedro, Eugenia Abella, Josep Comín, Silvia Saumell, Francesc García-Pallarols, Miquel Gómez, Carles Besses, Antonio Salar. (2011) Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma. Leukemia Research 35:3, 358-362
CrossRef177
Toshiro Kurokawa, Makiko Hase, Naoko Tokuman, Takashi Yoshida. (2011) Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab. Hematological Oncology 29:1, 5-9
CrossRef178
Mary J. Ninan, Punit D. Wadhwa, Pankaj Gupta. (2011) Prognostication of diffuse large B-cell lymphoma in the rituximab era. Leukemia & Lymphoma 52:3, 360-373
CrossRef179
Dorte Tholstrup, Peter De nully brown, Jesper Jurlander, Palle Bekker jeppesen, Mogens Groenvold. (2011) Quality of life in patients with diffuse large B-cell lymphoma treated with dose-dense chemotherapy is only affected temporarily. Leukemia & Lymphoma 52:3, 400-408
CrossRef180
Thoraya Abdelhamid, Mohamed Samra, Hanan Ramadan, Marowa Mehessin, Nadia Mokhtar. (2011) Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: A retrospective study. Journal of the Egyptian National Cancer Institute 23:1, 17-24
CrossRef181
Riad Abès, Jean-Luc Teillaud. (2011) Modulation of tumor immunity by therapeutic monoclonal antibodies. Cancer and Metastasis Reviews 30:1, 111-124
CrossRef182
Sotirios Sachanas, Gerassimos A. Pangalis, Theodoros P. Vassilakopoulos, Penelope Korkolopoulou, Flora N. Kontopidou, Maria Athanasoulia, Xanthi Yiakoumis, Christina Kalpadakis, Georgios Georgiou, Stavroula Masouridis, Maria Moschogiannis, Pantelis Tsirkinidis, Vassiliki Pappis, Styliani I. Kokoris, Marina P. Siakantaris, Panayiotis Panayiotidis, Maria K. Angelopoulou. (2011) Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen. Leukemia & Lymphoma 52:3, 387-393
CrossRef183
Roch Houot, Holbrook Kohrt, Matthew J. Goldstein, Ronald Levy. (2011) Immunomodulating antibodies and drugs for the treatment of hematological malignancies. Cancer and Metastasis Reviews 30:1, 97-109
CrossRef184
V Roland, C Bodet-Milin, A Moreau, T Gastinne, B Mahé, V Dubruille, H Maisonneuve, N Juge-Morineau, P Moreau, H Jardel, L Planche, M Mohty, P Moreau, J-L Harousseau, F Kraeber-Bodéré, S Le Gouill. (2011) Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients. Bone Marrow Transplantation 46:3, 393-399
CrossRef185
George Dranitsaris, Ilse Truter, Martie S. Lubbe, Eitan Amir, William Evans. (2011) Advances in Cancer Therapeutics and Patient Access to New Drugs. PharmacoEconomics 29:3, 213-224
CrossRef186
A D'Addio, A Curti, N Worel, K Douglas, M R Motta, S Rizzi, E Dan, S Taioli, V Giudice, H Agis, G Kopetzky, R Soutar, B Casadei, M Baccarani, R M Lemoli. (2011) The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplantation 46:3, 356-363
CrossRef187
Zi Chen, Zunguo Du, Jieqing Chen, Zhongqing Chen, Yun Bao, Feng Tang. (2011) Prognostic evaluation of immunohistochemical profiles in diffuse large B-cell lymphoma: a Chinese study. Medical Oncology 28:1, 241-248
CrossRef188
A.K. Alameddine, V.K. Alimov, J.E. Flack, J.A. Rousou. (2011) Is There a Role for Surgery in the Management of Giant B-Cell Right Atrial Lymphoma?. Journal of Cardiac Surgery 26:2, 166-168
CrossRef189
Daan Dierickx, André Delannoy, Khalid Saja, Gregor Verhoef, Drew Provan. (2011) Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders. American Journal of Hematology 86:3, 278-291
CrossRef190
Celso Arrais Rodrigues, Poliana Alves Patah, Yana A. S. Novis, Chitra Hosing, Marcos Lima. (2011) The Role of Transplantation in Diffuse Large B-Cell Lymphoma: The Impact of Rituximab Plus Chemotherapy in First-line and Relapsed Settings. Current Hematologic Malignancy Reports 6:1, 47-57
CrossRef191
Jorge Méndez-Navarro, Kathleen E. Corey, Hui Zheng, Lydia L. Barlow, Jae Young Jang, Wenyu Lin, Hong Zhao, Run-Xuan Shao, Steven L. McAfee, Raymond T. Chung. (2011) Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver International 31:3, 330-339
CrossRef192
H. E. Kohrt, R. Houot, M. J. Goldstein, K. Weiskopf, A. A. Alizadeh, J. Brody, A. Muller, R. Pachynski, D. Czerwinski, S. Coutre, M. P. Chao, L. Chen, T. F. Tedder, R. Levy. (2011) CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 117:8, 2423-2432
CrossRef193
Meenu Singh, Rashmi R Das, Meenu Singh. 2011. Zinc for the common cold. .
CrossRef194
Jasvinder A Singh, George A Wells, Robin Christensen, Elizabeth Tanjong Ghogomu, Lara Maxwell, John K MacDonald, Graziella Filippini, Nicole Skoetz, Damian Francis, Luciane C Lopes, Gordon H Guyatt, Jochen Schmitt, Loredana La Mantia, Tobias Weberschock, Juliana F Roos, Hendrik Siebert, Sarah Hershan, Michael PT Lunn, Peter Tugwell, Rachelle Buchbinder, Jasvinder A Singh. 2011. Adverse effects of biologics: a network meta-analysis and Cochrane overview. .
CrossRef195
S. J. Kim, H. J. Kang, J. S. Kim, S. Y. Oh, C. W. Choi, S. I. Lee, J. H. Won, M. K. Kim, J. H. Kwon, Y.-C. Mun, J.-Y. Kwak, J. M. Kwon, I. G. Hwang, H. J. Kim, J. Park, S. Oh, J. Huh, Y. H. Ko, C. Suh, W. S. Kim. (2011) Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone. Blood 117:6, 1958-1965
CrossRef196
Daniel Morgensztern, Gail R. Walker, Leonidas G. Koniaris, Izidore S. Lossos. (2011) Lack of survival improvement in patients with peripheral T-cell lymphoma: a Surveillance, Epidemiology, and End Results analysis. Leukemia & Lymphoma 52:2, 194-204
CrossRef197
Gillian M. Keating. (2011) Spotlight on Rituximab in Chronic Lymphocytic Leukemia, Low-Grade or Follicular Lymphoma, and Diffuse Large B-Cell Lymphoma†. BioDrugs 25:1, 55-61
CrossRef198
Anas Younes. (2011) Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nature Reviews Clinical Oncology 8:2, 85-96
CrossRef199
Robert O. Dillman. (2011) Cancer Immunotherapy. Cancer Biotherapy & Radiopharmaceuticals 26:1, 1-64
CrossRef200
Sari Riihijärvi, Minna Taskinen, Mats Jerkeman, Sirpa Leppä. (2011) Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy*. European Journal of Haematology 86:2, 124-128
CrossRef201
Sonia Novotny, Toya Ellis, Janet Stephens. (2011) Primary B-Cell Lymphoma of the Cervix Presenting With Bilateral Hydronephrosis. Obstetrics & Gynecology 117:2, Part 2, 444-446
CrossRef202
S D Smith, B J Bolwell, L A Rybicki, T Kang, R Dean, A Advani, S Thakkar, R Sobecks, M Kalaycio, B Pohlman, J W Sweetenham. (2011) Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab. Bone Marrow Transplantation 46:2, 262-266
CrossRef203
Hirokazu Nagai, Michinori Ogura, Shigeru Kusumoto, Naoto Takahashi, Motoko Yamaguchi, Nobuyuki Takayama, Tomohiro Kinoshita, Toshiko Motoji, Kazuma Ohyashiki, Hiroshi Kosugi, Shin Matsuda, Kazunori Ohnishi, Ken Omachi, Tomomitsu Hotta. (2011) Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma. European Journal of Haematology 86:2, 117-123
CrossRef204
Bjoern Chapuy, Nikolai Schuelper, Melanie Panse, Andrea Dohm, Elisabeth Hand, Roland Schroers, Lorenz Truemper, Gerald G. Wulf. (2011) Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation. British Journal of Haematology 152:4, 401-412
CrossRef205
Jun Ho Yi, Seok Jin Kim, Young Hyeh Ko, Won Seog Kim. (2011) Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy. Leukemia & Lymphoma 52:2, 317-320
CrossRef206
Fang Ko, Prem S. Subramanian. (2011) Orbital and Cavernous Sinus Lymphoma Masquerading as Post-Herpetic Neuralgia. Neuro-Ophthalmology 35:1, 27-31
CrossRef207
Omid Farokhzad, Robert S. Langer. (2011) Nanoparticle Delivery of Cancer Drugs. Annual Review of Medicine 63:1, 110301100719093
CrossRef208
Anita Kumar, Ann Vanderplas, Ann S. LaCasce, Maria A. Rodriguez, Allison L. Crosby, Eva Lepisto, Myron S. Czuczman, Auayporn Nademanee, Joyce Niland, Leo I. Gordon, Michael Millenson, Andrew D. Zelenetz, Jonathan W. Friedberg, Gregory A. Abel. (2011) Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era. Cancern/a-n/a
CrossRef209
Shigeru Kusumoto, Yasuhito Tanaka, Ryuzo Ueda, Masashi Mizokami. (2011) Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. Journal of Gastroenterology 46:1, 9-16
CrossRef210
Hiroki Yamaguchi, Tsuneaki Hirakawa, Koiti Inokuchi. (2011) Importance of Relative Dose Intensity in Chemotherapy for Diffuse Large B-Cell Lymphoma. Journal of Clinical and Experimental Hematopathology 51:1, 1-5
CrossRef211
Mison Chun, Sunmi Jo. (2011) Radiotherapy in Elderly Patients with Cancer. The Journal of the Korean Society for Therapeutic Radiology and Oncology 29:1, 1
CrossRef212
Ho-Young Yhim, Jin Seok Kim, Hye Jin Kang, Seok Jin Kim, Won Seog Kim, Chul Won Choi, Hyeon Seok Eom, Jeong-A. Kim, Jae Hoon Lee, Jong Ho Won, Hyeok Shim, Jooryung Huh, Dae-Ho Lee, Cheolwon Suh, Jae-Yong Kwak. (2011) Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy. International Journal of Cancern/a-n/a
CrossRef213
Seok Jin Kim. (2011) A therapeutic dilemma between the two "R"s: additional rituximab or radiotherapy for limited, non-bulky diffuse large B-cell lymphoma. The Korean Journal of Hematology 46:1, 57
CrossRef214
Takayoshi Tachibana, Naoto Tomita, Mitsuko Furuya, Shoji Yamanaka, Kengo Takeuchi, Naoya Nakamura, Hiroyuki Fujita, Yoshiaki Ishigatsubo. (2011) Aberrant CD20 Expression in Angioimmunoblastic T-cell Lymphoma. Internal Medicine 50:5, 495-499
CrossRef215
Taketo Yamada. (2011) Therapeutic Monoclonal Antibodies. The Keio Journal of Medicine 60:2, 37-46
CrossRef216
Ning-Ning Lu, Ye-Xiong Li, Wei-Hu Wang, Jing Jin, Yong-Wen Song, Li-Qiang Zhou, Shu-Lian Wang, Yue-Ping Liu, Xin-Fan Liu, Zi-Hao Yu. (2011) Clinical behavior and treatment outcome of primary nasal diffuse large B-cell lymphoma. Cancern/a-n/a
CrossRef217
Bo Guo, Hong-Li Zhu, Su-Xia Li, Xue-Chun Lu, Hui Fan. (2011) Individualized Liposomal Doxorubicin-Based Treatment in Elderly Patients with Non-Hodgkin’s Lymphoma. Onkologie 34:4, 184-188
CrossRef218
Carl Ruoff, Louay Hanna, Wanqing Zhi, Ghulamullah Shahzad, Vladimir Gotlieb, Muhammad Wasif Saif. (2011) Cancers of the Appendix: Review of the Literatures. ISRN Oncology 2011, 1-6
CrossRef219
Min Jung Suh, Dong Choon Park. (2011) A case of primary malignant lymphoma of the uterus. Korean Journal of Obstetrics 54:1, 57
CrossRef220
Theodoros Kelesidis, George Daikos, Dimitrios Boumpas, Sotirios Tsiodras. (2011) Does rituximab increase the incidence of infectious complications? A narrative review. International Journal of Infectious Diseases 15:1, e2-e16
CrossRef221
Tomoaki Akagi, Naoto Takahashi, Kouhei Yamaguchi, Kenichi Ishizawa, Kazunori Murai, Katsushi Tajima, Kazuhiko Ikeda, Yoshihiro Kameoka, Junnichi Kameoka, Shigeki Ito, Yuichi Kato, Hideyoshi Noji, Tsutomu Shichishima, Jugoh Itoh, Ryo Ichinohasama, Hideo Harigae, Yoji Ishida, Kenichi Sawada. (2011) Comparison of Long-Term Clinical Outcomes of CHOP Chemotherapy between Japanese Patients with Nodal Peripheral T-Cell Lymphomas and Those with Diffuse Large B-Cell Lymphoma in the Study Group of the Tohoku Hematology Forum. Journal of Clinical and Experimental Hematopathology 51:1, 29-35
CrossRef222
Abeer N. AbouYabis, Pareen J. Shenoy, Rajni Sinha, Christopher R. Flowers, Mary Jo Lechowicz. (2011) A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma. ISRN Hematology 2011, 1-14
CrossRef223
Geundoo Jang, Dok Hyun Yoon, Shin Kim, Dae Ho Lee, Sang-wook Lee, Jooryung Huh, Cheolwon Suh. (2011) Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma. The Korean Journal of Hematology 46:2, 103
CrossRef224
Daisuke Ennishi, Mitsune Tanimoto. (2011) Hepatic toxicity and prognosis in HCV-infected patients with diffuse large B-cell lymphoma in the rituximab era. Okayama Igakkai Zasshi (Journal of Okayama Medical Association) 123:2, 85-89
CrossRef225
Laura Bourdeanu, Rashmi Menon, George Somlo. (2011) Diffuse Large B-Cell Lymphoma with Calf Muscle Localization. Case Reports in Hematology 2011, 1-3
CrossRef226
Francesco Gaudio, Annamaria Giordano, Tommasina Perrone, Domenico Pastore, Paola Curci, Mario Delia, Anna Napoli, Clara de’ Risi, Alessandro Spina, Rosalia Ricco, Vincenzo Liso, Giorgina Specchia. (2011) High Ki67 Index and Bulky Disease Remain Significant Adverse Prognostic Factors in Patients with Diffuse Large B Cell Lymphoma before and after the Introduction of Rituximab. Acta Haematologica 126:1, 44-51
CrossRef227
Yukiko Miura, Noriko Fukuhara, Joji Yamamoto, Katsura Kohata, Kenichi Ishizawa, Ryo Ichinohasama, Hideo Harigae. (2011) Clinicopathological Features of Malignant Lymphoma in Japan: The Miyagi Study. The Tohoku Journal of Experimental Medicine 224:2, 151-160
CrossRef228
Sajir G. Mohamedbhai, Keith Sibson, Teresa Marafioti, Irfan Kayani, Lisa Lowry, Anthony H. Goldstone, David C. Linch, Kirit M. Ardeshna. (2011) Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%. British Journal of Haematology 152:2, 175-181
CrossRef229
Takashi Ishida, Ryuzo Ueda. (2011) Immunopathogenesis of lymphoma: Focus on CCR4. Cancer Science 102:1, 44-50
CrossRef230
Erika E Samlowski, Christopher Dechet, Alan Weissman, Wolfram E Samlowski. (2011) Large cell non-Hodgkin's lymphoma masquerading as renal carcinoma with inferior vena cava thrombosis: a case report. Journal of Medical Case Reports 5:1, 245
CrossRef231
Keni Gu, Dennis D Weisenburger, Kai Fu, Wing C Chan, Timothy C Greiner, Patricia Aoun, Lynette M Smith, Martin Bast, Zhongfen Liu, R. Gregory Bociek. (2011) Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation : Survival in DLBCL after transplantation. Hematological Oncologyn/a
CrossRef232
Chieh Lin, Emmanuel Itti, Alain Luciani, Benhalima Zegai, Shih-jui Lin, Frédérique Kuhnowski, Frédéric Pigneur, Isabelle Gaillard, Gaetano Paone, Michel Meignan, Corinne Haioun, Alain Rahmouni. (2011) Whole-Body Diffusion-Weighted Imaging With Apparent Diffusion Coefficient Mapping for Treatment Response Assessment in Patients With Diffuse Large B-Cell Lymphoma. Investigative Radiology1
CrossRef233
Rangaiah Shashidharamurthy, Erica N. Bozeman, Jaina Patel, Ramneet Kaur, Jeyandra Meganathan, Periasamy Selvaraj. (2011) Immunotherapeutic strategies for cancer treatment: A novel protein transfer approach for cancer vaccine development. Medicinal Research Reviewsn/a-n/a
CrossRef234
Mineko Murakami, Takamitsu Fujimaki, Shuichiro Asano, Hiroshi Nakaguchi, Shoko M. Yamada, Katsumi Hoya, Kazuto Yamazaki, Yasuo Ishida, Akira Matsuno. (2011) Combination Therapy with Rituximab and Temozolomide for Recurrent and Refractory Primary Central Nervous System Lymphoma. Yonsei Medical Journal 52:6, 1031
CrossRef235
R Pettengell, M Schwenkglenks, P Bacon, S Lawrinson, U Duehrsen. (2011) Pegfilgrastim primary prophylaxis in patients with non-Hodgkin lymphoma: results from an integrated analysis. Hematological Oncologyn/a-n/a
CrossRef236
Pairaya Rujirojindakul, Kumpol Aiempanakit, Kanita Kayasut, Arnuparp Lekhakula, Hutcha Sriplung. (2011) No Prognostic Impact of p53 and P-Glycoprotein Expression in Patients with Diffuse Large B-Cell Lymphoma. ISRN Oncology 2011, 1-6
CrossRef237
Kimberley Jones, Jamie P. Nourse, Colm Keane, Pauline Crooks, David Gottlieb, David S. Ritchie, Devinder Gill, Maher K. Gandhi. (2011) Tumor-specific but not non-specific cell-free circulating DNA can be used to monitor disease response in lymphoma. American Journal of Hematologyn/a-n/a
CrossRef238
Young Sin Ko, Young Ha Oh, Chan Kum Park, Wook Youn Kim, Hye Seung Han, So Dug Lim, Tae Sook Hwang, Wan Seop Kim. (2011) Prognostic Implication of Programmed Death-1-Positive Tumor-infiltrating Lymphocytes in Diffuse Large B-Cell Lymphoma. The Korean Journal of Pathology 45:6, 573
CrossRef239
Elizabeth A. Brem, Karen Thudium, Sapna Khubchandani, Ping-Chiao Tsai, Scott H. Olejniczak, Seema Bhat, Wasif Riaz, Jenny Gu, Arshad Iqbal, Ryan Campagna. (2011) Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas : Overcoming Rituximab Chemotherapy-Resistance with Obatoclax. British Journal of Haematology 153:5, 599
CrossRef240
Masayuki Kikukawa. (2011) Hematological malignancies in the elderly. Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 48:6, 622-625
CrossRef241
S. H. Olejniczak, J. Blickwedehl, A. Belicha-Villanueva, N. Bangia, W. Riaz, C. Mavis, J. L. Clements, J. Gibbs, F. J. Hernandez-Ilizaliturri, M. S. Czuczman. (2010) Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells. Blood 116:25, 5605-5614
CrossRef242
Pier Luigi Zinzani, Alessandro Broccoli, Vittorio Stefoni, Gerardo Musuraca, Elisabetta Abruzzese, Amalia De Renzo, Maria Cantonetti, Francesco Bacci, Michele Baccarani, Stefano A. Pileri. (2010) Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. Cancer 116:24, 5667-5675
CrossRef243
D. Rossi, S. Rasi, A. Di Rocco, A. Fabbri, F. Forconi, A. Gloghini, A. Bruscaggin, S. Franceschetti, M. Fangazio, L. De Paoli, R. Bruna, D. Capello, A. Chiappella, C. Lobetti Bodoni, M. Giachelia, M. C. Tisi, E. M. Pogliani, F. Lauria, M. Ladetto, S. Hohaus, M. Martelli, U. Vitolo, A. Carbone, R. Foa, G. Gaidano. (2010) The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma. Blood
CrossRef244
M. Pfreundschuh. (2010) How I treat elderly patients with diffuse large B-cell lymphoma. Blood 116:24, 5103-5110
CrossRef245
D. Ennishi, Y. Maeda, N. Niitsu, M. Kojima, K. Izutsu, J. Takizawa, S. Kusumoto, M. Okamoto, M. Yokoyama, Y. Takamatsu, K. Sunami, A. Miyata, K. Murayama, A. Sakai, M. Matsumoto, K. Shinagawa, A. Takaki, K. Matsuo, T. Kinoshita, M. Tanimoto. (2010) Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 116:24, 5119-5125
CrossRef246
Donald M. Arnold, Mark A. Crowther, Ralph M. Meyer, Julie Carruthers, Julie DiTomasso, Nancy M. Heddle, Anne McLeod, John G. Kelton. (2010) Misleading hepatitis B test results due to intravenous immunoglobulin administration: implications for a clinical trial of rituximab in immune thrombocytopenia. Transfusion 50:12, 2577-2581
CrossRef247
Fumihiko Sato, Asahi Ito, Takashi Ishida, Fumiko Mori, Hisashi Takino, Atsushi Inagaki, Masaki Ri, Shigeru Kusumoto, Hirokazu Komatsu, Shinsuke Iida, Noriko Okada, Hiroshi Inagaki, Ryuzo Ueda. (2010) A complement-dependent cytotoxicity-enhancing anti-CD20 antibody mediating potent antitumor activity in the humanized NOD/Shi-scid, IL-2Rγnull mouse lymphoma model. Cancer Immunology, Immunotherapy 59:12, 1791-1800
CrossRef248
Dai Maruyama, Takashi Watanabe, Akiko Miyagi Maeshima, Junko Nomoto, Hirokazu Taniguchi, Teruhisa Azuma, Masakazu Mori, Wataru Munakata, Sung-Won Kim, Yukio Kobayashi, Yoshihiro Matsuno, Kensei Tobinai. (2010) Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. International Journal of Hematology 92:5, 732-743
CrossRef249
Lisa C. Thomas, Christian Adonizio, Joanne Filicko-O'Hara, Ali R. Golshayan, Luciano J. Costa, Gloria J. Morris. (2010) Testicular Lymphoma. Seminars in Oncology 37:6, 549-554
CrossRef250
Kensei Tobinai, Michinori Ogura, Kuniaki Itoh, Tomohiro Kinoshita, Tomomitsu Hotta, Takashi Watanabe, Yasuo Morishima, Tadahiko Igarashi, Takashi Terauchi, Yasuo Ohashi, . (2010) Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results. Cancer Science 101:12, 2579-2585
CrossRef251
Christopher R. Flowers, James O. Armitage. (2010) A Decade of Progress in Lymphoma: Advances and Continuing Challenges. Clinical Lymphoma, Myeloma & Leukemia 10:6, 414-423
CrossRef252
D. Dornan, O. Spleiss, R.-F. Yeh, G. Duchateau-Nguyen, A. Dufour, J. Zhi, T. Robak, S. I. Moiseev, A. Dmoszynska, P. Solal-Celigny, K. Warzocha, J. Loscertales, J. Catalano, B. V. Afanasiev, L. Larratt, V. A. Rossiev, I. Bence-Bruckler, C. H. Geisler, M. Montillo, M. K. Wenger, M. Weisser. (2010) Effect of FCGR2A and FCGR3A variants on CLL outcome. Blood 116:20, 4212-4222
CrossRef253
S. I. Park, J. Shenoi, J. M. Pagel, D. K. Hamlin, D. S. Wilbur, N. Orgun, A. L. Kenoyer, S. Frayo, A. Axtman, T. Back, Y. Lin, D. R. Fisher, A. K. Gopal, D. J. Green, O. W. Press. (2010) Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood 116:20, 4231-4239
CrossRef254
N. Schmitz, L. Trumper, M. Ziepert, M. Nickelsen, A. D. Ho, B. Metzner, N. Peter, M. Loeffler, A. Rosenwald, M. Pfreundschuh. (2010) Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 116:18, 3418-3425
CrossRef255
Julie M. Vose, Dennis D. Weisenburger, Fausto R. Loberiza, Alejandro Arevalo, Martin Bast, Joel Armitage, Philip J. Bierman, Robert G. Bociek, James O. Armitage. (2010) Late relapse in patients with diffuse large B-cell lymphoma. British Journal of Haematology 151:4, 354-358
CrossRef256
Kyoko Hanzawa, Shuji Momose, Morihiro Higashi, Michihide Tokuhira, Reiko Watanabe, Kazunori Kajino, Okio Hino, Shinji Itoyama, Masahiro Kizaki, Jun-Ichi Tamaru. (2010) Y-box binding protein-1 expression in diffuse large B-cell lymphoma: an impact on prognosis in the rituximab era. Leukemia & Lymphoma 51:11, 2054-2062
CrossRef257
Fernando Cabanillas. (2010) Front-line management of diffuse large B cell lymphoma. Current Opinion in Oncology 22:6, 642-645
CrossRef258
P. Borentain, P. Colson, D. Coso, E. Bories, A. Charbonnier, A. M. Stoppa, T. Auran, A. Loundou, A. Motte, E. Ressiot, E. Norguet, C. Chabannon, R. Bouabdallah, C. Tamalet, R. Gérolami. (2010) Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer. Journal of Viral Hepatitis 17:11, 807-815
CrossRef259
Hatem A Azim Jr, Hamdy Azim, Fedro A Peccatori. (2010) Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge. Expert Review of Clinical Immunology 6:6, 821-826
CrossRef260
Kevin Yi-Lwern Yap, Yasmin Xiu Xiu Ho, Wai Keung Chui, Alexandre Chan. (2010) Harnessing the internet cloud for managing drug interactions with chemotherapy regimens in patients with cancer suffering from depression. Acta Oncologica 49:8, 1235-1245
CrossRef261
José Gómez Codina, Pilar Sabín Domínguez, Mariano Provencio Pulla, Antonio Rueda Domínguez, Dolores Isla Casado. (2010) SEOM clinical guidelines for the treatment of diffuse large B-cell lymphoma. Clinical and Translational Oncology 12:11, 765-769
CrossRef262
B. Glass, M. Ziepert, M. Reiser, M. Freund, L. Trumper, B. Metzner, A. Feller, M. Loeffler, M. Pfreundschuh, N. Schmitz, . (2010) High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. Annals of Oncology 21:11, 2255-2261
CrossRef263
Belinda Lee, Mark Bower, Thomas Newsom-Davis, Mark Nelson. (2010) HIV-related lymphoma. HIV Therapy 4:6, 649-659
CrossRef264
Mariano Provencio, Paloma Martín, Vanesa García, Antonio Candia, Antonio C. Sánchez, Carmen Bellas. (2010) Caspase 3a: new prognostic marker for diffuse large B-cell lymphoma in the rituximab era. Leukemia & Lymphoma 51:11, 2021-2030
CrossRef265
Niels Murawski, Michael Pfreundschuh. (2010) New drugs for aggressive B-cell and T-cell lymphomas. The Lancet Oncology 11:11, 1074-1085
CrossRef266
Kosei Matsue, Shun-Ichi Kimura, Yoko Takanashi, Kan-Ichi Iwama, Hideaki Fujiwara, Masayuki Yamakura, Masami Takeuchi. (2010) Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 116:20, 4769-4776
CrossRef267
Kenji Hashimoto, Yukio Kobayashi, Yoshitaka Asakura, Masakazu Mori, Teruhisa Azuma, Dai Maruyama, Sung-Won Kim, Takashi Watanabe, Kensei Tobinai. (2010) Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy. Leukemia & Lymphoma 51:10, 1816-1821
CrossRef268
Julie E. Chang, Songwong Seo, Kyungmann M. Kim, Jae E. Werndli, Wayne A. Bottner, Gilberto A. Rodrigues, Federico A. Sanchez, Thomas J. Saphner, Walter L. Longo, Brad S. Kahl. (2010) Rituximab and CHOP Chemotherapy Plus GM-CSF for Previously Untreated Diffuse Large B-Cell Lymphoma in the Elderly: A Wisconsin Oncology Network Study. Clinical Lymphoma, Myeloma & Leukemia 10:5, 379-384
CrossRef269
Ranjana H. Advani, Haiyan Chen, Thomas M. Habermann, Vicki A. Morrison, Edie A. Weller, Richard I. Fisher, Bruce A. Peterson, Randy D. Gascoyne, Sandra J. Horning, , , . (2010) Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic in. British Journal of Haematology 151:2, 143-151
CrossRef270
Lia Gore, Tanya M. Trippett. (2010) Emerging Non-transplant-based Strategies in Treating Pediatric Non-Hodgkin’s Lymphoma. Current Hematologic Malignancy Reports 5:4, 177-184
CrossRef271
Byung-Jo Kim, Ha-Rim Park, Hak Jae Roh, Du-Shin Jeong, Byung Soo Kim, Kun-Woo Park, S. Charles Cho, Yuen T. So, Sung Yong Oh, Seok Jin Kim. (2010) Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma. Quality of Life Research 19:8, 1097-1103
CrossRef272
Masaaki Hiura, Ryo Onizuka, Ryoichi Narita, Shintaro Abe, Akinari Tabaru, Masaru Harada. (2010) A case of severe acute hepatitis C and delayed antibody production due to rituximab therapy. Clinical Journal of Gastroenterology 3:5, 254-258
CrossRef273
N. Niitsu, M. Okamoto, J.- i. Tamaru, T. Yoshino, N. Nakamura, S. Nakamura, K. Ohshima, H. Nakamine, M. Hirano. (2010) Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma. Annals of Oncology 21:10, 2069-2074
CrossRef274
Moo-Kon Song, Joo-Seop Chung, Oh Sung-Yong, Gyeong-Won Lee, Seung-Geun Kim, Young-Mi Seol, Ho-Jin Shin, Young-Jin Choi, Goon-Jae Cho, Dong-Hoon Shin, Eun-Young Yun. (2010) Clinical impact of bulky mass in the patient with primary extranodal diffuse large B cell lymphoma treated with R-CHOP therapy. Annals of Hematology 89:10, 985-991
CrossRef275
Fatma V. Okur, Robert Krance. (2010) Stem Cell Transplantation in Childhood Non-Hodgkin’s Lymphomas. Current Hematologic Malignancy Reports 5:4, 192-199
CrossRef276
Jeong Il Yu, Heerim Nam, Yong Chan Ahn, Won Seog Kim, Keunchil Park, Seok Jin Kim. (2010) Involved-Lesion Radiation Therapy After Chemotherapy in Limited-Stage Head-and-Neck Diffuse Large B Cell Lymphoma. International Journal of Radiation Oncology*Biology*Physics 78:2, 507-512
CrossRef277
B. Coiffier, C. Thieblemont, E. Van Den Neste, G. Lepeu, I. Plantier, S. Castaigne, S. Lefort, G. Marit, M. Macro, C. Sebban, K. Belhadj, D. Bordessoule, C. Ferme, H. Tilly. (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116:12, 2040-2045
CrossRef278
Zafar Iqbal, Steven Sivils, Paul S. Pagel. (2010) Dizziness in a Patient With a Right Atrial Mass. Journal of Cardiothoracic and Vascular Anesthesia
CrossRef279
Jeremy S. Abramson, Matthew Hellmann, Jeffrey A. Barnes, Peter Hammerman, Christiana Toomey, Tak Takvorian, Alona Muzikansky, Ephraim P. Hochberg. (2010) Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer 116:18, 4283-4290
CrossRef280
Constantine S. Tam, Michael J. Keating. (2010) Chemoimmunotherapy of chronic lymphocytic leukemia. Nature Reviews Clinical Oncology 7:9, 521-532
CrossRef281
Mi Hwa Han, Hyeon-Seok Eom, Weon-Seo Park, Tak Yun, Sohee Park, Hyun-Ju Kim, Chang-Ho Jeon, Sun-Young Kong. (2010) Detection of circulating lymphoma cells in patients with non-Hodgkin lymphoma using MAGE-A3 gene expression in peripheral blood. Leukemia Research 34:9, 1127-1131
CrossRef282
Karin Rydström, Johan Linderoth, Heidi Nyman, Mats Ehinger, Patrick Joost, Pär-Ola Bendahl, Sirpa Leppä, Mats Jerkeman. (2010) CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leukemia & Lymphoma 51:9, 1643-1648
CrossRef283
Amrita Krishnan, Joycelynne M. Palmer, John A. Zaia, Ni-Chun Tsai, Joseph Alvarnas, Stephen J. Forman. (2010) HIV Status Does Not Affect the Outcome of Autologous Stem Cell Transplantation (ASCT) for Non-Hodgkin Lymphoma (NHL). Biology of Blood and Marrow Transplantation 16:9, 1302-1308
CrossRef284
Nozomi Niitsu. (2010) Current treatment strategy of diffuse large B-cell lymphomas. International Journal of Hematology 92:2, 231-237
CrossRef285
Yan-Yan Liu, Shu-Na Yao, Yan Zhao, Zhi-Hua Yao, Jie MA, Qing-Xin Xia, Kai Fu, Shu-Jun Yang. (2010) PTEN tumor suppressor plays less prognostic role than P53 tumor suppressor in diffuse large B-cell lymphoma. Leukemia & Lymphoma 51:9, 1692-1698
CrossRef286
Dongmei Ji, Junning Cao, Xiaonan Hong, Junmin Li, Jianmin Wang, Fangyuan Chen, Chun Wang, Shanhua Zou. (2010) Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study. European Journal of Haematology 85:3, 243-250
CrossRef287
David Hui, Bradley Proctor, Jane Donaldson, Tamara Shenkier, Paul Hoskins, Richard Klasa, Kerry Savage, Mukesh Chhanabhai, Randy D. Gascoyne, Joseph M. Connors, Laurie H. Sehn. (2010) Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone. Leukemia & Lymphoma 51:9, 1-10
CrossRef288
Tsuneaki Hirakawa, Hiroki Yamaguchi, Norio Yokose, Seiji Gomi, Koiti Inokuchi, Kazuo Dan. (2010) Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma. Annals of Hematology 89:9, 897-904
CrossRef289
Karissa M. Johnston, Carlo A. Marra, Joseph M. Connors, Mehdi Najafzadeh, Laurie Sehn, Stuart J. Peacock. (2010) Cost-Effectiveness of the Addition of Rituximab to CHOP Chemotherapy in First-Line Treatment for Diffuse Large B-Cell Lymphoma in a Population-Based Observational Cohort in British Columbia, Canada. Value in Health 13:6, 703-711
CrossRef290
Francesco D’Amore, John Radford, Thomas Relander, Mats Jerkeman, Hervé Tilly, Anders Österborg, Franck Morschhauser, Martin Gramatzki, Martin Dreyling, Bo Bang, Hans Hagberg. (2010) Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. British Journal of Haematology 150:5, 565-573
CrossRef291
R. Abes, E. Gelize, W. H. Fridman, J.-L. Teillaud. (2010) Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 116:6, 926-934
CrossRef292
Panagiotis Samaras, Helen Heider, Sarah R. Haile, Ulf Petrausch, Niklaus G. Schaefer, Raffaele Daniele Siciliano, Alexander Meisel, Axel Mischo, Martin Zweifel, Alexander Knuth, Frank Stenner-Liewen, Christoph Renner. (2010) Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP. Annals of Hematology 89:8, 783-787
CrossRef293
David Maloney, Franck Morschhauser, Ola Linden, Anton Hagenbeek, Christian Gisselbrecht. (2010) Diversity in antibody-based approaches to non-Hodgkin lymphoma. Leukemia & Lymphoma 51:S1, 20-27
CrossRef294
F. Grange, M. D’Incan, N. Ortonne, S. Dalac, L. Laroche, M. Beylot-Barry, M.-H. Delfau-Larue, B. Vergier, M. Bagot. (2010) Prise en charge des lymphomes B cutanés : recommandations du Groupe français d’étude des lymphomes cutanés. Annales de Dermatologie et de Vénéréologie 137:8-9, 523-531
CrossRef295
Michinori Ogura, Kensei Tobinai, Kiyohiko Hatake, Toshiki Uchida, Masanobu Kasai, Takashi Oyama, Tatsuya Suzuki, Yukio Kobayashi, Takashi Watanabe, Teruhisa Azuma, Masakazu Mori, Yasuhito Terui, Masahiro Yokoyama, Yuko Mishima, Shunji Takahashi, Chiho Ono, Junko Ohata. (2010) Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Cancer Science 101:8, 1840-1845
CrossRef296
D. T. Selewski, G. V. Shah, R. J. Mody, P. A. Rajdev, S. K. Mukherji. (2010) Rituximab (Rituxan). American Journal of Neuroradiology 31:7, 1178-1180
CrossRef297
Julie Lignon, David Sibon, Isabelle Madelaine, Pauline Brice, Patricia Franchi, Josette Briere, Nicolas Mounier, Christian Gisselbrecht, Pierre Faure, Catherine Thieblemont. (2010) Rituximab, Dexamethasone, Cytarabine, and Oxaliplatin (R-DHAX) Is an Effective and Safe Salvage Regimen in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. Clinical Lymphoma, Myeloma & Leukemia 10:4, 262-269
CrossRef298
John Gribben, Andreas Rosenwald, Randy Gascoyne, Georg Lenz. (2010) Targeting the microenvironment. Leukemia & Lymphoma 51:S1, 34-40
CrossRef299
Yvonne N. Pierpont, Brian M. Derby, Deepak K. Naidu, Erika L. Johnson, M. Georgina Uberti, Theodore J. Strickland, R. Emerick Salas, Terry E. Wright, Wyatt G. Payne. (2010) Primary Breast Lymphoma After Mastectomy With Reconstruction. Clinical Breast Cancer 10:4, 322-325
CrossRef300
Byung Woog Kang, Won Seog Kim, Chul Kim, Geundoo Jang, Sung Sook Lee, Yoon Hee Choi, Dae Ho Lee, Sang We Kim, Shin Kim, Jin-Sook Ryu, Jooryung Huh, Jung Shin Lee, Cheolwon Suh. (2010) Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. Investigational New Drugs 28:4, 516-522
CrossRef301
Jin-Man Cho, Il-Suk Sohn, You-Jung Yang. (2010) Heart in the heart: Dual faced primary cardiac lymphoma on PET–CT. International Journal of Cardiology 142:3, e40-e41
CrossRef302
Thomas E. Witzig. 2010. Radioimmunotherapy for B-Cell Non-Hodgkin Lymphoma. , 169-218.
CrossRef303
A. Bari, L. Marcheselli, S. Sacchi, R. Marcheselli, S. Pozzi, P. Ferri, E. Balleari, P. Musto, S. Neri, M. A. Aloe Spiriti, M. C. Cox. (2010) Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. Annals of Oncology 21:7, 1486-1491
CrossRef304
Filip Janku, David J. Stewart, Razelle Kurzrock. (2010) Targeted therapy in non-small-cell lung cancer—is it becoming a reality?. Nature Reviews Clinical Oncology 7:7, 401-414
CrossRef305
Mark J Ahn, Anne S York, Polly Rizova. (2010) Pathways to biomedical tipping points: Vertical, horizontal or other?. Journal of Commercial Biotechnology 16:3, 224-238
CrossRef306
Ajay K. Gopal, Oliver W. Press, Andrei R. Shustov, Stephen H. Petersdorf, Ted A. Gooley, Jasmine T. Daniels, Mitchell A. Garrison, George F. Gjerset, Matthew Lonergan, Anne E. Murphy, Julie C. Smith, John M. Pagel. (2010) Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leukemia & Lymphoma 51:8, 1523-1529
CrossRef307
Sophie Dupire, Bertrand Coiffier. (2010) Targeted treatment and new agents in diffuse large B cell lymphoma. International Journal of Hematology 92:1, 12-24
CrossRef308
Alexandra Stefanovic, Izidore S. Lossos. (2010) Primary testicular lymphoma: the site matters. Leukemia & Lymphoma 51:7, 1159-1160
CrossRef309
Gonzalo Gutiérrez-García, Lluis Colomo, Neus Villamor, Leonor Arenillas, Antonio Martínez, Teresa Cardesa, Adriana García-Herrera, Xavier Setoain, Sonia Rodríguez, Gabriela Ghita, Pau Abrisqueta, Eva Giné, Francesc Bosch, Elías Campo, Emilio Montserrat, Armando López-Guillermo. (2010) Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era. Leukemia & Lymphoma 51:7, 1225-1232
CrossRef310
S. Luminari, A. Montanini, D. Caballero, S. Bologna, M. Notter, M. J. S. Dyer, A. Chiappella, J. Briones, M. Petrini, A. Barbato, L. Kayitalire, M. Federico. (2010) Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial. Annals of Oncology 21:7, 1492-1499
CrossRef311
Xavier Poiré, Justin Kline, David Grinblatt, Todd Zimmerman, Kathy Conner, Carolyn Muhs, Thomas Gajewski, Koen Van Besien, Sonali M. Smith. (2010) Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leukemia & Lymphoma 51:7, 1241-1250
CrossRef312
L F Porrata, K Rsitow, D J Inwards, S M Ansell, I N Micallef, P B Johnston, T M Habermann, T E Witzig, J P Colgan, G S Nowakowski, C A Thompson, S N Markovic. (2010) Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. Leukemia 24:7, 1343-1349
CrossRef313
Gillian M. Keating. (2010) Rituximab. Drugs 70:11, 1445-1476
CrossRef314
Anne H. Blaes, Philippe Gaillard, Bruce A. Peterson, Douglas Yee, Beth Virnig. (2010) Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy. Breast Cancer Research and Treatment 122:2, 585-590
CrossRef315
C. Onal, Y. X. Li, R. C. Miller, P. Poortmans, N. Constantinou, D. C. Weber, B. M. Atasoy, S. Igdem, M. Ozsahin, E. Ozyar. (2010) Treatment results and prognostic factors in primary thyroid lymphoma patients: a Rare Cancer Network study. Annals of Oncology
CrossRef316
R. Stein, P. Gupta, X. Chen, T. M. Cardillo, R. R. Furman, S. Chen, C.-H. Chang, D. M. Goldenberg. (2010) Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways. Blood 115:25, 5180-5190
CrossRef317
Susan M. Geyer, Lindsay M. Morton, Thomas M. Habermann, Cristine Allmer, Scott Davis, Wendy Cozen, Richard K. Severson, Charles F. Lynch, Sophia S. Wang, Matthew J. Maurer, Patricia Hartge, James R. Cerhan. (2010) Smoking, alcohol use, obesity, and overall survival from non-Hodgkin lymphoma. Cancer 116:12, 2993-3000
CrossRef318
G. Dasmahapatra, D. Lembersky, L. Kramer, R. I. Fisher, J. Friedberg, P. Dent, S. Grant. (2010) The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood 115:22, 4478-4487
CrossRef319
D. Ennishi, H. Asai, Y. Maeda, K. Shinagawa, K. Ikeda, M. Yokoyama, Y. Terui, K. Takeuchi, T. Yoshino, K. Matsuo, K. Hatake, M. Tanimoto. (2010) Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Annals of Oncology 21:6, 1217-1221
CrossRef320
Sameer A. Parikh, William G. Wierda. (2010) Role of CD20 Monoclonal Antibodies in Previously Untreated Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma & Leukemia 10:0, S27-S33
CrossRef321
S N Madge, A McCormick, I Patel, E Hatef, V Menon, V C Prabhakaran, L Irion, R Bonshek, S Honovar, B Leatherbarrow, B Esmaeli, D Selva. (2010) Ocular adnexal diffuse large B-cell lymphoma: local disease correlates with better outcomes. Eye 24:6, 954-961
CrossRef322
Anne Parker, Kristin Bowles, J. Andrew Bradley, Vincent Emery, Carrie Featherstone, Girish Gupte, Robert Marcus, Jayan Parameshwar, Alan Ramsay, Charles Newstead, . (2010) Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines. British Journal of Haematology 149:5, 693-705
CrossRef323
S Nimmagadda, K Sweiss, N Mahmud, Y Park, D Rondelli. (2010) Plerixafor given before the third leukapheresis to rescue an unsuccessful stem cell mobilization with CY and G-CSF. Bone Marrow Transplantation 45:6, 1121-1122
CrossRef324
Rebecca L. Elstrom, Peter Martin, Katya Ostrow, Jacqueline Barrientos, Amy Chadburn, Richard Furman, Jia Ruan, Tsiporah Shore, Michael Schuster, Leandro Cerchietti, Ari Melnick, Morton Coleman, John P. Leonard. (2010) Response to Second-line Therapy Defines the Potential for Cure in Patients With Recurrent Diffuse Large B-Cell Lymphoma: Implications for the Development of Novel Therapeutic Strategies. Clinical Lymphoma, Myeloma & Leukemia 10:3, 192-196
CrossRef325
S. Gérard, C. Gaudin, M. Caperan, A. Larrayadieu, C. Goineau, L. Balardy. (2010) Lymphome B diffus à grande cellule chez un sujet âgé : un exemple de la collaboration entre oncologue et gériatre. Les cahiers de l'année gérontologique 2:2, 80-84
CrossRef326
Cara K Fraser, Michael P Brown, Kerrilyn R Diener, John D Hayball. (2010) Unravelling the complexity of cancer–immune system interplay. Expert Review of Anticancer Therapy 10:6, 917-934
CrossRef327
Louis M. Weiner, Rishi Surana, Shangzi Wang. (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews Immunology 10:5, 317-327
CrossRef328
David M. Goldenberg, Franck Morschhauser, William A. Wegener. (2010) Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leukemia & Lymphoma 51:5, 747-755
CrossRef329
H. A. Azim, L. Santoro, R. G. Bociek, S. Gandini, R. A. Malek, H. A. Azim. (2010) High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma: a literature-based meta-analysis. Annals of Oncology 21:5, 1064-1071
CrossRef330
Marie-Sarah Dilhuydy, Thierry Lamy, Charles Foussard, Remy Gressin, Philippe Casassus, Eric Deconninck, Christine Le Maignan, Diane Damotte, Noel Milpied. (2010) Front-line High-Dose Chemotherapy with Rituximab Showed Excellent Long-Term Survival in Adults with Aggressive Large B-Cell Lymphoma: Final Results of a Phase II GOELAMS Study. Biology of Blood and Marrow Transplantation 16:5, 672-677
CrossRef331
J. Crawford, C. Caserta, F. Roila, . (2010) Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Annals of Oncology 21:Supplement 5, v248-v251
CrossRef332
H. Tilly, M. Dreyling, . (2010) Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21:Supplement 5, v172-v174
CrossRef333
Tithi Biswas, Sughosh Dhakal, Rui Chen, Ollivier Hyrien, Steven Bernstein, Jonathan W. Friedberg, Richard I. Fisher, Jane Liesveld, Gordon Phillips, Louis S. Constine. (2010) Involved Field Radiation After Autologous Stem Cell Transplant for Diffuse Large B-Cell Lymphoma in the Rituximab Era. International Journal of Radiation Oncology*Biology*Physics 77:1, 79-85
CrossRef334
D. Villa, J. M. Connors, T. N. Shenkier, R. D. Gascoyne, L. H. Sehn, K. J. Savage. (2010) Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Annals of Oncology 21:5, 1046-1052
CrossRef335
Sean D. Delshad, Jacob J. Ahdoot, Donald J. Portocarrero. (2010) Primary Hepatic Lymphoma. Clinical Gastroenterology and Hepatology 8:5, e49-e50
CrossRef336
A.S. Michallet, B. Coiffier. 2010. Treatment of Lymphoma in the Elderly Population. , 66-71.
CrossRef337
Sverker Hasselblom, Ulrika Hansson, Markus Olsson, Leif Torén, Anders Bergström, Herman Nilsson-Ehle, Per-Ola Andersson. (2010) High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. British Journal of Haematology 149:4, 560-568
CrossRef338
Sari Riihijärvi, Satu Koivula, Heidi Nyman, Karin Rydström, Mats Jerkeman, Sirpa Leppä. (2010) Prognostic impact of protein kinase C β II expression in R-CHOP-treated diffuse large B-cell lymphoma patients. Modern Pathology 23:5, 686-693
CrossRef339
John S Lubel, Peter W Angus. (2010) Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: Diagnosis and management. Journal of Gastroenterology and Hepatology 25:5, 864-871
CrossRef340
Schwartz, Robert S., , Lenz, Georg, Staudt, Louis M., . (2010) Aggressive Lymphomas. New England Journal of Medicine 362:15, 1417-1429
Full Text341
A. M. Levine. (2010) HIV-associated lymphoma. Blood 115:15, 2986-2987
CrossRef342
J. A. Sparano, J. Y. Lee, L. D. Kaplan, A. M. Levine, J. C. Ramos, R. F. Ambinder, W. Wachsman, D. Aboulafia, A. Noy, D. H. Henry, J. Von Roenn, B. J. Dezube, S. C. Remick, M. H. Shah, L. Leichman, L. Ratner, E. Cesarman, A. Chadburn, R. Mitsuyasu, . (2010) Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood 115:15, 3008-3016
CrossRef343
Joseph R. Carver, Chaitali J. Desai. 2010. Cardiovascular Toxicity of Antitumor Drugs: Dimension of the Problem in Adult Settings. , 127-199.
CrossRef344
Shu-qing Lü, Jian-min Yang, Xian-min Song, Li Chen, Wei-ping Zhang, Xiao-qian Xu, Xiong Ni, Chong-mei Huang, Yi He, Jian-min Wang. (2010) CHOP-like regimen in combination with rituximab and peginterferon alpha-2b in newly-diagnosed diffuse large B-cell Non-Hodgkin’s lymphoma: Experience in a Chinese center. Clinical Oncology and Cancer Research 7:2, 103-109
CrossRef345
Pierre Soubeyran, Simone Mathoulin-Pélissier, Anna Josnin, Isabelle Soubeyran, Michèle Kind, Muriel Rainfray, Bernard Hœrni. (2010) Overview of aggressive lymphomas in the older adult. Aging Health 6:2, 191-200
CrossRef346
Juan C. Gea-Banacloche. (2010) Rituximab-Associated Infections. Seminars in Hematology 47:2, 187-198
CrossRef347
David C. Linch, Lynny Yung, Paul Smith, Ken Maclennan, Andrew Jack, Barry Hancock, David Cunningham, Peter Hoskin, Wendi Qian, Harald Holte, Anne-Marie Boesen, Andrew Grigg, Peter Browett, Marek Trneny. (2010) Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL. British Journal of Haematology 149:2, 237-243
CrossRef348
Danielle Troutaud, Barbara Petit, Cynthia Bellanger, Benoît Marin, Marie-Pierre Gourin-Chaury, Daniel Petit, Agnès Olivrie, Jean Feuillard, Marie-Odile Jauberteau, Dominique Bordessoule. (2010) Prognostic Significance of BAD and AIF Apoptotic Pathways in Diffuse Large B-Cell Lymphoma. Clinical Lymphoma, Myeloma & Leukemia 10:2, 118-124
CrossRef349
Ewa Lech-Maranda, Jacques Bienvenu, Florence Broussais-Guillaumot, Krzysztof Warzocha, Anne-Sophie Michallet, Tadeusz Robak, Bertrand Coiffier, Gilles Salles. (2010) Plasma TNF-α and IL-10 Level-Based Prognostic Model Predicts Outcome of Patients with Diffuse Large B-Cell Lymphoma in Different Risk Groups Defined by the International Prognostic Index. Archivum Immunologiae et Therapiae Experimentalis 58:2, 131-141
CrossRef350
Carsten Zwick, Niels Murawski, Michael Pfreundschuh. (2010) Rituximab in High-Grade Lymphoma. Seminars in Hematology 47:2, 148-155
CrossRef351
George J. Weiner. (2010) Rituximab: Mechanism of Action. Seminars in Hematology 47:2, 115-123
CrossRef352
Kieron Dunleavy, Kevin Tay, Wyndham H. Wilson. (2010) Rituximab-Associated Neutropenia. Seminars in Hematology 47:2, 180-186
CrossRef353
R. Seki, K. Ohshima, T. Fujisaki, N. Uike, F. Kawano, H. Gondo, S. Makino, T. Eto, Y. Moriuchi, F. Taguchi, T. Kamimura, H. Tsuda, K. Shimoda, T. Okamura. (2010) Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: effects of rituximab. Annals of Oncology 21:4, 833-841
CrossRef354
Trevor T. Hansel, Harald Kropshofer, Thomas Singer, Jane A. Mitchell, Andrew J. T. George. (2010) The safety and side effects of monoclonal antibodies. Nature Reviews Drug Discovery 9:4, 325-338
CrossRef355
Didier Decaudin. (2010) Clinicopathologic features and treatment options of ocular adnexal lymphoma. Expert Review of Ophthalmology 5:2, 241-258
CrossRef356
Wendy H. Vogel. (2010) Infusion Reactions. Clinical Journal of Oncology Nursing 14:2, E10-E21
CrossRef357
Arnon Nagler, Raanan Berger, Aliza Ackerstein, Jaroslaw A. Czyz, Jose Luis Diez-Martin, Elizabeth Naparstek, Reuven Or, Shlomit Gan, Avichai Shimoni, Shimon Slavin. (2010) A Randomized Controlled Multicenter Study Comparing Recombinant Interleukin 2 (rIL-2) in Conjunction With Recombinant Interferon Alpha (IFN-α) Versus no Immunotherapy for Patients With Malignant Lymphoma Postautologous Stem Cell Transplantation. Journal of Immunotherapy 33:3, 326-333
CrossRef358
Thomas M. Habermann. (2010) ASH 2009 meeting report-Top 10 clinically oriented abstracts in lymphoma. American Journal of Hematology 85:4, 280-283
CrossRef359
Ritsuko Seki, Koichi Ohshima, Koji Nagafuji, Tomoaki Fujisaki, Naokuni Uike, Fumio Kawano, Hisashi Gondo, Shigeyoshi Makino, Tetsuya Eto, Yukiyoshi Moriuchi, Fumihiro Taguchi, Tomohiko Kamimura, Hiroyuki Tsuda, Ryosuke Ogawa, Kazuya Shimoda, Kiyoshi Yamashita, Keiko Suzuki, Hitoshi Suzushima, Kunihiro Tsukazaki, Masakazu Higuchi, Atae Utsunomiya, Masahiro Iwahashi, Yutaka Imamura, Kazuo Tamura, Junji Suzumiya, Minoru Yoshida, Yasunobu Abe, Tadashi Matsumoto, Takashi Okamura. (2010) Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group. International Journal of Hematology 91:2, 258-266
CrossRef360
Michael A. Fridrik, Hubert Hausmaninger, Alois Lang, Johannes Drach, Otto Krieger, Dietmar Geissler, Gerhard Michlmayr, Ernst Ulsperger, Andreas Chott, Wilhelm Oberaigner, Richard Greil. (2010) Dose-dense therapy improves survival in aggressive non-Hodgkin’s lymphoma. Annals of Hematology 89:3, 273-282
CrossRef361
Andrea Borgerding, Justin Hasenkamp, Bertram Glaß, Gerald Wulf, Lorenz Trümper. (2010) Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma. Annals of Hematology 89:3, 283-289
CrossRef362
Wataru Yamamoto, Naoto Tomita, Reina Watanabe, Yukako Hattori, Yuki Nakajima, Rie Hyo, Chizuko Hashimoto, Shigeki Motomura, Yoshiaki Ishigatsubo. (2010) Central nervous system involvement in diffuse large B-cell lymphoma. European Journal of Haematology
CrossRef363
Panagiotis Tsirigotis, Liliane Dray, Igor B. Resnick, Aliza Ackerstein, Benjamin Gesundheit, Sharon Elad, Reuven Or, Michael-Yechiel Shapira. (2010) Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin’s lymphoma. Annals of Hematology 89:3, 263-272
CrossRef364
Niels Murawski, Carsten Zwick, Michael Pfreundschuh. (2010) Unresolved issues in diffuse large B-cell lymphomas. Expert Review of Anticancer Therapy 10:3, 387-402
CrossRef365
Ryan A Metcalf, Shuchun Zhao, Matthew W Anderson, Zhi Shun Lu, Ilana Galperin, Robert J Marinelli, Athena M Cherry, Izidore S Lossos, Yasodha Natkunam. (2010) Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. Modern Pathology 23:3, 420-433
CrossRef366
Tri K. Nguyen, Nicholas Jordan, Jonathan Friedberg, Richard I. Fisher, Paul Dent, Steven Grant. (2010) Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis. Leukemia Research 34:3, 379-386
CrossRef367
Wasif Riaz, Francisco J. Hernandez-Ilizaliturri, Myron S. Czuczman. (2010) Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms. Immunologic Research 46:1-3, 192-205
CrossRef368
K A Foon, M J Hallek. (2010) Changing paradigms in the treatment of chronic lymphocytic leukemia. Leukemia 24:3, 500-511
CrossRef369
Gerald DeNardo, Sally DeNardo. (2010) Dose Intensified Molecular Targeted Radiotherapy for Cancer—Lymphoma as a Paradigm. Seminars in Nuclear Medicine 40:2, 136-144
CrossRef370
Donato Mannina, Stefano Luminari, Alessandra Dondi, Giuseppe Polimeno, Luca Baldini, Caterina Stelitano, Francesco Merli, Matteo Dell'olio, Paolo G. Gobbi, Gianfranco Giglio, Elisa Barbolini, Maura Brugiatelli, Massimo Federico. (2010) Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi. Leukemia & Lymphoma 51:3, 422-429
CrossRef371
Silvia Montoto, Jamie Wilson, Kate Shaw, Maureen Heath, Andy Wilson, Christopher McNamara, Chloe Orkin, Mark Nelson, Margaret Johnson, Mark Bower, and Kate Cwynarski. (2010) Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkittʼs lymphoma. AIDS 24:6, 851-856
CrossRef372
Martin Dreyling, Christian Schmidt. (2010) Rituximab in relapsed aggressive lymphoma: play it again, Sam?. Leukemia & Lymphoma 51:3, 355-356
CrossRef373
Paolo F. Caimi, Paul M. Barr, Nathan A. Berger, Hillard M. Lazarus. (2010) Non-Hodgkinʼs Lymphoma in the Elderly. Drugs & Aging 27:3, 211-238
CrossRef374
Amin M. Alousi, Joseph Uberti, Voravit Ratanatharathorn. (2010) The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant. Leukemia & Lymphoma 51:3, 376-389
CrossRef375
Mutsuko Yasuda, Nobu Akiyama, Sachio Miyamoto, Masahiro Warabi, Yumiko Takahama, Mari Kitamura, Fumiatsu Yakushiji, Hiroyuki Kinoshita. (2010) Primary sellar lymphoma: intravascular large B-cell lymphoma diagnosed as a double cancer and improved with chemotherapy, and literature review of primary parasellar lymphoma. Pituitary 13:1, 39-47
CrossRef376
Alan S Wayne, Christian M Capitini, Crystal L Mackall. (2010) Immunotherapy of childhood cancer: from biologic understanding to clinical application. Current Opinion in Pediatrics 22:1, 2-11
CrossRef377
Yee Soo Chae, Jong Gwang Kim, Sang Kyun Sohn, Joon Ho Moon, Shi Nae Kim, Su Jeong Lee, Tae-In Park, Myung-Hoon Lee. (2010) Lymphotoxin alfa and receptor-interacting protein kinase 1 gene polymorphisms may correlate with prognosis in patients with diffuse large B cell lymphoma treated with R-CHOP. Cancer Chemotherapy and Pharmacology 65:3, 571-577
CrossRef378
Pasquale Niscola. (2010) Mucositis in malignant hematology. Expert Review of Hematology 3:1, 57-65
CrossRef379
John D. Hainsworth, Ian W. Flinn, David R. Spigel, Bobby L. Clark, Paula L. Griner, Elizabeth R. Vazquez, Habib H. Doss, Dianna Shipley, Luis A. Franco, Howard A. Burris, III, F. Anthony Greco. (2010) Brief-Duration Rituximab/Chemotherapy Followed by Maintenance Rituximab in Patients With Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy: A Phase II Trial of the Sarah Cannon Oncology Research Consortium. Clinical Lymphoma, Myeloma & Leukemia 10:1, 44-50
CrossRef380
Umberto Vitolo, Giovanni Barosi, Stefano Fanti, Alessandro M. Gianni, Maurizio Martelli, Mario Petrini, Pier Luigi Zinzani, Sante Tura. (2010) Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian Society of Hematology. American Journal of Hematology 85:2, 147-155
CrossRef381
Berthe M.P. Aleman, Rick L.M. Haas, Richard W.M. van der Maazen. (2010) Role of radiotherapy in the treatment of lymphomas of the gastrointestinal tract. Best Practice & Research Clinical Gastroenterology 24:1, 27-34
CrossRef382
Zu-Guang Xia, Zi-Zhen Xu, Wei-Li Zhao, Shu-Qing Zhao, Fei Ding, Yu Chen, Qiu-Sheng Chen, Yu Zheng, Qi Zhu, Jun-Pei Hu, Zhi-Xiang Shen, Jun-Min Li. (2010) The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment. Annals of Hematology 89:2, 171-177
CrossRef383
Alexandar Tzankov, Inti Zlobec, Philip Went, Hannes Robl, Sylvia Hoeller, Stephan Dirnhofer. (2010) Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leukemia & Lymphoma 51:2, 199-212
CrossRef384
J E Benjamin, G L Chen, T M Cao, P D Cao, R M Wong, K Sheehan, J A Shizuru, L J Johnston, R S Negrin, R Lowsky, G G Laport. (2010) Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure. Bone Marrow Transplantation 45:2, 303-309
CrossRef385
K. JONES, J. NOURSE, G. CORBETT, M. K. GANDHI. (2010) Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity. International Journal of Laboratory Hematology 32:1p1, e169-e174
CrossRef386
Miriam Moreno, Juan-Manuel Sancho, Santiago Gardella, Rosa Coll, Olga García, David Gallardo, Josep-María Ribera. (2010) Doxorrubicina liposomal no pegilada en combinación con ciclofosfamida, vincristina, prednisona y rituximab en el tratamiento de linfomas no hodgkinianos: estudio de 26 pacientes. Medicina Clínica 134:2, 72-75
CrossRef387
M.-K. Song, J.-S. Chung, Y.-M. Seol, S.-G. Kim, H.-J. Shin, Y.-J. Choi, G.-J. Cho, D.-H. Shin. (2010) Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy. Annals of Oncology 21:1, 140-144
CrossRef388
Junshik Hong, Ae Jin Kim, Jin Sun Park, Seok Ho Lee, Kyu Chan Lee, Jinny Park, Sun Jin Sym, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee. (2010) Additional rituximab-CHOP (R-CHOP) versus involved-field radiotherapy after a brief course of R-CHOP in limited, non-bulky diffuse large B-cell lymphoma: a retrospective analysis. The Korean Journal of Hematology 45:4, 253
CrossRef389
Noriyasu Fukushima, Shinya Kimura. (2010) Current and future issue of molecular target therapy in hematological malignancy. Drug Delivery System 25:2, 126-133
CrossRef390
Katsumi AMIKURA, Hirohiko SAKAMOTO, Yoichi TANAKA, Yasuhumi KOBAYASHI, Toshiyuki IZUMO. (2010) A CASE OF MALIGNANT LYMPHOMA OF THE GALLBLADDER. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) 71:2, 494-499
CrossRef391
Alvaro Alencar, David Pitcher, Gerald Byrne, Izidore S. Lossos. (2010) Primary bone lymphoma – the University of Miami experience. Leukemia & Lymphoma 51:1, 39-49
CrossRef392
Nozomi Niitsu, Mika Kohri, Yuki Hagiwara, Ken Tanae, Naoki Takahashi, Masami Bessho, Masataka Okamoto. (2010) Multicentre phase II study of CyclOBEAP plus rituximab in patients with diffuse large B-cell lymphoma. Hematological Oncologyn/a-n/a
CrossRef393
Anne Sirvent, Nathalie Dhedin, Mauricette Michallet, Nicolas Mounier, Catherine Faucher, Ibrahim Yakoub-Agha, Mohamad Mohty, Marie Robin, Reza Tabrizi, Laurence Clement, Karin Bilger, Fabrice Larosa, Nathalie Contentin, Anne Huyn, Sylvie François, Claude-Eric Bulabois, Patrice Ceballos, Jean-Henri Bourrhis, Agnès Buzyn, Jérôme Cornillon, Gaelle Guillerm, Thierry de Revel, Jacques-Olivier Bay, François Guilhot, Noël Milpied. (2010) Low Nonrelapse Mortality and Prolonged Long-Term Survival after Reduced-Intensity Allogeneic Stem Cell Transplantation for Relapsed or Refractory Diffuse Large B Cell Lymphoma: Report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Biology of Blood and Marrow Transplantation 16:1, 78-85
CrossRef394
Kyu-Hyoung Lim, Ho-Il Yoon, Young Ae Kang, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jae Ho Lee, Choon-Taek Lee, Jong Seok Lee. (2010) Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab. The Korean Journal of Internal Medicine 25:1, 86
CrossRef395
Toshiro Kurokawa, Hiroyasu Kaya, Takashi Yoshida. (2010) Two Cases of Pneumocystis jiroveci Pneumonia with Non-Hodgkin's Lymphoma after CHOP-Based Chemotherapy Containing Rituximab. Journal of Clinical and Experimental Hematopathology 50:2, 159-162
CrossRef396
Marcelo Bellesso, Flavia Dias Xavier, Renata Oliveira Costa, Juliana Pereira, Sheila Aparecida Coelho Siqueira, Dalton Alencar Fischer Chamone. (2010) Disease progression after R-CHOP treatment associated with the loss of CD20 antigen expression. Revista Brasileira de Hematologia e Hemoterapia 33:2, 148-150
CrossRef397
Takeshi Hara, Hisashi Tsurumi, Naoe Goto, Jun-ichi Kitagawa, Nobuhiro Kanemura, Takeshi Yoshikawa, Senji Kasahara, Hideko Goto, Kenji Fukuno, Toshiki Yamada, Michio Sawada, Ichiro Yasuda, Naoki Katsumura, Takeshi Takahashi, Tsuyoshi Takami, Hisataka Moriwaki. (2010) Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma. Journal of Cancer Research and Clinical Oncology 136:1, 65-70
CrossRef398
Giulia Motta, Michele Cea, Eva Moran, Federico Carbone, Valeria Augusti, Franco Patrone, Alessio Nencioni. (2010) Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives. Clinical and Developmental Immunology 2010, 1-14
CrossRef399
Susumu Uchiyama, Yasuhiko Suzuki, Kentaro Otake, Masami Yokoyama, Mitsuo Ohta, Shuichi Aikawa, Midori Komatsu, Tetsuji Sawada, Yoshitoyo Kagami, Yasuo Morishima, Kiichi Fukui. (2010) Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope. Cancer Science 101:1, 201-209
CrossRef400
James L. Frazier, James E. Han, Michael Lim, Alessandro Olivi. (2010) Immunotherapy Combined with Chemotherapy in the Treatment of Tumors. Neurosurgery Clinics of North America 21:1, 187-194
CrossRef401
Hillard M. Lazarus, Mei-Jie Zhang, Jeanette Carreras, Brandon M. Hayes-Lattin, Asli Selmin Ataergin, Jacob D. Bitran, Brian J. Bolwell, César O. Freytes, Robert Peter Gale, Steven C. Goldstein, Gregory A. Hale, David J. Inwards, Thomas R. Klumpp, David I. Marks, Richard T. Maziarz, Philip L. McCarthy, Santiago Pavlovsky, J. Douglas Rizzo, Thomas C. Shea, Harry C. Schouten, Shimon Slavin, Jane N. Winter, Koen van Besien, Julie M. Vose, Parameswaran N. Hari. (2010) A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B Cell Lymphoma: A Report from the CIBMTR. Biology of Blood and Marrow Transplantation 16:1, 35-45
CrossRef402
Guanghui Gao, Xiaohua Liang, Jingwei Jiang, Xinli Zhou, Ruofan Huang, Zhaohui Chu, Qiong Zhan. (2010) A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma. Acta Oncologica 49:1, 3-12
CrossRef403
Aiko Nagayama, Naoyuki Kobayashi, Junichi Saito, Tetsuya Nakamura, Eiji Kurihara, Toshiaki Ikeda, Yoshito Ueyama, Mitsuhiro Saito, Hitomi Horikawa, Hidetomo Muto, Hiroko Murata, Hitomi Nakamura, Reina Tatsumi, Shinji Takahashi. (2010) Malignant Lymphoma of the Ileum Treated by Laparoscopically Assisted Bowel Resection : A Case Report. The Kitakanto Medical Journal 60:4, 367-370
CrossRef404
Cristina Michaela Precupanu, Patricia Validire, Christine Lévy, Corine Plancher, Anne Vincent-Salomon, Rémi Dendale, Bernard Asselain, Vincent Servois, Laurence Desjardins, Manuela Zanni, Rafika Sahli, Livia Lumbroso-le Rouic, Didier Decaudin. (2010) Primary high-grade ocular adnexal lymphoma: Clinicopathological characteristics and prognostic factors of a single-centre series. American Journal of HematologyNA-NA
CrossRef405
Xiaoyan Ke, Jing Wang, Zifen Gao, Lingzhi Zhao, Min Li, Hongmei Jing, Jijun Wang, Wei Zhao, Heather Gilbert, Xiao-Feng Yang. (2010) Clinical characteristics and prognostic analysis of Chinese patients with diffuse large B-cell lymphoma. Blood Cells, Molecules, and Diseases 44:1, 55-61
CrossRef406
Hirotsugu YANAI, Masaki MIZUMOTO, Yasuko MIYAHARA, Takeshi YAMANO, Yozi URATA, Taisuke MORIMOTO. (2010) A CASE REPORT OF PRIMARY MALIGNANT LYMPHOMA OF THE APPENDIX TREATED BY SURGERY AND POST-OPERATIVE CHEMOTHERAPY. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) 71:3, 736-741
CrossRef407
In-Suk Kim, Dong Chul Kim, Hoon-Gu Kim, Hyeon-Seok Eom, Sun-Young Kong, Ho-Jin Shin, Sang-Hyun Hwang, Eun-Yup Lee, Sunjoo Kim, Gyeong-Won Lee. (2010) DNA repair gene XRCC1 polymorphisms and haplotypes in diffuse large B-cell lymphoma in a Korean population. Cancer Genetics and Cytogenetics 196:1, 31-37
CrossRef408
Linzhu Zhai, Chengcheng Guo, Yabing Cao, Jian Xiao, Xiaohong Fu, Jiajia Huang, Huiqiang Huang, Zhongzhen Guan, Tongyu Lin. (2010) Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin’s lymphoma: single center, 15-year experience. International Journal of Hematology 91:1, 78-86
CrossRef409
Irene Cavattoni, Tatjana Zabelina, Francis Ayuk, Christine Wolschke, Ulrike Bacher, Axel Zander, Nicolaus Kröger. (2010) Pilot study of rituximab plus donor-lymphocyte infusion to prevent or treat relapse in B-cell lymphoma after allogeneic stem cell transplantation. Leukemia & Lymphoma 51:1, 146-148
CrossRef410
Joshua M Lang, Adin-Cristian Andrei, Douglas G McNeel. (2009) Prioritization of cancer antigens: keeping the target in sight. Expert Review of Vaccines 8:12, 1657-1661
CrossRef411
Hossein Borghaei, Mitchell R. Smith, Kerry S. Campbell. (2009) Immunotherapy of cancer. European Journal of Pharmacology 625:1-3, 41-54
CrossRef412
C. Haioun, N. Mounier, J. F. Emile, D. Ranta, B. Coiffier, H. Tilly, C. Recher, C. Ferme, J. Gabarre, R. Herbrecht, F. Morchhauser, C. Gisselbrecht. (2009) Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. Annals of Oncology 20:12, 1985-1992
CrossRef413
Takumi Sugimoto, Akihiro Tomita, Junji Hiraga, Kazuyuki Shimada, Hitoshi Kiyoi, Tomohiro Kinoshita, Tomoki Naoe. (2009) Escape mechanisms from antibody therapy to lymphoma cells: Downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation. Biochemical and Biophysical Research Communications 390:1, 48-53
CrossRef414
M. Guglin, M. Aljayeh, S. Saiyad, R. Ali, A. B. Curtis. (2009) Introducing a new entity: chemotherapy-induced arrhythmia. Europace 11:12, 1579-1586
CrossRef415
Voravit Ratanatharathorn, Steven Pavletic, Joseph P. Uberti. (2009) Clinical applications of rituximab in allogeneic stem cell transplantation: Anti-tumor and immunomodulatory effects. Cancer Treatment Reviews 35:8, 653-661
CrossRef416
Péter Rajnics, Judit Demeter, Judit Csomor, László Krenács, László Pajor, Balázs Kollár, Zsuzsanna Kertész, Miklós Egyed. (2009) Rare primary extranodal lymphomas: diffuse large B-cell lymphomas of the genital tract. Annals of Hematology 88:12, 1223-1228
CrossRef417
Gyeong-Won Lee, Jung-Hun Kang, In-Suk Kim, Hoon-Gu Kim, Gyung Hyuck Ko, Jeong Hee Lee, Dong Chool Kim, Dae Hyun Song, Jung Wook Yang, Jong Sil Lee. (2009) Is inactivation of O 6 -methylguanine DNA methyltransferase still a favorable prognostic factor of patients with diffuse large B-cell lymphoma in the era of R-CHOP chemotherapy?. Leukemia & Lymphoma 50:12, 1992-1998
CrossRef418
N. George Mikhaeel. (2009) Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now?. Leukemia & Lymphoma 50:12, 1931-1936
CrossRef419
Nikolaos S. Salemis, Stavros Gourgiotis, Evangelos Tsiambas, Grigorios Karagkiouzis, Georgios Nakos, Vasilios Karathanasis. (2009) Diffuse Large B Cell Lymphoma of the Mesentery: An Unusual Presentation and Review of the Literature. Journal of Gastrointestinal Cancer 40:3-4, 79-82
CrossRef420
Antonio Salar, Eva Domingo-Domenech, Cristina Estany, Miguel A. Canales, Fernando Gallardo, Octavio Servitje, Guadalupe Fraile, Carlos Montalb
n. (2009) Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer 115:22, 5210-5217
CrossRef421
D.S. Mestel, M. Beyer, M. Steinhoff, W. Sterry. (2009) Treatment of Cutaneous Lymphomas: Today and Tomorrow. Actas Dermo-Sifiliográficas 100, 18-32
CrossRef422
Hiroo Katsuya, Junji Suzumiya, Hidenori Sasaki, Kenji Ishitsuka, Takao Shibata, Yasushi Takamatsu, Kazuo Tamura. (2009) Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma. Leukemia & Lymphoma 50:11, 1818-1823
CrossRef423
Tamás Schneider, Zsuzsanna Molnár, Beáta Deák, Erika Várady, Erika Tóth, Judit Csomor, András Matolcsy, József Lővey, Zsolt Lengyel, Klára Petri, István Gaudi, András Rosta. (2009) Diffúz nagy B-sejtes lymphomák immunokemoterápiás kezelésével elért eredményeink. Orvosi Hetilap 150:44, 2019-2026
CrossRef424
Laurie H. Sehn. (2009) Early detection of patients with poor risk diffuse large B-cell lymphoma. Leukemia & Lymphoma 50:11, 1744-1747
CrossRef425
Shu-Nan Qi, Ye-Xiong Li, Hua Wang, Wei-Hu Wang, Jing Jin, Yong-Wen Song, Shu-Lian Wang, Yue-Ping Liu, Li-Qiang Zhou, Zi-Hao Yu. (2009) Diffuse large B-cell lymphoma. Cancer 115:21, 4980-4989
CrossRef426
Riad Abès, Charles-Antoine Dutertre, Lauren Agnelli, Jean-Luc Teillaud. (2009) Activating and inhibitory Fcγ receptors in immunotherapy: being the actor or being the target. Expert Review of Clinical Immunology 5:6, 735-747
CrossRef427
Kristopher A. Sarosiek, Hovav Nechushtan, Xiaoqing Lu, Joseph D. Rosenblatt, Izidore S. Lossos. (2009) Interleukin-4 distinctively modifies responses of germinal centre-like and activated B-cell-like diffuse large B-cell lymphomas to immuno-chemotherapy. British Journal of Haematology 147:3, 308-318
CrossRef428
Yutaka Tsutsumi, Yoshiya Yamamoto, Junji Tanaka, Masahiro Asaka, Masahiro Imamura, Nobuo Masauzi. (2009) Prevention of hepatitis B virus reactivation under rituximab therapy. Immunotherapy 1:6, 1053-1061
CrossRef429
M. Ellis, R. Bernsen, H. Ali-Zadeh, J. Kristensen, U. Hedstrom, L. Poughias, M. Bresnik, A. Al-Essa, D. A. Stevens. (2009) A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever. Journal of Medical Microbiology 58:11, 1474-1485
CrossRef430
K. J. Savage, N. A. Johnson, S. Ben-Neriah, J. M. Connors, L. H. Sehn, P. Farinha, D. E. Horsman, R. D. Gascoyne. (2009) MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 114:17, 3533-3537
CrossRef431
Gerald Illerhaus. (2009) Primary CNS lymphoma and secondary involvement of the central nervous system. memo - Magazine of European Medical Oncology 2:3, 146-149
CrossRef432
Alessandra Tucci, Samantha Ferrari, Chiara Bottelli, Erika Borlenghi, Monica Drera, Giuseppe Rossi. (2009) A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer 115:19, 4547-4553
CrossRef433
Hsiang-Yu Yang, Hung-Yen Ke, Gou-Jieng Hong, Yi-Ting Tsai, Chih-Yuan Lin, Chung-Yi Li, Chien-Sung Tsai. (2009) Monotherapy with Anti-CD20 Monoclonal Antibody in a Heart Transplant Recipient with Sick Sinus Syndrome and Posttransplantation Lymphoproliferative Disorder: A Case Report. The Heart Surgery Forum 12:5, E300-E302
CrossRef434
Jason R. Westin, Luis E. Fayad. (2009) Beyond R-CHOP and the IPI in large-cell lymphoma: Molecular markers as an opportunity for stratification. Current Hematologic Malignancy Reports 4:4, 218-224
CrossRef435
Takeshi Hara, Hisashi Tsurumi, Naoe Goto, Nobuhiro Kanemura, Takeshi Yoshikawa, Senji Kasahara, Toshiki Yamada, Michio Sawada, Hideko Goto, Kenji Fukuno, Jun-ichi Kitagawa, Ichiro Yasuda, Naoki Katsumura, Masao Takemura, Takeshi Takahashi, Tsuyoshi Takami, Hisataka Moriwaki. (2009) Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP. Journal of Cancer Research and Clinical Oncology 135:10, 1421-1428
CrossRef436
Hélène Blasco, Etienne Chatelut, Isabelle Benz de Bretagne, Nicolas Congy-Jolivet, Chantal Le Guellec. (2009) Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma. Fundamental & Clinical Pharmacology 23:5, 601-608
CrossRef437
Vincent Ribrag, Christian Gisselbrecht, Corinne Haioun, Gilles Salles, Jean-Baptiste Golfier, Marjan Ertault, Christophe Ferme, Josette Briere, Pauline Brice, Nicolas Mounier. (2009) Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma. Cancer 115:19, 4540-4546
CrossRef438
Pierre Soubeyran, Cécile Mertens, Carine Bellera, Simone Mathoulin-Pélissier, Muriel Rainfray. (2009) Management of unfit patients with unfavourable non-Hodgkin’s lymphomas. Cancer Treatment Reviews 35:6, 528-532
CrossRef439
Deborah A. Thomas, Susan O'Brien, Hagop M. Kantarjian. (2009) Monoclonal Antibody Therapy with Rituximab for Acute Lymphoblastic Leukemia. Hematology/Oncology Clinics of North America 23:5, 949-971
CrossRef440
Ritsuko Seki, Koichi Ohshima, Tomoaki Fujisaki, Naokuni Uike, Fumio Kawano, Hisashi Gondo, Shigeyoshi Makino, Tetsuya Eto, Yukiyoshi Moriuchi, Fumihiro Taguchi, Tomohiko Kamimura, Hiroyuki Tsuda, Ryosuke Ogawa, Kazuya Shimoda, Kiyoshi Yamashita, Keiko Suzuki, Hitoshi Suzushima, Kunihiro Tsukazaki, Masakazu Higuchi, Atae Utsunomiya, Masahiro Iwahashi, Yutaka Imamura, Kazuo Tamura, Junji Suzumiya, Minoru Yoshida, Yasunobu Abe, Tadashi Matsumoto, Takashi Okamura. (2009) Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Science 100:10, 1842-1847
CrossRef441
M. Gupta, S. M. Ansell, A. J. Novak, S. Kumar, S. H. Kaufmann, T. E. Witzig. (2009) Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood 114:14, 2926-2935
CrossRef442
N. A. Johnson, K. J. Savage, O. Ludkovski, S. Ben-Neriah, R. Woods, C. Steidl, M. J. S. Dyer, R. Siebert, J. Kuruvilla, R. Klasa, J. M. Connors, R. D. Gascoyne, D. E. Horsman. (2009) Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 114:11, 2273-2279
CrossRef443
Shen Yang, Yao Yu, Li Jun-Min, Mi Jian-Qing, Chen Qiu-Sheng, Chen Yu, Zhao Wei-Li, You Jian-Hua, Zhao Hui-Jin, Wang Yan, Wang Li, Cheng Shu, Shen Zhi-Xiang. (2009) Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population. Annals of Hematology 88:9, 863-869
CrossRef444
Keun-Wook Lee, Jongyoun Yi, In Sil Choi, Jee Hyun Kim, Soo-Mee Bang, Dong-Wan Kim, Seock-Ah Im, Tae-You Kim, Sung-Soo Yoon, Jong Seok Lee, Yung-Jue Bang, Seonyang Park, Byoung Kook Kim, Han Ik Cho, Dae Seog Heo. (2009) Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement. Annals of Hematology 88:9, 829-838
CrossRef445
John C. Morris, Thomas A. Waldmann. (2009) Antibody-based therapy of leukaemia. Expert Reviews in Molecular Medicine 11,
CrossRef446
Waleed Alduaij, Tim M. Illidge. (2009) Radioimmunotherapy: Strategies for the future in indolent and aggressive lymphoma. Current Oncology Reports 11:5, 363-370
CrossRef447
David Aguiar Bujanda, José Aguiar Morales, Uriel Bohn Sarmiento, Salvador Saura Grau, Carlos Rodríguez Franco. (2009) Clinical experience with biweekly CHOP plus rituximab chemoimmunotherapy for the treatment of aggressive B-cell non-Hodgkin lymphoma. Clinical and Translational Oncology 11:9, 604-608
CrossRef448
Daniel O Persky, Thomas P Miller. (2009) Localized large cell lymphoma: is there any need for radiation therapy?. Current Opinion in Oncology 21:5, 401-406
CrossRef449
Catherine Thieblemont, Christian Gisselbrecht. (2009) Second-line treatment paradigms for diffuse large B-cell lymphomas. Current Oncology Reports 11:5, 386-393
CrossRef450
Ya-Chen Tina Shih, Linda S. Elting, Michael T. Halpern. (2009) Factors Associated With Immunotherapy Use Among Newly Diagnosed Cancer Patients. Medical Care 47:9, 948-958
CrossRef451
M. Pfreundschuh. (2009) Therapy of diffuse large B-cell lymphomas. European Journal of Cancer 45, 386-387
CrossRef452
Hideaki Ohta, Norihide Fukushima, Keiichi Ozono. (2009) Pediatric post-transplant lymphoproliferative disorder after cardiac transplantation. International Journal of Hematology 90:2, 127-136
CrossRef453
Pierpaolo Peruzzi, Abhik Ray-Chaudhuri, Wayne H. Slone, Hagop S. Mekhjian, Pierluigi Porcu, E. Antonio Chiocca. (2009) Reversal of neurological deficit after chemotherapy in BCL-6–positive neurolymphomatosis. Journal of Neurosurgery 111:2, 247-251
CrossRef454
Heidi Nyman, Mats Jerkeman, Marja-Liisa Karjalainen-Lindsberg, Alison H Banham, Sirpa Leppä. (2009) Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP. Modern Pathology 22:8, 1094-1101
CrossRef455
Ruth Pettengell, Matti Aapro, Ercole Brusamolino, Dolores Caballero, Bertrand Coiffier, Michael Pfreundschuh, Marek Trneny, Jan Walewski. (2009) Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) Guidelines on the Use of Granulocyte Colony-Stimulating Factor (G-CSF) for Lymphoma Care. Clinical Drug Investigation 29:8, 491-513
CrossRef456
Asahi Ito, Takashi Ishida, Hiroki Yano, Atsushi Inagaki, Susumu Suzuki, Fumihiko Sato, Hisashi Takino, Fumiko Mori, Masaki Ri, Shigeru Kusumoto, Hirokazu Komatsu, Shinsuke Iida, Hiroshi Inagaki, Ryuzo Ueda. (2009) Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rγnull mouse model. Cancer Immunology, Immunotherapy 58:8, 1195-1206
CrossRef457
Arturo J Martí-Carvajal, Ivan Solà, Luis H Agreda-Pérez, Arturo J Martí-Carvajal. 2009. Treatment for avascular necrosis of bone in people with sickle cell disease. .
CrossRef458
Alan S. Wayne. (2009) Application of immunotherapy in pediatric leukemia. Current Hematologic Malignancy Reports 4:3, 159-166
CrossRef459
Alain P. Algazi, Cigall Kadoch, James L. Rubenstein. (2009) Biology and treatment of primary central nervous system lymphoma. Neurotherapeutics 6:3, 587-597
CrossRef460
P G Gobbi, F Valentino, P Lambelet, V Perfetti, G Bergamaschi, M Girino, G R Corazza. (2009) Shortened and intensified MJMA: an effective salvage therapy for relapsed and refractory lymphomas and a strong mobilizer of PBSCs. Bone Marrow Transplantation 44:1, 19-25
CrossRef461
Gillianne Geet Yi Lai, Soon-Thye Lim, Miriam Tao, Alexandre Chan, Huihua Li, Richard Quek. (2009) Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma. American Journal of Hematology 84:7, 414-417
CrossRef462
Charles H. Lawrie, Jianxiang Chi, Stephen Taylor, Daniela Tramonti, Erica Ballabio, Stefano Palazzo, Nigel J. Saunders, Francesco Pezzella, Jacqueline Boultwood, James S. Wainscoat, Christian S. R. Hatton. (2009) Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. Journal of Cellular and Molecular Medicine 13:7, 1248-1260
CrossRef463
Jonathan Said. (2009) Diffuse Aggressive B-cell Lymphomas. Advances in Anatomic Pathology 16:4, 216-235
CrossRef464
Michael Darmon, Elie Azoulay. (2009) Critical care management of cancer patients: cause for optimism and need for objectivity. Current Opinion in Oncology 21:4, 318-326
CrossRef465
Atsushi Inagaki, Takashi Ishida, Hiroki Yano, Toshihiko Ishii, Shigeru Kusumoto, Asahi Ito, Masaki Ri, Fumiko Mori, Jianmin Ding, Hirokazu Komatsu, Shinsuke Iida, Ryuzo Ueda. (2009) Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC. International Journal of Cancer 125:1, 212-221
CrossRef466
K. Dunleavy, S. Pittaluga, M. S. Czuczman, S. S. Dave, G. Wright, N. Grant, M. Shovlin, E. S. Jaffe, J. E. Janik, L. M. Staudt, W. H. Wilson. (2009) Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 113:24, 6069-6076
CrossRef467
D Rossi, S Rasi, S Franceschetti, D Capello, A Castelli, L De Paoli, A Ramponi, A Chiappella, E M Pogliani, U Vitolo, I Kwee, F Bertoni, A Conconi, G Gaidano. (2009) Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leukemia 23:6, 1118-1126
CrossRef468
H. Boyle, V. Girre, C. Mertens, C. Falandry, F. Gouttenoire, G. Freyer, E. G. C. Brain. (2009) Recherche clinique en oncogériatrie. Oncologie 11:6, 331-336
CrossRef469
Yasufumi Masaki, Lingli Dong, Akio Nakajima, Haruka Iwao, Miyuki Miki, Nozomu Kurose, Eriko Kinoshita, Takayuki Nojima, Toshioki Sawaki, Takafumi Kawanami, Masao Tanaka, Kumiko Shimoyama, Changi Kim, Masaaki Fukutoku, Hiroshi Kawabata, Toshihiro Fukushima, Yuko Hirose, Tomoo Takiguchi, Susumu Konda, Susumu Sugai, Hisanori Umehara. (2009) Intravascular large B cell lymphoma: proposed of the strategy for early diagnosis and treatment of patients with rapid deteriorating condition. International Journal of Hematology 89:5, 600-610
CrossRef470
Patrick G Morris, Lauren E Abrey. (2009) Therapeutic challenges in primary CNS lymphoma. The Lancet Neurology 8:6, 581-592
CrossRef471
Michela Cesco-Gaspere, Emma Morris, Hans J. Stauss. (2009) Immunomodulation in the treatment of haematological malignancies. Clinical and Experimental Medicine 9:2, 81-92
CrossRef472
Voravit Ratanatharathorn, Brent Logan, Dan Wang, Mary Horowitz, Joseph P. Uberti, Olle Ringden, Robert Peter Gale, Hanna Khoury, Mukta Arora, Stephen Spellman, Corey Cutler, Joseph Antin, Martin Bornhaüser, Gregory Hale, Leo Verdonck, Mitchell Cairo, Vikas Gupta, Steven Pavletic, . (2009) Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. British Journal of Haematology 145:6, 816-824
CrossRef473
Anne Sonet, André Bosly. (2009) Rituximab and chemotherapy in diffuse large B-cell lymphoma. Expert Review of Anticancer Therapy 9:6, 719-726
CrossRef474
Meili Zhang, Zhengsheng Yao, Kayhan Garmestani, Sarah Yu, Carolyn K. Goldman, Chang H. Paik, Martin W. Brechbiel, Jorge A. Carrasquillo, Thomas A. Waldmann. (2009) Preclinical Evaluation of an Anti-CD25 Monoclonal Antibody, 7G7/B6, Armed with the β-Emitter, Yttrium-90, as a Radioimmunotherapeutic Agent for Treating Lymphoma. Cancer Biotherapy & Radiopharmaceuticals 24:3, 303-309
CrossRef475
S. J. Vedel, D. Tholstrup, L. Kolte, J. Gaardbo, L. P. Ryder, A. Ersbøll, E. Albrecht-Beste, J. Jurlander, J. O. Nielsen, S. D. Nielsen. (2009) Limited Impact of the Thymus on Immunological Recovery During and After Chemotherapy in Patients with Diffuse Large B-cell Lymphoma. Scandinavian Journal of Immunology 69:6, 547-554
CrossRef476
Masatsugu Ohta. (2009) Present status and perspectives regarding the therapeutic strategy for acute myeloid leukemia, non-Hodgkin's lymphoma and multiple myeloma in the elderly. Geriatrics & Gerontology International 9:2, 115-123
CrossRef477
Yutaka Shimazu, Kenji Notohara, Yasunori Ueda. (2009) Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience. International Journal of Hematology 89:5, 577-583
CrossRef478
K. R. Carson, A. M. Evens, E. A. Richey, T. M. Habermann, D. Focosi, J. F. Seymour, J. Laubach, S. D. Bawn, L. I. Gordon, J. N. Winter, R. R. Furman, J. M. Vose, A. D. Zelenetz, R. Mamtani, D. W. Raisch, G. W. Dorshimer, S. T. Rosen, K. Muro, N. R. Gottardi-Littell, R. L. Talley, O. Sartor, D. Green, E. O. Major, C. L. Bennett. (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113:20, 4834-4840
CrossRef479
J. Hiraga, A. Tomita, T. Sugimoto, K. Shimada, M. Ito, S. Nakamura, H. Kiyoi, T. Kinoshita, T. Naoe. (2009) Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 113:20, 4885-4893
CrossRef480
Nilanjan Ghosh, William Matsui. (2009) Cancer stem cells in multiple myeloma. Cancer Letters 277:1, 1-7
CrossRef481
Heidi Nyman, Mats Jerkeman, Marja-Liisa Karjalainen-Lindsberg, Alison H. Banham, Gunilla Enblad, Sirpa Leppä. (2009) Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas. European Journal of Haematology 82:5, 364-372
CrossRef482
Nozomi Niitsu, Daisuke Okamura, Naoki Takahashi, Ken Tanae, Yuki Hagiwara, Hidekazu Kayano, Masami Bessho. (2009) Renal intravascular large B-cell lymphoma with early diagnosis by renal biopsy: A case report and review of the literature. Leukemia Research 33:5, 728-730
CrossRef483
Shimrit Shabbat, Jonas Aharoni, Liat Sarid, Miriam Ben-Harush, Joseph Kapelushnik. (2009) Rituximab as monotherapy and in addition to reduced CHOP in children with primary immunodeficiency and non-Hodgkin lymphoma. Pediatric Blood & Cancer 52:5, 664-666
CrossRef484
H. Tilly, M. Dreyling, . (2009) Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology 20:Supplement 4, iv110-iv112
CrossRef485
J. Crawford, C. Caserta, F. Roila, . (2009) Hematopoietic growth factors: ESMO Recommendations for the applications. Annals of Oncology 20:Supplement 4, iv162-iv165
CrossRef486
W.H. Knapp. (2009) Szintigraphie und Single-Photon-Emissions-Computertomographie (SPECT und PET). Der Onkologe 15:5, 474-486
CrossRef487
Kazushi Tanimoto, Yoshihiro Yakushijin, Hiroshi Fujiwara, Masaki Otsuka, Koichi Ohshima, Atsuro Sugita, Akira Sakai, Takaaki Hato, Hitoshi Hasegawa, Masaki Yasukawa. (2009) Clinical significance of co-expression of CD21 and LFA-1 in B-cell lymphoma. International Journal of Hematology 89:4, 497-507
CrossRef488
Gregorius J. Sips, Colum F. Amory, Bradley N. Delman, George M. Kleinman, Lewis R. Lipsey, Stanley Tuhrim. (2009) Intravascular lymphomatosis of the brain in a patient with myelodysplastic syndrome. Nature Reviews Neurology 5:5, 288-292
CrossRef489
V. Boehme, N. Schmitz, S. Zeynalova, M. Loeffler, M. Pfreundschuh. (2009) CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 113:17, 3896-3902
CrossRef490
N. A. Johnson, M. Boyle, A. Bashashati, S. Leach, A. Brooks-Wilson, L. H. Sehn, M. Chhanabhai, R. R. Brinkman, J. M. Connors, A. P. Weng, R. D. Gascoyne. (2009) Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood 113:16, 3773-3780
CrossRef491
Mary J Ninan, Vicki A Morrison. (2009) Therapeutic approaches to non-Hodgkin’s lymphoma in the elderly patient. Expert Review of Hematology 2:2, 173-182
CrossRef492
Tianqian Zhang, Dorothee Herlyn. (2009) Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer. Cancer Immunology, Immunotherapy 58:4, 475-492
CrossRef493
Seung-Cheol Lee, Edward J. Delikatny, Harish Poptani, Stephen Pickup, Jerry D. Glickson. (2009) In vivo 1 H MRS of WSU-DLCL2 human non-Hodgkin's lymphoma xenografts: response to rituximab and rituximab plus CHOP. NMR in Biomedicine 22:3, 259-265
CrossRef494
, Hisakazu Nishimori, Keitaro Matsuo, Yoshinobu Maeda, Yuichiro Nawa, Kazutaka Sunami, Kazuto Togitani, Hidetaka Takimoto, Yasushi Hiramatsu, Toru Kiguchi, Tomofumi Yano, Hiromichi Yamane, Takayuki Tabayashi, Makoto Takeuchi, Masanori Makita, Nobuo Sezaki, Yoshiko Yamasuji, Haruko Sugiyama, Takahiro Tabuchi, Itaru Kataoka, Nobuharu Fujii, Fumihiko Ishimaru, Katsuji Shinagawa, Kazuma Ikeda, Masamichi Hara, Tadashi Yoshino, Mitsune Tanimoto. (2009) The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis. International Journal of Hematology 89:3, 326-331
CrossRef495
Jan-Lukas Robertus, Geert Harms, Tjasso Blokzijl, Marije Booman, Daphne de Jong, Gustaaf van Imhoff, Stefano Rosati, Ed Schuuring, Philip Kluin, Anke van den Berg. (2009) Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. Modern Pathology 22:4, 547-555
CrossRef496
C. Bouchikhi, H. Bouguern, A. Mimouni, H. Chaara, A. Melhouf, A. Amarti, A. Banani. (2009) Lymphome malin non hodgkinien primitif de l’ovaire: à propos d’un cas. Oncologie 11:4, 248-251
CrossRef497
Michael Dougan, Glenn Dranoff. (2009) Immune Therapy for Cancer. Annual Review of Immunology 27:1, 83-117
CrossRef498
Kholood Alasfoor, Mona Alrasheed, Faisal Alsayegh, Shaker A. Mousa. (2009) Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP). Annals of Hematology 88:3, 239-243
CrossRef499
James O. Armitage. (2009) Targeted therapy and hematological malignancy. Targeted Oncology 4:1, 1-2
CrossRef500
Davide Rossi, Gianluca Gaidano. (2009) Richter syndrome: molecular insights and clinical perspectives. Hematological Oncology 27:1, 1-10
CrossRef501
Ruth Pettengell, André Bosly, Thomas D. Szucs, Christian Jackisch, Robert Leonard, Robert Paridaens, Manuel Constenla, Matthias Schwenkglenks, . (2009) Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. British Journal of Haematology 144:5, 677-685
CrossRef502
P. Schütt, K. Zimmermann, C. Derks, P. Ebeling, A. Welt, M. Poser, J. Hense, K. Metz, J. Anhuf, M. Sandmann, M. Neise, T. Moritz, M. Stuschke, N. Niederle, S. Seeber, Mohammad R. Nowrousian. (2009) Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin’s lymphoma. Journal of Cancer Research and Clinical Oncology 135:3, 459-466
CrossRef503
Giuseppe Visani, Alessandro Isidori. (2009) Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin’s lymphoma: where we stand. Expert Review of Anticancer Therapy 9:3, 357-363
CrossRef504
A. Carbone, E. Cesarman, M. Spina, A. Gloghini, T. F. Schulz. (2009) HIV-associated lymphomas and gamma-herpesviruses. Blood 113:6, 1213-1224
CrossRef505
Mario García-Carrasco, Mario Jiménez-Hernández, Ricardo O. Escárcega, Claudia Mendoza-Pinto, Claudio Galarza-Maldonado, Manuel Sandoval-Cruz, Leticia Zamudio-Huerta, Aurelio López-Colombo, Ricard Cervera. (2009) Use of rituximab in patients with systemic lupus erythematosus: An update. Autoimmunity Reviews 8:4, 343-348
CrossRef506
Takamasa Nishiuchi, Hitomi Imachi, Mako Fujiwara, Koji Murao, Hiroaki Onishi, Tohru Kiguchi, Hidetaka Takimoto, Yoshio Kushida, Reiji Haba, Toshihiko Ishida. (2009) A case of non-Hodgkin’s lymphoma primary arising in both adrenal glands associated with adrenal failure. Endocrine 35:1, 34-37
CrossRef507
Sujit Itty, Jose S. Pulido. (2009) Rituximab for Intraocular Lymphoma. Retina 29:2, 129-132
CrossRef508
Christopher Y Park, Diane Tseng, Irving L Weissman. (2009) Cancer Stem Cell–Directed Therapies: Recent Data From the Laboratory and Clinic. Molecular Therapy 17:2, 219-230
CrossRef509
N. Asano, K. Yamamoto, J.-I. Tamaru, T. Oyama, F. Ishida, K. Ohshima, T. Yoshino, N. Nakamura, S. Mori, O. Yoshie, Y. Shimoyama, Y. Morishima, T. Kinoshita, S. Nakamura. (2009) Age-related Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders: comparison with EBV-positive classic Hodgkin lymphoma in elderly patients. Blood 113:12, 2629-2636
CrossRef510
Dimitrios Kalkanis, Alexandra Stefanovic, Fabio Paes, Maricer P. Escalon, Aldo Serafini, Izidore S. Lossos. (2009) [18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy. Leukemia & Lymphoma 50:6, 904-911
CrossRef511
Soo-Young Bae, Yeo-Kyeoung Kim, Joo-Young Yoon, Sung-Ji Lee, Dae Eun Kim, Sung Yoon Rew, Seung Dok Hong, Dae-Ho Jo, Joon-Il Hwang, Woo-Kyun Bae, Hyun-Jeong Shim, Jae-Sook Ahn, Deok-Hwan Yang, Sang-Hee Cho, Je-Jung Lee, Ik-Joo Chung, Hyeoung-Joon Kim. (2009) Toxic Epidermal Necrolysis after Rituximab Therapy for Immune Thrombocytopenic Purpura. The Korean Journal of Hematology 44:2, 108
CrossRef512
Jessica Hochberg, Ian M. Waxman, Kara M. Kelly, Erin Morris, Mitchell S. Cairo. (2009) Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. British Journal of Haematology 144:1, 24-40
CrossRef513
Makoto Motoishi, Toru Enokibori, Rikuro Hatakenaka. (2009) A case of mediastinal malignant lymphoma with cystic shadow and acute inflammation. The Journal of the Japanese Association for Chest Surgery 23:2, 195-198
CrossRef514
Mathias Witzens-Harig, Monika Reiz, Christiane Heiß, Axel Benner, Manfred Hensel, Kai Neben, Peter Dreger, Alwin Kraemer, Anthony D. Ho. (2009) Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin’s lymphoma: results of a prospective randomized controlled trial. Annals of Hematology 88:1, 51-57
CrossRef515
Maki Nemoto, Gou Takahashi, Takahito Sugisaki, Kazuyoshi Kawakami, Shutaro Higuchi, Hajime Sugiyama, Nao Tunoda, Yasuo Nakamura, Masami Hanade, Naoko Kuroda, Toshihiro Hama. (2009) Preparation of Brochure for Patients Undergoing R-CHOP Chemotherapy Based on Adverse Reactions Survey. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 35:2, 129-135
CrossRef516
Thomas C. Shea, Anne W. Beaven, Dominic T. Moore, Jonathan S. Serody, Don A. Gabriel, Nelson Chao, Jon P. Gockerman, Reynaldo A. Garcia, David A. Rizzieri. (2009) Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival. Leukemia & Lymphoma 50:5, 741-748
CrossRef517
Maria Giuseppina Cabras, Angela Maria Mamusa, Umberto Vitolo, Roberto Freilone R., Paolo Dessalvi, Lorella Orsucci, Anna Tonso, Alessandro Levis, Marina Liberati, Giancarlo Lay, Emanuele Angelucci. (2009) Long term outcome of localized aggressive non-Hodgkin lymphoma treated with a short weekly chemotherapy regimen (doxorubicin, cyclophosphamide, bleomycin, vincristine, and prednisone) and involved field radiotherapy: result of a Gruppo Italiano Multiregionale per lo Studio dei Linfomi e Leucenie (GIMURELL) study. Leukemia & Lymphoma 50:9, 1475-1481
CrossRef518
Hannah H. Wong, Jun Wang. (2009) Epstein-Barr virus positive diffuse large B-cell lymphoma of the elderly. Leukemia & Lymphoma 50:3, 335-340
CrossRef519
Christian Geisler, Arne Kolstad, Anna Laurell, Riikka Räty, For Nordic Lymphoma Group, Mantle Cell Lymphoma Subcommittee. (2009) Mantle cell lymphoma – does primary intensive immunochemotherapy improve overall survival for younger patients?. Leukemia & Lymphoma 50:8, 1249-1256
CrossRef520
Philippe Fagnoni, Noel Milpied, Samuel Limat, Eric Deconinck, Virginie Nerich, Charles Foussard, Philippe Colombat, Jean-Luc Harousseau, Marie-Christine Woronoff-Lemsi. (2009) Cost Effectiveness of High-Dose Chemotherapy with Autologous Stem Cell Support as Initial Treatment of Aggressive Non-Hodgkinʼs Lymphoma. PharmacoEconomics 27:1, 55-68
CrossRef521
Marnelli A. Bautista, Walter D. Y. Quan, Jun Wang. (2009) A Case of Chronic Conjunctivitis following Rituximab Therapy. Advances in Hematology 2009, 1-4
CrossRef522
Claudia Stolz, Martin Schuler. (2009) Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention. Leukemia & Lymphoma 50:6, 873-885
CrossRef523
Sima Jeha. (2009) New Therapeutic Strategies in Acute Lymphoblastic Leukemia. Seminars in Hematology 46:1, 76-88
CrossRef524
Lazar Popovic, Darjana Jovanovic, Gorana Matovina-Brko, Dragana Petrovic, Zoran Nikin, Tatjana Roganovic. (2009) Primary diffuse large B-cell lymphoma of the breast. Archive of oncology 17:3-4, 80-82
CrossRef525
Philip Savage, Justin Stebbing, Mark Bower, Tim Crook. (2009) Why does cytotoxic chemotherapy cure only some cancers?. Nature Clinical Practice Oncology 6:1, 43-52
CrossRef526
Kyung Min Kim, Dok Hyun Yoon, Seung Geun Lee, Sung Nam Lim, Lyu Jin Sug, Jooryung Huh, Cheolwon Suh. (2009) A Case of Primary Adrenal Diffuse Large B-cell Lymphoma Achieving Complete Remission with Rituximab-CHOP Chemotherapy. Journal of Korean Medical Science 24:3, 525
CrossRef527
Tomer Mark, Peter Martin, John P Leonard, Ruben Niesvizky. (2009) Milatuzumab: a promising new agent for the treatment of lymphoid malignancies. Expert Opinion on Investigational Drugs 18:1, 99-104
CrossRef528
Kristin Feuerlein, Emanuele Zucca, Michele Ghielmini. (2009) First-line treatment of follicular lymphoma–a patient-oriented algorithm. Leukemia & Lymphoma 50:3, 325-334
CrossRef529
Ron Ram, Isaac Ben-Bassat, Ofer Shpilberg, Aaron Polliack, Pia Raanani. (2009) The late adverse events of rituximab therapy – rare but there!. Leukemia & Lymphoma 50:7, 1083-1095
CrossRef530
Mariano Provencio, Antonio Sanchez, Constanza Maximiano, Blanca Cantos, Miriam Méndez, Félix Bonilla. (2009) A prospective study of left ventricle function after treatment with rapid-infusion Rituximab in patients with non-Hodgkin lymphoma. Leukemia & Lymphoma 50:10, 1642-1646
CrossRef531
H TATETSU, F MATSUNO, N TAKATSU, H MIYAKE, K HOSHINO, K NOSAKA, K HORIKAWA, H HATA, H MITSUYA, N ASOU. (2009) Treatment of therapy-related acute myeloid leukemia occurring in elderly non-Hodgkin lymphoma patients with low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor. Leukemia Research 33:1, 197-200
CrossRef532
Shun AMIYA, Norihito NURUKI, Koichi HARAGUCHI, Nobuhito OHNOU, Shuho SHIGENOBU, Naoyuki SATA, Katsunori TOFUKU, Yoshihiro FUKUOKA, Kazuyuki TANOUE, Hirohito TSUBOUCHI. (2009) Successful treatment of cardiac lymphoma showing right atrial mass involving free wall of right ventricle with rituximab plus chemotherapy. Choonpa Igaku 36:1, 53-58
CrossRef533
A MICHALLET, B COIFFIER. (2009) Recent developments in the treatment of aggressive non-Hodgkin lymphoma. Blood Reviews 23:1, 11-23
CrossRef534
Kristie A. Blum, Mehdi Hamadani, Gary S. Phillips, Gerard Lozanski, Amy J. Johnson, David M. Lucas, Lisa L. Smith, Robert Baiocchi, Thomas S. Lin, Pierluigi Porcu, Steven M. Devine, John C. Byrd. (2009) Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. Leukemia & Lymphoma 50:3, 349-356
CrossRef535
Zunguo Du, Jieqing Chen, Xiaoyan Zhou, Taiming Zhang, Bobin Chen, Feng Tang. (2009) Composite lymphoma with relapse of enteropathy-type T-cell lymphoma. Leukemia & Lymphoma 50:5, 749-756
CrossRef536
Yasuharu Sato, Naoko Onishi, Toshiaki Morito, Katsuyoshi Takata, Kohichi Mizobuchi, Hitoshi Nagatsuka, Kouichi Ichimura, Takehiro Tanaka, Maiko Tamura, Tadashi Yoshino. (2009) Patients with localized primary non-tonsillar oral diffuse large B-cell lymphoma exhibit favorable prognosis despite a non-germinal center B-cell-like phenotype. Cancer Science 100:1, 42-46
CrossRef537
Rie Hyo, Naoto Tomita, Kengo Takeuchi, Tomohiro Aoshima, Atsuko Fujita, Hideyuki Kuwabara, Chizuko Hashimoto, Sachiya Takemura, Jun Taguchi, Rika Sakai, Hiroyuki Fujita, Shin Fujisawa, Koji Ogawa, Shigeki Motomura, Ritsuro Suzuki, Yoshiaki Ishigatsubo. (2009) The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma. Hematological Oncologyn/a-n/a
CrossRef538
W Klapper, H Stoecklein, S Zeynalova, G Ott, F Kosari, A Rosenwald, M Loeffler, L Trümper, M Pfreundschuh, Reiner Siebert. (2008) Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Leukemia 22:12, 2226-2229
CrossRef539
G. Hess. (2008) Radioimmunotherapy – still experimental? Rational, proven indications and future trends. memo - Magazine of European Medical Oncology 1:4, 193-203
CrossRef540
Lucile Couronné, Pascale Schneider, Jean Michel Picquenot, Sophie Laberge, Christian Bastard, Jean Pierre Vannier. (2008) Refractory Nodular Lymphocyte Predominant Hodgkin Lymphoma Transformed to T-cell/Histiocyte-rich B-cell Lymphoma in an Adolescent. Journal of Pediatric Hematology/Oncology 30:12, 959-962
CrossRef541
Michael Wang, Keith D. Burau, Shenying Fang, Harry Wang, Xianglin L. Du. (2008) Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population-based cohort of elderly patients with non-Hodgkin lymphoma. Cancer 113:11, 3231-3241
CrossRef542
Masami Miyagawa, Masahito Minami, Kota Fujii, Rei Sendo, Kojiro Mori, Daisuke Shimizu, Tomoaki Nakajima, Kohichiroh Yasui, Yoshito Itoh, Masafumi Taniwaki, Takeshi Okanoue, Toshikazu Yoshikawa. (2008) Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy with rituximab. Journal of Medical Virology 80:12, 2069-2078
CrossRef543
M. Coory, D. Gill. (2008) Decreasing mortality from non-Hodgkin lymphoma in Australia. Internal Medicine Journal 38:12, 921-924
CrossRef544
Christian Gisselbrecht. (2008) Use of rituximab in diffuse large B-cell lymphoma in the salvage setting. British Journal of Haematology 143:5, 607-621
CrossRef545
Pascal Sève, Pierre Philippe, Jean-François Dufour, Christiane Broussolle, Marc Michel. (2008) Autoimmune hemolytic anemia: classification and therapeutic approaches. Expert Review of Hematology 1:2, 189-204
CrossRef546
Hirokazu Nagai, Takahiro Yano, Tomoyuki Watanabe, Naokuni Uike, Seiichi Okamura, Shuichi Hanada, Fumio Kawano, Kazutaka Sunami, Nobumasa Inoue, Morio Sawamura, Tetsuo Nishiura, Tomomitsu Hotta, Keizo Horibe. (2008) Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma. British Journal of Haematology 143:5, 672-680
CrossRef547
Sandro Barni, Mary Cabiddu, F Petrelli. (2008) Toxicity of targeted therapies in elderly patients. Expert Review of Anticancer Therapy 8:12, 1965-1976
CrossRef548
Yasuhiro Oki, Kazuhito Yamamoto, Harumi Kato, Yachiyo Kuwatsuka, Hirofumi Taji, Yoshitoyo Kagami, Yasuo Morishima. (2008) Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients’ survival benefit from rituximab. European Journal of Haematology 81:6, 448-453
CrossRef549
Maurizio Martelli, Andrés J.M. Ferreri, Peter Johnson. (2008) Primary mediastinal large B-cell lymphoma. Critical Reviews in Oncology/Hematology 68:3, 256-263
CrossRef550
Saadettin Kilickap, Bunyamin Yavuz, Sercan Aksoy, Levent Sahiner, Murat Dincer, Hakan Harputluoglu, Mustafa Erman, Kudret Aytemir, Lale Tokgozoglu, Ibrahim Barista. (2008) Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin’s lymphoma. Medical Oncology 25:4, 437-442
CrossRef551
Lenz, G., Wright, G., Dave, S.S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., Vose, J., Bast, M., Fu, K., Weisenburger, D.D., Greiner, T.C., Armitage, J.O., Kyle, A., May, L., Gascoyne, R.D., Connors, J.M., Troen, G., Holte, H., Kvaloy, S., Dierickx, D., Verhoef, G., Delabie, J., Smeland, E.B., Jares, P., Martinez, A., Lopez-Guillermo, A., Montserrat, E., Campo, E., Braziel, R.M., Miller, T.P., Rimsza, L.M., Cook, J.R., Pohlman, B., Sweetenham, J., Tubbs, R.R., Fisher, R.I., Hartmann, E., Rosenwald, A., Ott, G., Muller-Hermelink, H.-K., Wrench, D., Lister, T.A., Jaffe, E.S., Wilson, W.H., Chan, W.C., Staudt, L.M., . (2008) Stromal Gene Signatures in Large-B-Cell Lymphomas. New England Journal of Medicine 359:22, 2313-2323
Full Text552
Enrico Derenzini, Gerardo Musuraca, Stefano Fanti, Vittorio Stefoni, Monica Tani, Lapo Alinari, Filippo Venturini, Letizia Gandolfi, Michele Baccarani, Pier Luigi Zinzani. (2008) Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. Cancer 113:9, 2496-2503
CrossRef553
Hossein Borghaei, Corey J. Langer, Michael Millenson, Karen J. Ruth, Samuel Litwin, Holly Tuttle, Judie Sylvester Seldomridge, Marc Rovito, David Mintzer, Roger Cohen, Joseph Treat. (2008) Phase II Study of Paclitaxel, Carboplatin, and Cetuximab as First Line Treatment, for Patients with Advanced Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology 3:11, 1286-1292
CrossRef554
Timothy S Fenske, Heather Benjamin, Steven H Kroft, Eric J Hohenwalter, William S Rilling. (2008) Treatment of diffuse large B-cell lymphoma of the liver with yttrium-90 microsphere embolization. Nature Clinical Practice Oncology 5:11, 677-681
CrossRef555
SALVATORE GUASTAFIERRO, UMBERTO FALCONE, MARIA CELENTANO, FRANCA FERRARACCIO, FRANCESCO IOVINO. (2008) Primary Non-Hodgkin Lymphoma of the Breast as Third Malignancy in One Patient. The American Journal of the Medical Sciences 336:5, 434-436
CrossRef556
Ruth Pettengell, Matthias Schwenkglenks, Robert Leonard, André Bosly, Robert Paridaens, Manuel Constenla, Thomas D. Szucs, Christian Jackisch, . (2008) Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Supportive Care in Cancer 16:11, 1299-1309
CrossRef557
K M Ramadan, J M Connors, A J Al-Tourah, K W Song, R D Gascoyne, M J Barnett, T J Nevill, J D Shepherd, S H Nantel, H J Sutherland, D L Forrest, D E Hogge, J C Lavoie, Y R Abou-Mourad, M Chhanabhai, N J Voss, R R Brinkman, C A Smith, C L Toze. (2008) Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results. Bone Marrow Transplantation 42:9, 601-608
CrossRef558
C. Stolz, G. Hess, P. S. Hahnel, F. Grabellus, S. Hoffarth, K. W. Schmid, M. Schuler. (2008) Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. Blood 112:8, 3312-3321
CrossRef559
D. Ennishi, M. Yokoyama, Y. Terui, H. Asai, S. Sakajiri, Y. Mishima, S. Takahashi, H. Komatsu, K. Ikeda, K. Takeuchi, M. Tanimoto, K. Hatake. (2008) Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. Annals of Oncology 20:3, 526-533
CrossRef560
Vincenzo La Mura, Amalia De Renzo, Fabiana Perna, Diego D’Agostino, Mario Masarone, Marco Romano, Savino Bruno, Roberto Torella, Marcello Persico. (2008) Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin’s lymphoma. Journal of Hepatology 49:4, 557-563
CrossRef561
J-P Jais, C Haioun, T J Molina, D S Rickman, A de Reynies, F Berger, C Gisselbrecht, J Brière, F Reyes, P Gaulard, P Feugier, E Labouyrie, H Tilly, C Bastard, B Coiffier, G Salles, K Leroy. (2008) The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia 22:10, 1917-1924
CrossRef562
A Buser, M Stern, C Arber, M Medinger, J Halter, A Rovo, G Favre, A Lohri, A Tichelli, A Gratwohl. (2008) Impaired B-cell reconstitution in lymphoma patients undergoing allogeneic HSCT: an effect of pretreatment with rituximab?. Bone Marrow Transplantation 42:7, 483-487
CrossRef563
Kyu Yun Jang, Sung Ho Hwang, Keun Sang Kwon, Kyung Ryoul Kim, Ha Na Choi, Na-Ri Lee, Jae-Yong Kwak, Byung-Hyun Park, Ho Sung Park, Myoung Ja Chung, Myoung Jae Kang, Dong Geun Lee, Hun Soo Kim, Hyeok Shim, Woo Sung Moon. (2008) SIRT1 Expression is Associated With Poor Prognosis of Diffuse Large B-Cell Lymphoma. The American Journal of Surgical Pathology 32:10, 1523-1531
CrossRef564
Vicki A Morrison. (2008) Evolution of R-CHOP therapy for older patients with diffuse large B-cell lymphoma. Expert Review of Anticancer Therapy 8:10, 1651-1658
CrossRef565
D WRENCH, J GRIBBEN. (2008) Stem Cell Transplantation for Non-Hodgkin's Lymphoma. Hematology/Oncology Clinics of North America 22:5, 1051-1079
CrossRef566
Byung Hyun Byun, Im Il Na, Gi Jeong Cheon, Hye Jin Kang, Kyeong Min Kim, Seung-Sook Lee, Baek-Yeol Ryoo, Chang Woon Choi, Sang Moo Lim, Sung Hyun Yang. (2008) Clinical significance of 18F-FDG uptake by primary sites in patients with diffuse large B cell lymphoma in the head and neck: a pilot study. Annals of Nuclear Medicine 22:8, 645-651
CrossRef567
Eiji Tanaka, Takeji Umemura. (2008) History and prevention of de novo hepatitis B virus-related hepatitis in Japan and the world. Clinical Journal of Gastroenterology 1:3, 83-86
CrossRef568
Jonathan W. Friedberg, Richard I. Fisher. (2008) Diffuse Large B-Cell Lymphoma. Hematology/Oncology Clinics of North America 22:5, 941-952
CrossRef569
Andrés J. M. Ferreri, Giuseppina P. Dognini, Osnat Bairey, Arpad Szomor, Carlos Montalbán, Barbara Horvath, Judit Demeter, Lilj Uziel, Riccardo Soffietti, John F. Seymour, Achille Ambrosetti, Rein Willemze, Maurizio Martelli, Giuseppe Rossi, Anna Candoni, Amalia De Renzo, Claudio Doglioni, Emanuele Zucca, Franco Cavalli, Maurilio Ponzoni, . (2008) The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in ‘Western’ patients with intravascular large B-cell lymphoma. British Journal of Haematology 143:2, 253-257
CrossRef570
T. M. Habermann, S. S. Wang, M. J. Maurer, L. M. Morton, C. F. Lynch, S. M. Ansell, P. Hartge, R. K. Severson, N. Rothman, S. Davis, S. M. Geyer, W. Cozen, S. J. Chanock, J. R. Cerhan. (2008) Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. Blood 112:7, 2694-2702
CrossRef571
P W M Johnson. (2008) Survival from non-Hodgkin lymphoma in England and Wales up to 2001. British Journal of Cancer 99, S107-S109
CrossRef572
G. M. Mead, S. L. Barrans, W. Qian, J. Walewski, J. A. Radford, M. Wolf, S. M. Clawson, S. P. Stenning, C. L. Yule, A. S. Jack, . (2008) A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 112:6, 2248-2260
CrossRef573
Andrew Z. Wang, Vaishali Bagalkot, Christophoros C. Vasilliou, Frank Gu, Frank Alexis, Liangfang Zhang, Mariam Shaikh, Kai Yuet, Michael J. Cima, Robert Langer, Philip W. Kantoff, Neil H. Bander, Sangyong Jon, Omid C. Farokhzad. (2008) Superparamagnetic Iron Oxide Nanoparticle-Aptamer Bioconjugates for Combined Prostate Cancer Imaging and Therapy. ChemMedChem 3:9, 1311-1315
CrossRef574
Nada Vujasinovic-Stupar, Nada Pejnovic, Olivera Markovic, Goran Babic. (2008) Influence of rituximab–CHOP therapy on clinical course and autoimmune parameters in rheumatoid arthritis associated with diffuse large B cell non-Hodgkin lymphoma. Annals of Hematology 87:9, 767-769
CrossRef575
D. G. Power, G. P. McVey, G. Korpanty, A. Treacy, P. Dervan, C. O’Keane, D. N. Carney. (2008) Primary bone lymphoma: single institution case series. Irish Journal of Medical Science 177:3, 247-251
CrossRef576
Vaishalee Padgaonkar Kenkre, Sonali M. Smith. (2008) Management of relapsed diffuse large B-cell lymphoma. Current Oncology Reports 10:5, 393-403
CrossRef577
Alexandra M Levine. (2008) Management of AIDS-related lymphoma. Current Opinion in Oncology 20:5, 522-528
CrossRef578
Pieternella J. Lugtenburg, Pieter Sonneveld. (2008) Treatment of diffuse large B-cell lymphoma in the elderly: Strategies integrating oncogeriatric themes. Current Oncology Reports 10:5, 412-419
CrossRef579
Maricer P Escalón, Izidore S Lossos. (2008) Pharmacotherapy of large B-cell lymphoma. Expert Opinion on Pharmacotherapy 9:13, 2247-2258
CrossRef580
N. J. Senff, E. M. Noordijk, Y. H. Kim, M. Bagot, E. Berti, L. Cerroni, R. Dummer, M. Duvic, R. T. Hoppe, N. Pimpinelli, S. T. Rosen, M. H. Vermeer, S. Whittaker, R. Willemze. (2008) European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 112:5, 1600-1609
CrossRef581
Hervé Ghesquières, Céline Ferlay, Catherine Sebban, Catherine Chassagne, Liana Carausu, Thérèse Gargi, Bertrand Favier, Irène Philip, Jean-Yves Blay, Pierre Biron. (2008) Combination of rituximab with chemotherapy in diffuse large B-cell lymphoma. Evaluation in daily practice before and after approval of rituximab in this indication. Hematological Oncology 26:3, 139-147
CrossRef582
José Rodríguez, Eulogio Conde, Antonio Gutiérrez, Juan Carlos García, Juan José Lahuerta, María Rosario Varela, Catalina Pérez, Carmen Albo, María Dolores Caballero. (2008) Primary mediastinal large cell lymphoma (PMBL): frontline treatment with autologous stem cell transplantation (ASCT). The GEL-TAMO experience. Hematological Oncology 26:3, 171-178
CrossRef583
David E. Gerber. (2008) EGFR inhibition in the treatment of non-small cell lung cancer. Drug Development Research 69:6, 359-372
CrossRef584
Cheson, Bruce D., Leonard, John P., . (2008) Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma. New England Journal of Medicine 359:6, 613-626
Full Text585
Rajni Sinha, Pareen J Shenoy, Christopher R Flowers. (2008) Idiotype vaccine strategies for improving outcomes in follicular lymphoma. Expert Opinion on Biological Therapy 8:8, 1213-1223
CrossRef586
G. Held, J. Schubert, M. Pfreundschuh. (2008) Therapie bösartiger Hämoblastosen mit monoklonalen Antikörpern. Der Internist 49:8, 929-937
CrossRef587
Luciano J. Costa, Andrew L. Feldman, Ivana N. Micallef, David J. Inwards, Patrick B. Johnston, Luis F. Porrata, Stephen M. Ansell. (2008) Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation. British Journal of Haematology 142:3, 404-412
CrossRef588
Naoto Fujita, Tetsuya Mori, Tetsuo Mitsui, Hiroko Inada, Keizo Horibe, Masahito Tsurusawa, . (2008) The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: A retrospective analysis of enrolled cases in Japan. Pediatric Blood & Cancer 51:2, 188-192
CrossRef589
Andrei Ivanov, Ruth Swann, Tim Illidge. (2008) New insights into the mechanisms of action of radioimmunotherapy in lymphoma. Journal of Pharmacy and Pharmacology 60:8, 987-998
CrossRef590
Andrew Z Wang, Frank Gu, Liangfang Zhang, Juliana M Chan, Aleksander Radovic-Moreno, Mariam R Shaikh, Omid C Farokhzad. (2008) Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opinion on Biological Therapy 8:8, 1063-1070
CrossRef591
S. HASHINO, M. MORIOKA, T. IRIE, N. SHIROSHITA, T. KAWAMURA, S. SUZUKI, H. IWASAKI, S. UMEHARA, Y. KAKINOKI, M. KUROSAWA, K. KAHATA, K. IZUMIYAMA, H. KOBAYASHI, M. ONOZAWA, M. TAKAHATA, F. FUJISAWA, T. KONDO, M. ASAKA. (2008) Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma. International Journal of Laboratory Hematology 30:4, 292-299
CrossRef592
Michael Boyiadzis, Kenneth A Foon. (2008) Approved monoclonal antibodies for cancer therapy. Expert Opinion on Biological Therapy 8:8, 1151-1158
CrossRef593
Didier Decaudin, Rémi Dendale, Livia Lumbroso-Le Rouic. (2008) Treatment of mucosa-associated lymphoid tissue-type ocular adnexal lymphoma. Anti-Cancer Drugs 19:7, 673-680
CrossRef594
Alfred Reiter, Wolfram Klapper. (2008) Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. British Journal of Haematology 142:3, 329-347
CrossRef595
V. González, E. Salgueiro, F. J. Jimeno, A. Hidalgo, T. Rubio, G. Manso. (2008) Post‐marketing safety of antineoplasic monoclonal antibodies: rituximab and trastuzumab. Pharmacoepidemiology and Drug Safety 17:7, 714-721
CrossRef596
Hye Jin Kang, Won Seog Kim, Cheolwon Suh, Yeon Hee Park, Bong Seog Kim, Young Jin Yuh, Baek-Yeol Ryoo. (2008) Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP. Cancer Chemotherapy and Pharmacology 62:2, 299-304
CrossRef597
Barrett W. Newsome, Marc S. Ernstoff. (2008) The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?. British Journal of Clinical Pharmacology 66:1, 6-19
CrossRef598
F ROLLOTTRAD, H LAHJIBI, C LAZAROVICI, C BAUER, O SAINTJEAN, M GISSELBRECHT. (2008) Hémopathies et sujets âgés : expérience d’un service de court séjour gériatrique. La Revue de Médecine Interne 29:7, 541-549
CrossRef599
Jorge Castillo, Eric Winer, Peter Quesenberry. (2008) Newer monoclonal antibodies for hematological malignancies. Experimental Hematology 36:7, 755-768
CrossRef600
Elizabeth N. Le, Meg R. Gerstenblith, Allan C. Gelber, Rebecca L. Manno, Padmini D. Ranasinghe, Ronald J. Sweren, Laura Y. McGirt. (2008) The use of blind skin biopsy in the diagnosis of intravascular B-cell lymphoma. Journal of the American Academy of Dermatology 59:1, 148-151
CrossRef601
D. Ennishi, K. Takeuchi, M. Yokoyama, H. Asai, Y. Mishima, Y. Terui, S. Takahashi, H. Komatsu, K. Ikeda, M. Yamaguchi, R. Suzuki, M. Tanimoto, K. Hatake. (2008) CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Annals of Oncology 19:11, 1921-1926
CrossRef602
R. Malumbres, J. Chen, R. Tibshirani, N. A. Johnson, L. H. Sehn, Y. Natkunam, J. Briones, R. Advani, J. M. Connors, G. E. Byrne, R. Levy, R. D. Gascoyne, I. S. Lossos. (2008) Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood 111:12, 5509-5514
CrossRef603
Robert J. Gray. 2008. Eastern Cooperative Oncology Group (ECOG). .
CrossRef604
Yi-Fu He, Yu-Hong Li, Feng-Hua Wang, Wen-Qi Jiang, Rui-Hua Xu, Xiao-Fei Sun, Zhong-Jun Xia, Hui-Qiang Huang, Tong-Yu Lin, Li Zhang, Shi-Ping Bao, You-Jian He, Zhong-zhen Guan. (2008) The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma. Annals of Hematology 87:6, 481-485
CrossRef605
Björkholm Magnus, Andersson Tomas, Ahlbom Anders, Ösby Eva. (2008) CNOP (mitoxantrone) chemotherapy is inferior to CHOP (doxorubicin) in the treatment of patients with aggressive non-Hodgkin lymphoma (meta-analysis). European Journal of Haematology 80:6, 477-482
CrossRef606
Shireen Kassam, Silvia Montoto. (2008) Oncologic, Endocrine & Metabolic Emerging drugs in B-cell non-Hodgkin's lymphoma. Expert Opinion on Emerging Drugs 13:2, 323-343
CrossRef607
E. Pelosi, P. Pregno, D. Penna, D. Deandreis, A. Chiappella, G. Limerutti, U. Vitolo, M. Mancini, G. Bisi, E. Gallo. (2008) Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma. La radiologia medica 113:4, 578-590
CrossRef608
Christoph Oehler-Jänne, Christian Taverna, Nadine Stanek, Laura Negretti, Urs M. Lütolf, Ilja F. Ciernik. (2008) Consolidative involved field radiotherapy after high dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma: a case-control study. Hematological Oncology 26:2, 82-90
CrossRef609
W. Klapper, M. Szczepanowski, B. Burkhardt, H. Berger, M. Rosolowski, S. Bentink, C. Schwaenen, S. Wessendorf, R. Spang, P. Moller, M. L. Hansmann, H.-W. Bernd, G. Ott, M. Hummel, H. Stein, M. Loeffler, L. Trumper, M. Zimmermann, A. Reiter, R. Siebert, . (2008) Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials. Blood 112:4, 1374-1381
CrossRef610
C. Wilhelm, A. Neubauer. (2008) Molekulare Tumortherapie. Der Internist 49:5, 581-592
CrossRef611
Umberto Basso, Singora Tonti, Catia Bassi, Antonella Brunello, Lara Maria Pasetto, Daniela Scaglione, Cristina Falci, Manuela Beda, Savina Maria Luciana Aversa, Micaela Stefani, Eugenio Castegnaro, Fabio Tamellini, Silvio Monfardini. (2008) Management of Frail and Not-Frail elderly cancer patients in a hospital-based geriatric oncology program. Critical Reviews in Oncology/Hematology 66:2, 163-170
CrossRef612
José Manuel Cervera Grau, Gaspar Esquerdo Galiana, Ana Belso Candela, Cristina Llorca Ferrándiz, Asunción Juárez Marroquí, Sonia Maciá Escalante. (2008) Complete atrioventricular block induced by rituximab in monotherapy in an aged patient with non-Hodgkin’s diffuse large B-cell lymphoma. Clinical and Translational Oncology 10:5, 298-299
CrossRef613
Daisuke Ennishi, Yasuhito Terui, Masahiro Yokoyama, Yuko Mishima, Shunji Takahashi, Kengo Takeuchi, Kazuma Ikeda, Mitsune Tanimoto, Kiyohiko Hatake. (2008) Increased incidence of interstitial pneumonia by CHOP combined with rituximab. International Journal of Hematology 87:4, 393-397
CrossRef614
Mitchell R. Smith. (2008) Antibodies and Hematologic Malignancies. The Cancer Journal 14:3, 184-190
CrossRef615
M PAIVA, H MARQUES, A MARTINS, P FERREIRA, R CATARINO, R MEDEIROS. (2008) FcγRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients. Cancer Genetics and Cytogenetics 183:1, 35-40
CrossRef616
Michael Pfreundschuh, Anthony D Ho, Eva Cavallin-Stahl, Max Wolf, Ruth Pettengell, Ingrid Vasova, Andrew Belch, Jan Walewski, Pier-Luigi Zinzani, Walter Mingrone, Stein Kvaloy, Ofer Shpilberg, Ulrich Jaeger, Mads Hansen, Claudia Corrado, Adriana Scheliga, Markus Loeffler, Evelyn Kuhnt. (2008) Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. The Lancet Oncology 9:5, 435-444
CrossRef617
A. Bosly, D. Bron, A. Hoof, R. Bock, Z. Berneman, A. Ferrant, L. Kaufman, M. Dauwe, G. Verhoef, . (2008) Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Annals of Hematology 87:4, 277-283
CrossRef618
Brad Kahl. (2008) Chemotherapy Combinations With Monoclonal Antibodies in Non-Hodgkin’s Lymphoma. Seminars in Hematology 45:2, 90-94
CrossRef619
Ercole Brusamolino, Margherita Maffioli, Maurizio Bonfichi, Umberto Vitolo. (2008) Front-line therapy for nonlocalized diffuse large B-cell lymphoma: what has been demonstrated and what is yet to be established. Future Oncology 4:2, 199-210
CrossRef620
Rekha Wuntakal, Deepa Janga, Durga Satyanarayana, Karina Reynolds, Antony Hollingworth. (2008) An Unusual Cause of Postmenopausal Bleeding. Journal of Lower Genital Tract Disease 12:2, 130-133
CrossRef621
Howland E. Crosswell, Daniel J. Bergsagel, Robert Yost, Glen Lew. (2008) Successful treatment with modified CHOP-rituximab in pediatric AIDS-related advanced stage Burkitt lymphoma. Pediatric Blood & Cancer 50:4, 883-885
CrossRef622
Prashant Kapoor, Patricia T. Greipp, William G. Morice, S. Vincent Rajkumar, Thomas E. Witzig, Philip R. Greipp. (2008) Anti-CD20 monoclonal antibody therapy in multiple myeloma. British Journal of Haematology 141:2, 135-148
CrossRef623
L J Costa, I N Micallef, D J Inwards, P B Johnston, L F Porrata, S M Ansell. (2008) Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation. Bone Marrow Transplantation 41:8, 715-720
CrossRef624
Brian K. Link, Jonathan W. Friedberg. (2008) Monoclonal Antibodies in Lymphoma: The First Decade. Seminars in Hematology 45:2, 71-74
CrossRef625
G. Lenz, R. E. Davis, V. N. Ngo, L. Lam, T. C. George, G. W. Wright, S. S. Dave, H. Zhao, W. Xu, A. Rosenwald, G. Ott, H. K. Muller-Hermelink, R. D. Gascoyne, J. M. Connors, L. M. Rimsza, E. Campo, E. S. Jaffe, J. Delabie, E. B. Smeland, R. I. Fisher, W. C. Chan, L. M. Staudt. (2008) Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma. Science 319:5870, 1676-1679
CrossRef626
P. Martin, A. Chadburn, P. Christos, R. Furman, J. Ruan, M. A. Joyce, E. Fusco, P. Glynn, R. Elstrom, R. Niesvizky, E. J. Feldman, T. B. Shore, M. W. Schuster, S. Ely, D. M. Knowles, S. Chen-Kiang, M. Coleman, J. P. Leonard. (2008) Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Annals of Oncology 19:7, 1327-1330
CrossRef627
J. King, J. Waxman, H. Stauss. (2008) Advances in tumour immunotherapy. QJM 101:9, 675-683
CrossRef628
Heiko Schöder, Craig Moskowitz. (2008) PET Imaging for Response Assessment in Lymphoma: Potential and Limitations. Radiologic Clinics of North America 46:2, 225-241
CrossRef629
Robert C. Lee, Denise Zou, Douglas. J. Demetrick, Lisa M. DiFrancesco, Konrad Fassbender, Douglas Stewart. (2008) Costs Associated with Diffuse Large B-Cell Lymphoma Patient Treatment in a Canadian Integrated Cancer Care Center. Value in Health 11:2, 221-230
CrossRef630
Ken-Hong Lim, Tzeun-Yuh Chiou, Cheng-Jui Lin, Ruey-Kuen Hsieh. (2008) Rituximab in the treatment of primary bilateral adrenal lymphoma with adrenal crisis. Medical Oncology 25:1, 107-109
CrossRef631
Christophe de Romeuf, Charles-Antoine Dutertre, Magali Le Garff-Tavernier, Nathalie Fournier, Christine Gaucher, Arnaud Glacet, Sylvie Jorieux, Nicolas Bihoreau, Christian K. Behrens, Roland Béliard, Vincent Vieillard, Bruno Cazin, Dominique Bourel, Jean-François Prost, Jean-Luc Teillaud, Hélène Merle-Béral. (2008) Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16. British Journal of Haematology 140:6, 635-643
CrossRef632
Kristen N. Ganjoo, Annette M. Moore, Attilio Orazi, Joy A. Sen, Cynthia S. Johnson, Caroline S. An. (2008) The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients. Journal of Cancer Research and Clinical Oncology 134:3, 381-387
CrossRef633
Pilar Miralles, Juan Berenguer, José María Ribera Santasusana, Felipe Calvo, Joaquín Díaz Mediavilla, José Luis Díez-Martín, José Gomez Codina, José López Aldeguer, Rafael Rubio, Jesús Santos, Eulalia Valencia. (2008) Recomendaciones de GESIDA/PETHEMA sobre el diagnóstico y el tratamiento de los linfomas en pacientes infectados por el virus de la inmunodeficiencia humana. Medicina Clínica 130:8, 300-311
CrossRef634
Silvio Monfardini, Cesare Gridelli, Lara M. Pasetto, Pierre Soubeyran, Jean-Pierre Droz, Umberto Basso. (2008) Vulnerable and frail elderly: An approach to the management of the main tumour types. European Journal of Cancer 44:4, 488-493
CrossRef635
Matthew J. Matasar, Andrew D. Zelenetz. (2008) Overview of Lymphoma Diagnosis and Management. Radiologic Clinics of North America 46:2, 175-198
CrossRef636
Reyes Arranz, Eulogio Conde, Carlos Grande, Maria Victoria Mateos, Marco Gandarillas, Carmen Albo, Juan J. Lahuerta, José M. Fernández-Rañada, Miguel T. Hernández, Natalia Alonso, José A. García Vela, Sebastián Garzón, José Rodríguez, Dolores Caballero, . (2008) Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL–TAMO Study Group. European Journal of Haematology 80:3, 227-235
CrossRef637
Michael Pfreundschuh, Joerg Schubert, Marita Ziepert, Rudolf Schmits, Martin Mohren, Eva Lengfelder, Marcel Reiser, Christina Nickenig, Michael Clemens, Norma Peter, Carsten Bokemeyer, Hartmut Eimermacher, Anthony Ho, Martin Hoffmann, Roland Mertelsmann, Lorenz Trümper, Leopold Balleisen, Ruediger Liersch, Bernd Metzner, Frank Hartmann, Bertram Glass, Viola Poeschel, Norbert Schmitz, Christian Ruebe, Alfred C Feller, Markus Loeffler. (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). The Lancet Oncology 9:2, 105-116
CrossRef638
Arturo Molina. (2008) A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin's Lymphoma. Annual Review of Medicine 59:1, 237-250
CrossRef639
Panagiotis Tsirigotis, Theofanis Economopoulos. (2008) Monoclonal antibodies in the treatment of lymphoid malignancies. The Journal of Steroid Biochemistry and Molecular Biology 108:3-5, 267-271
CrossRef640
Andrés López, Antonio Gutiérrez, Andrés Palacios, Isabel Blancas, Maite Navarrete, Miguel Morey, Antonia Perelló, Jesús Alarcón, Jordi Martínez, José Rodríguez. (2008) GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. European Journal of Haematology 80:2, 127-132
CrossRef641
Josep-Maria Ribera, Albert Oriol, Mireia Morgades, Eva González-Barca, Pilar Miralles, Armando López-Guillermo, Santiago Gardella, Andres López, Eugenia Abella, Marta García, . (2008) Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. British Journal of Haematology 140:4, 411-419
CrossRef642
Bertrand Coiffier, Hervé Tilly. (2008) Dose dance in lymphomas. The Lancet Oncology 9:2, 84-86
CrossRef643
I. Shimanovich, M. Nitschke, C. Rose, J. Grabbe, D. Zillikens. (2008) Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. British Journal of Dermatology 158:2, 382-388
CrossRef644
Dina Attias, Sheila Weitzman. (2008) The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence. Current Opinion in Pediatrics 20:1, 17-22
CrossRef645
B FILIP, D LOUKE, G INGEBORG, O FRITZ, D PHILIPPE. (2008) Diffuse large B-cell lymphoma with pancreatic localisation. European Journal of Radiology Extra 65:2, 61-64
CrossRef646
Alexander Greb, Julia Bohlius, Daniel Schiefer, Guido Schwarzer, Holger Schulz, Andreas Engert, Alexander Greb. 2008. High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults. .
CrossRef647
E. Vellenga, W. L. J. van Putten, M. B. van 't Veer, J. M. Zijlstra, W. E. Fibbe, M. H. J. van Oers, L. F. Verdonck, P. W. Wijermans, G. W. van Imhoff, P. J. Lugtenburg, P. C. Huijgens. (2008) Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood 111:2, 537-543
CrossRef648
Tim Illidge, Shaun Tolan. (2008) Current treatment approaches for diffuse large B-cell lymphoma. Leukemia & Lymphoma 49:4, 663-676
CrossRef649
A Tefferi. (2008) The history of myeloproliferative disorders: before and after Dameshek. Leukemia 22:1, 3-13
CrossRef650
Biljana Mihaljevic, Snezana Jankovic, Ljubomir Jakovic, Maja Jovanovic-Perunicic, Bosko Andjelic, Violeta Milosevic, Aleksandra Sretenovic, Marjana Virijevic, Milan Petrovic. (2008) Application of monoclonal anti-CD20 antibody rituximab in the treatment of non-Hodgkin's lymphoma. Vojnosanitetski pregled 65:3, 229-233
CrossRef651
Felicetto Ferrara, Roberto Ravasio. (2008) Cost-Effectiveness Analysis of the??Addition of Rituximab to CHOP??in Young Patients with Good-Prognosis Diffuse Large-B-Cell Lymphoma. Clinical Drug Investigation 28:1, 55-65
CrossRef652
Alessandro Pavan, Michele Spina, Vincenzo Canzonieri, Silvia Sansonno, Giuseppe Toffoli, Valli De Re. (2008) Recent prognostic factors in diffuse large B-cell lymphoma indicate NF-κB pathway as a target for new therapeutic strategies. Leukemia & Lymphoma 49:11, 2048-2058
CrossRef653
Naru Kondo, Hiroshi Furuya, Shigeru Yamamoto, Akinobu Nakano, Yoshihiro Sakashita. (2008) Diffuse Large B-cell Lymphoma in the Ampulla of Vater Causing Obstructive Jaundice: Report of a Case. Surgery Today 38:1, 76-80
CrossRef654
Yoshimasa Saito, Kazumasa Naruhashi, Natsuko Inoue, Anna Kubo, Yoshimitsu Takahashi, Masaru Kobori, Yasufumi Masaki, Kohji Nishio. (2008) Investigation of Usefulness of Drugs Prescribed for Supportive Therapy for CHOP-related Chemotherapy Based on Clinical Pathway. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 34:1, 52-58
CrossRef655
Lawrence D. Kaplan. 2008. HIV-associated Neoplasia. , 463-474.
CrossRef656
Antonio Rueda, Pilar Sabin, Juli Rifá, Marta Llanos, José Gómez-Codina, Francisco Lobo, Ramón García, Joaquin Herrero, Mariano Provencio, Carlos Jara, . (2008) R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study. Hematological Oncology 26:1, 27-32
CrossRef657
Maria Christina Cox, Italo Nofroni, Luigi Ruco, Rachele Amodeo, Antonella Ferrari, Giacinto La Verde, Patrizia Cardelli, Enrico Montefusco, Esmeralda Conte, Bruno Monarca, Maria Antonietta Aloe-Spiriti. (2008) Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leukemia & Lymphoma 49:9, 1745-1751
CrossRef658
Xin Liu, Xiao-Nan Hong, Ya-Jia Gu, Bi-Yun Wang, Zhi-Guo Luo, Junning Cao. (2008) Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma. Leukemia & Lymphoma 49:9, 1778-1783
CrossRef659
Renata Zaucha, Ted Gooley, Leona Holmberg, Ajay K. Gopal, Oliver Press, David Maloney, William I. Bensinger. (2008) High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma. Leukemia & Lymphoma 49:10, 1899-1906
CrossRef660
John C. Morris, Thomas A. Waldmann, John E. Janik. (2008) Receptor-Directed Therapy of T-Cell Leukemias and Lymphomas. Journal of Immunotoxicology 5:2, 235-248
CrossRef661
Stefan Wilop, Oliver Galm, Reyad Dada, Rainhardt Osieka, Edgar Jost. (2008) Rituximab-associated changes in platelet count in patients with non-Hodgkin lymphoma. Leukemia & Lymphoma 49:11, 2116-2124
CrossRef662
Yasuhiro Oki, Harumi Kato, Keitaro Matsuo, Yachiyo Kuwatsuka, Hirofumi Taji, Kazuhito Yamamoto, Yoshitoyo Kagami, Yasuo Morishima. (2008) Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy. Leukemia & Lymphoma 49:7, 1345-1351
CrossRef663
Giuseppe Visani, Felicetto Ferrara, Francesco Alesiani, Sonia Ronconi, Massimo Catarini, Francesca D'adamo, Barbara Guiducci, Daniele Bernardi, Sara Barulli, Pierpaolo Piccaluga, Marco Rocchi, Alessandro Isidori. (2008) R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: A pilot study. Leukemia & Lymphoma 49:6, 1081-1086
CrossRef664
Ock Bae Ko, Geundoo Jang, Shin Kim, Jooryung Huh, Cheolwon Suh. (2008) Autologous stem cell transplantation for diffuse large B-cell lymphoma with residual extranodal involvement. The Korean journal of internal medicine 23:4, 182
CrossRef665
Siddhartha Laskar, Pranshu Mohindra, Sudeep Gupta, Tanuja Shet, Mary Ann Muckaden. (2008) Non-Hodgkin lymphoma of the Waldeyer's ring: clinicopathologic and therapeutic issues. Leukemia & Lymphoma 49:12, 2263-2271
CrossRef666
Chun-Yu Liu, Hao-Wei Teng, Jiing-Feng Lirng, Tzeon-Jye Chiou, Po-Min Chen, Liang-Tsai Hsiao. (2008) Sustained remission and long-term survival of secondary central nervous system involvement by aggressive B-cell lymphoma after combination treatment of systemic high-dose chemotherapy and intrathecal rituximab. Leukemia & Lymphoma 49:10, 2018-2021
CrossRef667
P. W.M. Johnson, A. J. Davies. (2008) Primary Mediastinal B-Cell Lymphoma. Hematology 2008:1, 349-358
CrossRef668
Thomas E. Witzig, Susan M. Geyer, Paul J. Kurtin, Joseph P. Colgan, David J. Inwards, Ivana N. M. Micallef, Betsy R. LaPlant, John C. Michalak, Muhammad Salim, Robert J. Dalton, Dennis F. Moore, Craig B. Reeder. (2008) Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group. Leukemia & Lymphoma 49:6, 1074-1080
CrossRef669
Peter Mclaughlin, Julie M. Vose. (2008) R-DHAP: A good small step, but not the journey's end. Leukemia & Lymphoma 49:6, 1019-1021
CrossRef670
Kazuyuki Shimada, Hiroshi Kosugi, Hiroto Narimatsu, Satoko Shimada, Tatsuya Suzuki, Masafumi Ito, Tomohiro Kinoshita, Naoyoshi Mori, Tomoki Naoe. (2008) Sustained Remission after Rituximab-containing Chemotherapy for Intravascular Large B-cell Lymphoma. Journal of Clinical and Experimental Hematopathology 48:1, 25-28
CrossRef671
Paul L. R Mitchell, Paula Marlton, Andrew Grigg, John F Seymour, Mark Hertzberg, Arno Enno, Richard Herrmann, Rodney Bond, Chris Arthur. (2008) A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma. Leukemia & Lymphoma 49:5, 924-931
CrossRef672
Joseph P. Catlett, Stephen A. Williams, Shannon C. O'Connor, Jayashree Krishnan, Vera Malkovska. (2008) Primary lymphoma of bone: an institutional experience. Leukemia & Lymphoma 49:11, 2125-2132
CrossRef673
David Murdoch, Jason Sager. (2008) Will targeted therapy hold its promise? An evidence-based review. Current Opinion in Oncology 20:1, 104-111
CrossRef674
Helge Menzel, Andrea Müller, Christoph Von Schilling, Thomas Licht, Christian Peschel, Ulrich Keller. (2008) Ifosfamide, epirubicin and etoposide rituximab in refractory or relapsed B-cell lymphoma: Analysis of remission induction and stem cell mobilization. Leukemia & Lymphoma 49:7, 1337-1344
CrossRef675
Ye Guo, Jiade J. Lu, Xuejun Ma, Biyun Wang, Xiaonan Hong, Xiaoqiu Li, Jin Li. (2008) Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: Elucidating the significance of systemic chemotherapy. Oral Oncology 44:1, 23-30
CrossRef676
Izidore S. Lossos. (2008) Diffuse Large B Cell Lymphoma: From Gene Expression Profiling to Prediction of Outcome. Biology of Blood and Marrow Transplantation 14:1, 108-111
CrossRef677
Lynette Ngo, Siew-Wan Hee, Lay-Cheng Lim, Miriam Tao, Richard Quek, Swee-Peng Yap, Er-Li Loong, Ivy Sng, Tan Leonard Hwan-Cheong, Mei-Kim Ang, Joanne Ngeow, Chee-Kian Tham, Min-Han Tan, Soon-Thye Lim. (2008) Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab. Leukemia & Lymphoma 49:3, 462-469
CrossRef678
Benjamin Leader, Quentin J. Baca, David E. Golan. (2008) Protein therapeutics: a summary and pharmacological classification. Nature Reviews Drug Discovery 7:1, 21-39
CrossRef679
David B Fenske, Pieter R Cullis. (2008) Liposomal nanomedicines. Expert Opinion on Drug Delivery 5:1, 25-44
CrossRef680
Isabelle Madelaine, Pierre Faure, Émilie Franchon, Pierre Faure. 2008. Traitement des lymphomes (lymphome de Hodgkin et lymphome non hodgkinien). , 645-653.
CrossRef681
K. H. Young, D. D. Weisenburger, B. J. Dave, L. Smith, W. Sanger, J. Iqbal, E. Campo, J. Delabie, R. D. Gascoyne, G. Ott, L. Rimsza, H. K. Muller-Hermelink, E. S. Jaffe, A. Rosenwald, L. M. Staudt, W. C. Chan, T. C. Greiner. (2007) Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood 110:13, 4396-4405
CrossRef682
Bruce D. Cheson. (2007) Clinical Management of T-Cell Malignancies: Current Perspectives, Key Issues, and Emerging Therapies. Seminars in Oncology 34, S3-S7
CrossRef683
Luigi Rigacci, Silvia Mappa, Luca Nassi, Renato Alterini, Valentina Carrai, Franco Bernardi, Alberto Bosi. (2007) Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines. Hematological Oncology 25:4, 198-203
CrossRef684
(2007) Reply: Why R-CHOP for first line treatment of chronic lymphocytic leukemia?. International Journal of Laboratory Hematology 29:6, 479-479
CrossRef685
Fabio M. Iwamoto, Jazmin Schwartz, Neeta Pandit-Taskar, Scott Peak, Chaitanya R. Divgi, Andrew D. Zelenetz, John Humm, Lauren E. Abrey. (2007) Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. Cancer 110:11, 2528-2534
CrossRef686
Pamela M. Aubert, Richard J. O’Donnell. (2007) Palliative care in orthopaedic surgical oncology. Surgical Oncology 16:4, 311-330
CrossRef687
Ralf U. Trappe, Sylvain Choquet, Petra Reinke, Martin Dreyling, Hans-Günther Mergenthaler, Ulrich Jäger, Christian Kebelmann-Betzing, Sven Jonas, Hans Lehmkuhl, Ioannis Anagnostopoulos, Véronique Leblond, Roland Hetzer, Bernd Dörken, Hanno Riess, Stephan Oertel. (2007) Salvage Therapy for Relapsed Posttransplant Lymphoproliferative Disorders (PTLD) With a Second Progression of PTLD After Upfront Chemotherapy: The Role of Single-Agent Rituximab. Transplantation 84:12, 1708-1712
CrossRef688
G. FELDMANN, J. NATTERMANN, T. GERHARDT, C. P. NÄHLE, U. SPENGLER, R. WOITAS. (2007) Partial remission of a newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma in a hemodialysis patient after administration of immuno-chemotherapy with rituximab-CHOP. International Journal of Laboratory Hematology 29:6, 469-473
CrossRef689
Qingyuan Zhang, Jingxuan Wang, Jincai Wang. (2007) Biweekly CHOP therapy improves therapeutic effect in the non-GCB subtype of diffuse large B-cell lymphoma. Central European Journal of Medicine 2:4, 488-498
CrossRef690
Nishitha Reddy, Francisco J. Hernandez-Ilizaliturri, George Deeb, Mark Roth, Mary Vaughn, Joy Knight, Paul Wallace, Myron S. Czuczman. (2007) Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. British Journal of Haematology 0:0, 071113214049001-???
CrossRef691
Zs. Simon, T. Tarr, Zs. Ress, L. Gergely, E. Kiss, A. Illes. (2007) Successful rituximab-CHOP treatment of systemic lupus erythematosus associated with diffuse large B-cell non-Hodgkin lymphoma. Rheumatology International 28:2, 179-183
CrossRef692
Yasuhiro Oki, Michinori Ogura, Harumi Kato, Ako Kikuchi, Hirofumi Taji, Yoshitoyo Kagami, Aya Oshiro, Akane Tsujimura, Kazuhito Yamamoto, Yasuo Morishima. (2007) Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Science 0:0, 071107051717002-???
CrossRef693
Pier F. Ferrucci, Anna Vanazzi, Chiara M. Grana, Marta Cremonesi, Mirco Bartolomei, Marco Chinol, Mahila Ferrari, Davide Radice, Stefano Papi, Giovanni Martinelli, Giovanni Paganelli. (2007) High activity 90 Y-ibritumomab tiuxetan (Zevalin ® ) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas. British Journal of Haematology 139:4, 590-599
CrossRef694
Samuel A Jacobs, Kenneth A Foon. (2007) The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas. Expert Opinion on Biological Therapy 7:11, 1749-1762
CrossRef695
N. D. Doolittle, L. E. Abrey, T. N. Shenkier, S. Tali, J. E.C. Bromberg, E. A. Neuwelt, C. Soussain, K. Jahnke, P. Johnston, G. Illerhaus, D. Schiff, T. Batchelor, S. Montoto, D. F. Kraemer, E. Zucca. (2007) Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood 111:3, 1085-1093
CrossRef696
Kensei Tobinai. (2007) Proteasome inhibitor, bortezomib, for myeloma and lymphoma. International Journal of Clinical Oncology 12:5, 318-326
CrossRef697
Bharat B. Aggarwal, Gautam Sethi, Veera Baladandayuthapani, Sunil Krishnan, Shishir Shishodia. (2007) Targeting cell signaling pathways for drug discovery: An old lock needs a new key. Journal of Cellular Biochemistry 102:3, 580-592
CrossRef698
John G. Gribben. 2007. Management of Haematological Malignancies. .
CrossRef699
Norbert Schmitz, Christian Buske, Christian Gisselbrecht. (2007) Autologous Stem Cell Transplantation in Lymphoma. Seminars in Hematology 44:4, 234-245
CrossRef700
Jane N. Winter. (2007) Prognostic markers in diffuse large B-cell lymphoma: Keys to the underlying biology. Current Hematologic Malignancy Reports 2:4, 235-241
CrossRef701
D H Kim, J H Baek, Y S Chae, Y-K Kim, H J Kim, Y H Park, H S Song, J S Chung, M S Hyun, S K Sohn. (2007) Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia 21:10, 2227-2230
CrossRef702
Daphne R. Friedman, Amy P. Abernethy. (2007) <I>REVIEW</I>. Progress in Palliative Care 15:5, 225-232
CrossRef703
Eva Kimby. (2007) Management of advanced-stage peripheral T-cell lymphomas. Current Hematologic Malignancy Reports 2:4, 242-248
CrossRef704
Fariba N??mati, Claire Mathiot, Isabelle Grandjean, Olivier Lantz, Vincent Bordier, S??bastien Dewulf, Richard Ekue, James P. Di Santo, Marie-France Poupon, Didier Decaudin. (2007) Imatinib mesylate reduces rituximab-induced tumor-growth inhibition in vivo on Epstein???Barr virus-associated human B-cell lymphoma. Anti-Cancer Drugs 18:9, 1029-1037
CrossRef705
Jean-Emmanuel Filmont, Christian Gisselbrecht, Xavier Cuenca, Laure Deville, Marjan Ertault, Pauline Brice, Eric De Kerviler, Josette Briere, Jérome Larghero, Jean-Luc Moretti, Nicolas Mounier. (2007) The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer 110:6, 1361-1369
CrossRef706
D P Hart, K S Peggs. (2007) Current Status of Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies. Clinical Pharmacology & Therapeutics 82:3, 325-329
CrossRef707
Hisashi Tsurumi, Takeshi Hara, Naoe Goto, Nobuhiro Kanemura, Senji Kasahara, Michio Sawada, Ichiro Yasuda, Toshiki Yamada, Masahito Shimizu, Tsuyoshi Takami, Hisataka Moriwaki. (2007) A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma. Hematological Oncology 25:3, 107-114
CrossRef708
Byeong-Bae Park, Jong Gwang Kim, Sang Kyun Sohn, Hye Jin Kang, Seung Sook Lee, Hyeon Seok Eom, Hyuck Chan Kwon, Sung Yong Oh, Jung Hun Kang, Suk Joong Oh, Ho-Jin Shin, Cheolwon Suh, Jung Han Kim, Ho Young Kim, Kihyun Kim, Baek Yeol Ryoo, Won Seog Kim. (2007) Consideration of aggressive therapeutic strategies for primary testicular lymphoma. American Journal of Hematology 82:9, 840-845
CrossRef709
Shigeru Shimadoi, Akiyoshi Takami, Yukio Kondo, Hirokazu Okumura, Shinji Nakao. (2007) Macrophage colony-stimulating factor enhances rituximab-dependent cellular cytotoxicity by monocytes. Cancer Science 98:9, 1368-1372
CrossRef710
Joseph A Sparano. (2007) HIV-associated lymphoma: the evidence for treating aggressively but with caution. Current Opinion in Oncology 19:5, 458-463
CrossRef711
T Economopoulos, A Psyrri, M A. Dimopoulos, A Kalogera-Fountzila, N Pavlidis, C Tsatalas, C Nikolaides, S Mellou, N Xiros, G Fountzilas. (2007) CEOP-21 Versus CEOP-14 Chemotherapy With or Without Rituximab for the First-Line Treatment of Patients With Aggressive Lymphomas: Results of the HE22A99 Trial of the Hellenic Cooperative Oncology Group. The Cancer Journal 13:5, 327-334
CrossRef712
R. Chung, R. Lai, P. Wei, J. Lee, J. Hanson, A. R. Belch, A. R. Turner, T. Reiman. (2007) Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index. Blood 110:4, 1278-1282
CrossRef713
Dorte Tholstrup, Peter de Nully Brown, Jesper Jurlander, Mads Hansen. (2007) Feasibility, efficacy and safety of CHOP-14 in elderly patients with very high-risk diffuse large B-cell lymphoma. European Journal of Haematology 79:2, 100-106
CrossRef714
Min Kyoung Kim, Shin Kim, Sung Sook Lee, Sun Jin Sym, Dae Ho Lee, Sang We Kim, Seongsoo Jang, Chan Jeong Park, Hyun Sook Chi, Jooryung Huh, Cheolwon Suh. (2007) Rituximab-ESHAP as a mobilization regimen for relapsed or refractory B-cell lymphomas: a comparison with ESHAP. Transfusion 47:8, 1447-1454
CrossRef715
Jon Kah-Choun Yoong, Li-Ching Chew, Richard Quek, Chong-Hee Lim, Justinian Qiaojian Zai, Kok-Yong Fong, Julian Thumboo. (2007) Cardiac lymphoma in primary Sjogren syndrome: A novel case established by targeted imaging and pericardial window. The Journal of Thoracic and Cardiovascular Surgery 134:2, 513-514
CrossRef716
Christopher Knight, Fiona Maciver. (2007) The cost–effectiveness of rituximab in non-Hodgkin’s lymphoma. Expert Review of Pharmacoeconomics & Outcomes Research 7:4, 319-326
CrossRef717
C Tarella, M Zanni, M Di Nicola, C Patti, R Calvi, A Pescarollo, V Zoli, A Fornari, D Novero, A Cabras, M Stella, A Comino, D Remotti, M Ponzoni, D Caracciolo, M Ladetto, M Magni, L Devizzi, R Rosato, M Boccadoro, M Bregni, P Corradini, A Gallamini, I Majolino, S Mirto, A M Gianni. (2007) Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia 21:8, 1802-1811
CrossRef718
J. M. Li, L. Wang, Y. Shen, Z. G. Xia, Y. Chen, Q. S. Chen, Y. Chen, X. Y. Zeng, J. H. You, Y. Qian, Z. X. Shen. (2007) Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients. Annals of Hematology 86:9, 639-645
CrossRef719
D. Aguiar-Bujanda, I. Quiñones-Morales, R. Camacho-Galán, I. Llorca-Martínez, J. C. Rivero-Vera, U. Bohn-Sarmiento, J. Aguiar-Morales. (2007) Primary duodenal follicular lymphoma successfully treated with rituximab. Clinical and Translational Oncology 9:7, 471-472
CrossRef720
Kristen Ganjoo, Ranjana Advani, M. Rajan Mariappan, Alex McMillan, Sandra Horning. (2007) Non-Hodgkin lymphoma of the breast. Cancer 110:1, 25-30
CrossRef721
J. O. Armitage. (2007) How I treat patients with diffuse large B-cell lymphoma. Blood 110:1, 29-36
CrossRef722
F. Morschhauser, T. Illidge, D. Huglo, G. Martinelli, G. Paganelli, P. L. Zinzani, S. Rule, A. M. Liberati, N. Milpied, G. Hess, H. Stein, J. Kalmus, R. Marcus. (2007) Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 110:1, 54-58
CrossRef723
Francesco Turturro. (2007) Update on front-line therapy for follicular lymphoma: chemo-immunotherapy with rituximab and survival. Expert Review of Anticancer Therapy 7:7, 959-965
CrossRef724
Sylvain Choquet, Stephan Oertel, Veronique LeBlond, Hanno Riess, Nathalie Varoqueaux, Bernd Dörken, Ralf Trappe. (2007) Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Annals of Hematology 86:8, 599-607
CrossRef725
Ulrich J. M. Mey, Anna Maier, Ingo G. H. Schmidt-Wolf, Carsten Ziske, Helmut Forstbauer, Gamal-Andre Banat, Michael Reber, John W. Strehl, Marcus Gorschlueter. (2007) Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. Supportive Care in Cancer 15:7, 877-884
CrossRef726
Christopher R Flowers. (2007) BiovaxID™ idiotype vaccination: active immunotherapy for follicular lymphoma. Expert Review of Vaccines 6:3, 307-317
CrossRef727
N. Schmitz, M. Nickelsen, A. Sureda. (2007) Hochdosistherapie bei malignen Lymphomen. Der Onkologe 13:5, 427-433
CrossRef728
H. Nyman, M. Adde, M.-L. Karjalainen-Lindsberg, M. Taskinen, M. Berglund, R.-M. Amini, C. Blomqvist, G. Enblad, S. Leppa. (2007) Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 109:11, 4930-4935
CrossRef729
Alexander Greb, Julia Bohlius, Sven Trelle, Daniel Schiefer, Carmino A. De Souza, Christian Gisselbrecht, Tanin Intragumtornchai, Ulrich Kaiser, Hanneke C. Kluin-Nelemans, Maurizio Martelli, Noel Jean Milpied, Gino Santini, Leo F. Verdonck, Umberto Vitolo, Guido Schwarzer, Andreas Engert. (2007) High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma – Results of a comprehensive meta-analysis. Cancer Treatment Reviews 33:4, 338-346
CrossRef730
Stephen Smith, John W Sweetenham. (2007) Iodine 131 tositumomab in the treatment of non-Hodgkin’s lymphoma. Future Oncology 3:3, 255-262
CrossRef731
Deepti Behl, Kay Ristow, Svetomir N. Markovic, Thomas E. Witzig, Thomas M. Habermann, Joseph P. Colgan, David J. Inwards, William L. White, Stephen M. Ansell, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata. (2007) Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. British Journal of Haematology 137:5, 409-415
CrossRef732
Petros I. Rafailidis, Ourania K. Kakisi, Konstantinos Vardakas, Matthew E. Falagas. (2007) Infectious complications of monoclonal antibodies used in cancer therapy. Cancer 109:11, 2182-2189
CrossRef733
Thomas E. Witzig, David J. Inwards, Thomas M. Habermann, Ahmet Dogan, Paul J. Kurtin, John B. Gross, Anuradha Ananthamurthy, Kay M. Ristow, James A. Garrity. (2007) Treatment of Benign Orbital Pseudolymphomas With the Monoclonal Anti-CD20 Antibody Rituximab. Mayo Clinic Proceedings 82:6, 692-699
CrossRef734
T. E. Witzig, D. J. Inwards, T. M. Habermann, A. Dogan, P. J. Kurtin, J. B. Gross, A. Ananthamurthy, K. M. Ristow, J. A. Garrity. (2007) Treatment of Benign Orbital Pseudolymphomas With the Monoclonal Anti-CD20 Antibody Rituximab. Mayo Clinic Proceedings 82:6, 692-699
CrossRef735
B Coiffier. (2007) Rituximab therapy in malignant lymphoma. Oncogene 26:25, 3603-3613
CrossRef736
A J Davies. (2007) Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab. Oncogene 26:25, 3614-3628
CrossRef737
J P Leonard, D M Goldenberg. (2007) Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene 26:25, 3704-3713
CrossRef738
M. Zhang, Z. Yao, H. Patel, K. Garmestani, Z. Zhang, V. S. Talanov, P. S. Plascjak, C. K. Goldman, J. E. Janik, M. W. Brechbiel, T. A. Waldmann. (2007) Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1. Proceedings of the National Academy of Sciences 104:20, 8444-8448
CrossRef739
Eric M. Bessell, Khe Hoang-Xuan, Andres J.M. Ferreri, Michele Reni. (2007) Primary central nervous system lymphoma – Biological aspects and controversies in management. European Journal of Cancer 43:7, 1141-1152
CrossRef740
Christopher R. Flowers, Roni Glover, Sagar Lonial, Otis W. Brawley. (2007) Racial Differences in the Incidence and Outcomes for Patients with Hematological Malignancies. Current Problems in Cancer 31:3, 182-201
CrossRef741
S VANDENHEILIGENBERG, C VANGROENINGEN. (2007) Bilateral adrenal enlargement with an unexpected diagnosis. European Journal of Internal Medicine 18:3, 249-250
CrossRef742
K Kamezaki, Y Kikushige, A Numata, T Miyamoto, K Takase, H Henzan, K Aoki, K Kato, A Nonami, T Kamimura, F Arima, K Takenaka, N Harada, T Fukuda, S Hayashi, Y Ohno, T Eto, M Harada, K Nagafuji. (2007) Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma. Bone Marrow Transplantation 39:9, 523-527
CrossRef743
Ralf Trappe, Hanno Riess, Nina Babel, Manfred Hummel, Hans Lehmkuhl, Sven Jonas, Ioannis Anagnostopoulos, Matthias Papp-Vary, Petra Reinke, Roland Hetzer, Bernd D??rken, Stephan Oertel. (2007) Salvage Chemotherapy for Refractory and Relapsed Posttransplant Lymphoproliferative Disorders (PTLD) After Treatment With Single-Agent Rituximab. Transplantation 83:7, 912-918
CrossRef744
Michelle L. Hicks, Sagar Lonial, Amelia Langston, Christopher Flowers, John D. Roback, Kenneth J. Smith, Sarah Mossavi Sai, Diane Teagarden, Ellie S. Hamilton, Edmund K. Waller. (2007) Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. Transfusion 47:4, 629-635
CrossRef745
Guillaume Cartron, Hélène Blasco, Gilles Paintaud, Hervé Watier, Chantal Le Guellec. (2007) Pharmacokinetics of rituximab and its clinical use: Thought for the best use?. Critical Reviews in Oncology/Hematology 62:1, 43-52
CrossRef746
B. Gleissner, C. Zwick, M. Pfreundschuh. (2007) Therapie großzelliger Lymphome. Der Internist 48:4, 389-395
CrossRef747
Javier P. Berrios-Rivera, Shenying Fang, Maria E. Cabanillas, Fernando Cabanillas, Huifang Lu, Xianglin L. Du. (2007) Variations in Chemotherapy and Radiation Therapy in a Large Nationwide and Community-Based Cohort of Elderly Patients With Non-Hodgkin Lymphoma. American Journal of Clinical Oncology 30:2, 163-171
CrossRef748
Matthew C. Cheung, Adam E. Haynes, Ralph M. Meyer, Adrienne Stevens, Kevin R. Imrie. (2007) Rituximab in lymphoma: A systematic review and consensus practice guideline from Cancer Care Ontario. Cancer Treatment Reviews 33:2, 161-176
CrossRef749
Avichai Shimoni, S. Tzila Zwas, Yakov Oksman, Izhar Hardan, Noga Shem-Tov, Ronit Yerushalmi, Abraham Avigdor, Isaac Ben-Bassat, Arnon Nagler. (2007) Yttrium-90–ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. Experimental Hematology 35:4, 534-540
CrossRef750
Nicolas Mounier, Michele Spina, Christian Gisselbrecht. (2007) Modern management of non-Hodgkin lymphoma in HIV-infected patients. British Journal of Haematology 136:5, 685-698
CrossRef751
Bridgette Collins-Burow, Edgardo S Santos. (2007) Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma. Expert Review of Anticancer Therapy 7:3, 257-273
CrossRef752
M.J. Rummel. (2007) Rituximab zur Therapie des Non-Hodgkin-Lymphoms. Der Onkologe 13:3, 227-235
CrossRef753
Severin Daum, Eckhard Thiel, Martin Zeitz. (2007) Is intestinal diffuse large b cell lymphoma a relatively benign disease?. Leukemia Research 31:3, 287-289
CrossRef754
P. Soubeyran. (2007) Prise en charge des lymphomes chez les personnes âgées. Oncologie 9:3, 214-218
CrossRef755
Semra Aydin, Ulrich Dührsen, Holger Nückel. (2007) Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin’s lymphoma: a single-centre study of 20 patients. Annals of Hematology 86:4, 271-276
CrossRef756
P. Schütt, J. Passon, P. Ebeling, A. Welt, S. Müller, K. Metz, T. Moritz, S. Seeber, M. R. Nowrousian. (2007) Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. European Journal of Haematology 78:2, 93-101
CrossRef757
Pier Francesco Ferrucci, Emanuele Zucca. (2007) Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10
CrossRef758
Pilar Miralles, Juan Berenguer, Jos?? Mar??a Ribera, Rafael Rubio, Beatriz Mahillo, Mar??a Jes??s T??llez, Jos?? Lacruz, Eulalia Valencia, Jes??s Santos, Francisco Rodr??guez-Arrondo, Vicente Pintado. (2007) Prognosis of AIDS-Related Systemic Non-Hodgkin Lymphoma Treated With Chemotherapy and Highly Active Antiretroviral Therapy Depends Exclusively on Tumor-Related Factors. JAIDS Journal of Acquired Immune Deficiency Syndromes 44:2, 167-173
CrossRef759
Ching-Hon Pui, Sima Jeha. (2007) New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nature Reviews Drug Discovery 6:2, 149-165
CrossRef760
Marie Scully, Hannah Cohen, Jamie Cavenagh, Sylvia Benjamin, Richard Starke, Sally Killick, Ian Mackie, Samuel J. Machin. (2007) Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. British Journal of Haematology 136:3, 451-461
CrossRef761
M. Dungarwalla, J. C. W. Marsh, J. A. Tooze, G. Lucas, W. Ouwehand, R. Pettengell, C. E. Dearden, E. C. Gordon Smith, M. O. Elebute. (2007) Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology. Annals of Hematology 86:3, 191-197
CrossRef762
Julio García-Suárez, Helena Bañas, Ignacio Arribas, Dunia De Miguel, Teresa Pascual, Carmen Burgaleta. (2007) Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study. British Journal of Haematology 136:2, 276-285
CrossRef763
Ikuo Shimizu, Naoaki Ichikawa, Mihoko Yotsumoto, Masahiko Sumi, Mayumi Ueno, Hikaru Kobayashi. (2007) Asian Variant of Intravascular Lymphoma: Aspects of Diagnosis and the Role of Rituximab. Internal Medicine 46:17, 1381-1386
CrossRef764
T. M. Habermann. (2007) Antibody Therapy in Aggressive Lymphomas. Hematology 2007:1, 257-264
CrossRef765
Daniel E. Lopes de Menezes, Kimberly Denis-Mize, Yan Tang, Helen Ye, John C. Kunich, Evelyn N. Garrett, Jing Peng, Lawrence S. Cousens, Arnold B. Gelb, Carla Heise, Susan E. Wilson, Bahija Jallal, Sharon L. Aukerman. (2007) Recombinant Interleukin-2 Significantly Augments Activity of Rituximab in Human Tumor Xenograft Models of B-cell Non-Hodgkin Lymphoma. Journal of Immunotherapy 30:1, 64-74
CrossRef766
Olga M Klibanov, Rachel Clark-Vetri. (2007) Oncologic Complications of Human Immunodeficiency Virus Infection: Changing Epidemiology, Treatments, and Special Considerations in the Era of Highly Active Antiretroviral Therapy. Pharmacotherapy 27:1, 122-136
CrossRef767
Ock Bae Ko, Shin Kim, Dae Ho Lee, Sang We Kim, Jooryung Huh, Cheolwon Suh. (2007) Rituximab and ESHAP as Second-line Therapy for Relapsed or Primary Refractory Diffuse Large B Cell Lymphoma: The Experience of a Single Center in Korea. The Korean Journal of Hematology 42:4, 309
CrossRef768
Raymond I. Cruz, Francisco J. Hernandez-Ilizaliturri, Scott Olejniczak, George Deeb, Joy Knight, Paul Wallace, Beth L. Thurberg, William Kennedy, Myron S. Czuczman. (2007) CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: Preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma. Leukemia & Lymphoma 48:12, 2424-2436
CrossRef769
M. Potter, A. Li, P. Cirone, F. Shen, P. Chang. 2007. Artificial cells as a novel approach to gene therapy. , 236-291.
CrossRef770
Moulod R. El-Agnaf, Cathy McCoy, Young-Lee Ong, Abdul-Hakeem Eswedi, Barbra Black, Khaled M. Ramadan. (2007) Infusion of rituximab over 90 minutes on an out-patient basis is safe and improves resource utilization. Leukemia & Lymphoma 48:9, 1875-1877
CrossRef771
Masahiro Imamura. (2007) Treatment of elderly patients with hematological diseases. Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 44:5, 587-590
CrossRef772
C. Bello, E. M. Sotomayor. (2007) Monoclonal Antibodies for B-Cell Lymphomas: Rituximab and Beyond. Hematology 2007:1, 233-242
CrossRef773
Robert Marcus, Anton Hagenbeek. (2007) The therapeutic use of rituximab in non-Hodgkin's lymphoma. European Journal of Haematology 78, 5-14
CrossRef774
Luis Fayad, Fredrick Hagemeister. (2007) Treatment of the patient with diffuse large B-cell lymphoma with medical co-morbidities: Newer therapies needed. Leukemia & Lymphoma 48:4, 657-658
CrossRef775
Sverker Hasselblom, Börje Ridell, Herman Nilsson-Ehle, Per-Ola Andersson. (2007) The impact of gender, age and patient selection on prognosis and outcome in diffuse large B-cell lymphoma—a population-based study. Leukemia & Lymphoma 48:4, 736-745
CrossRef776
Avichai Shimoni, Arnon Nagler. (2007) Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma. Leukemia & Lymphoma 48:11, 2110-2120
CrossRef777
Sean O. Ryan, Kira R. Gantt, Olivera J. Finn. (2007) Tumor Antigen-Based Immunotherapy and Immunoprevention of Cancer. International Archives of Allergy and Immunology 142:3, 179-189
CrossRef778
Kieron Dunleavy, Louis M. Staudt, Wyndham H. Wilson. (2007) The BCL-2 biomarker in the era of molecular diagnosis of diffuse large B-cell lymphoma. Leukemia & Lymphoma 48:6, 1061-1063
CrossRef779
Sercan Aksoy, Hakan Harputluoglu, Saadettin Kilickap, Didem Sener Dede, Omer Dizdar, Kadri Altundag, Ibrahim Barista. (2007) Rituximab-related viral infections in lymphoma patients. Leukemia & Lymphoma 48:7, 1307-1312
CrossRef780
A. Reiter. (2007) Diagnosis and Treatment of Childhood Non-Hodgkin Lymphoma. Hematology 2007:1, 285-296
CrossRef781
Andrew Wirth. (2007) The rationale and role of radiation therapy in the treatment of patients with diffuse large B-cell lymphoma in the Rituximab era. Leukemia & Lymphoma 48:11, 2121-2136
CrossRef782
Lijo Simpson, Stephen M. Ansell, Joseph P. Colgan, Thomas M. Habermann, David J. Inwards, Kay M. Ristow, Patrick B. Johnston, Svetomir N. Markovic, Ivana N. Micallef, Luis F. Porrata, Thomas E. Witzig. (2007) Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone. Leukemia & Lymphoma 48:7, 1332-1337
CrossRef783
Franck Morschhauser, Pier Luigi Zinzani, Michael Burgess, Lisette Sloots, Fadela Bouafia, Charles Dumontet. (2007) Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leukemia & Lymphoma 48:4, 708-715
CrossRef784
Robert Marcus, Anton Hagenbeek. (2007) The therapeutic use of rituximab in non-Hodgkin's lymphoma. European Journal of Haematology 78:s67, 5-14
CrossRef785
Bruce A. Peterson, Jeffrey Johnson, Margaret A. Shipp, Maurice Barcos, Jon P. Gockerman, George P. Canellos, For the Cancer and Leukemia Group B. (2007) High dose CHOP: A phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351. Leukemia & Lymphoma 48:5, 870-880
CrossRef786
Nicolas Novitzky, Valda Thomas. (2007) Allogeneic Stem Cell Transplantation with T Cell-Depleted Grafts for Lymphoproliferative Malignancies. Biology of Blood and Marrow Transplantation 13:1, 107-115
CrossRef787
Dong Mee Lee, Sung Yong Oh, Hyun Ah Yoon, Suee Lee, Sung-Hyun Kim, Hyuk-Chan Kwon, Soo-Keol Lee, Hyo-Jin Kim. (2007) Rituximab-induced Interstitial Pneumonitis in a Young Patient: A Case Report and Review of the Literature. The Korean Journal of Hematology 42:4, 423
CrossRef788
W.W.K. Cheng, D. Das, M. Suresh, T.M. Allen. (2007) Expression and purification of two anti-CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cells. Biochimica et Biophysica Acta (BBA) - Biomembranes 1768:1, 21-29
CrossRef789
Kosei Matsue, Masami Takeuchi, Hidetaka Uryu, Mihoko Koseki, Noboru Asada, Yosinori Kaneko. (2007) Rapid improvement of hypoxemia by the use of rituximab in patients with pulmonary intravascular lymphoma. Leukemia & Lymphoma 48:1, 197-200
CrossRef790
A. Kolstad, O. Nome, J. Delabie, G. F. Lauritzsen, A. Fossa, H. Holte. (2007) Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma. Leukemia & Lymphoma 48:3, 570-576
CrossRef791
Abby B. Siegel, John P. Leonard. (2007) Therapy for older patients with diffuse large cell lymphoma: Targeting the treatment to the patient. Leukemia & Lymphoma 48:2, 225-226
CrossRef792
David M. Kurtz, Loren K. Tschetter, Jacob B. Allred, Susan M. Geyer, Paul J. Kurtin, Wesley D. Putnam, Kendrith M. Rowland, Martin Wiesenfeld, Gamini S. Soori, Richard C. Tenglin, Albert M. Bernath, Thomas E. Witzig. (2007) Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51. Leukemia & Lymphoma 48:7, 1290-1298
CrossRef793
F. Merli, M. Bertini, S. Luminari, R. Mozzana, B. Botto, A. M. Liberati, L. Baldini, G. Cabras, F. Di Vito, L. Orsucci, E. Naglieri, G. Polimeno, L. Marcheselli, E. Pennese, U. Vitolo, M. Federico, E. Gallo. (2007) Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. Leukemia & Lymphoma 48:2, 367-373
CrossRef794
Evan Tobin, Gerald Denardo, Nan Zhang, Alan L. Epstein, Cathy Liu, Sally Denardo. (2007) Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines. Leukemia & Lymphoma 48:5, 944-956
CrossRef795
Jun Ishiko, Masao Mizuki, Masato Yasumi, Hidetoshi Ujiie, Itsuko Nakamichi, Katsuyuki Aozasa, Yuzuru Kanakura. (2007) An indolent subtype of “intravascular lymphoma”: A case with a 3-year history of LDH elevation. Leukemia & Lymphoma 48:9, 1872-1874
CrossRef796
P. Daniel. (2007) Molekulare Grundlagen der zielgerichteten Tumortherapie. Der Onkologe 13:1, 8-19
CrossRef797
Chi Hoon Maeng, Sang Ouk Chin, Byung Hyuk Yang, Si-young Kim, Hwi-Joong Youn, Kyung Sam Cho, Sun Kyung Baek, Sun Lee. (2007) A Case of Organizing Pneumonia Associated with Rituximab. Cancer Research and Treatment 39:2, 88
CrossRef798
Régis Peffault de Latour, Driss Chaoui, Jean-Henri Bourhis, Ramdane Belhocine, Sophie Park, Ollivier Legrand, Philippe Brault, Bernard Rio, F. Heshmati, Sabine Assouad, Didier Decaudin. (2007) Mobilization of peripheral blood progenitor cells after DHAP regimen with or without rituximab: A large multicenter comparative study in patients with malignant lymphoma. Leukemia & Lymphoma 48:5, 897-904
CrossRef799
Michiko Yamagata, Toshimitsu Murohisa, Kohei Tsuchida, Yutaka Okamoto, Saburo Tsunoda, Masae Nakamura, Koji Kusano, Yuichi Majima, Toru Kuniyoshi, Makoto Iijima, Hitoshi Sugaya, Hideyuki Hiraishi. (2007) Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab. Leukemia & Lymphoma 48:2, 431-433
CrossRef800
Mariapaola Fina, Monica Tani, Vittorio Stefoni, Gerardo Musuraca, Enrica Marchi, Cinzia Pellegrini, Lapo Alinari, Enrico Derenzini, Francesco Bacci, Stefano Pileri, Michele Baccarani, Pier Luigi Zinzani. (2007) VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. Leukemia & Lymphoma 48:11, 2167-2171
CrossRef801
Peter C Taylor. (2007) Rituximab in the treatment of rheumatoid arthritis. Expert Review of Clinical Immunology 3:1, 17-26
CrossRef802
Christos Emmanouilides. (2007) Current treatment options in follicular lymphoma: Science and bias. Leukemia & Lymphoma 48:11, 2098-2109
CrossRef803
Kenneth S. Wilson, Laurie H. Sehn, Brian Berry, Mukesh Chhanabhai, Catherine A. Fitzgerald, Karamjit K. Gill, Richard Klasa, Brian Skinnider, Judy Sutherland, Joseph M. Connors, Randy D. Gascoyne. (2007) CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. Leukemia & Lymphoma 48:6, 1102-1109
CrossRef804
Ivana N. M. Micallef, Brad S. Kahl, Matthew J. Maurer, Ahmet Dogan, Stephen M. Ansell, Joseph P. Colgan, Susan Geyer, David J. Inwards, William L. White, Thomas M. Habermann. (2006) A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. Cancer 107:12, 2826-2832
CrossRef805
Michal Sieniawski, Oliver Staak, Jan-Peter Glossmann, Thorsten Reineke, Helena Scheuß, Volker Diehl, Andreas Engert, Andreas Josting. (2006) Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma. Annals of Hematology 86:2, 107-115
CrossRef806
Peng-Chan Lin, Liang-Tsai Hsiao, Say-Bee Poh, Wei-Shu Wang, Chueh-Chuan Yen, Ta-Chung Chao, Jin-Hwang Liu, Tzeon-Jye Chiou, Po-Min Chen. (2006) Higher fungal infection rate in elderly patients (more than 80 years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP. Annals of Hematology 86:2, 95-100
CrossRef807
David J. Inwards, Jeffrey C. Cilley, Jane N. Winter. (2006) Radioimmunotherapeutic strategies in autologous hematopoietic stem-cell transplantation for malignant lymphoma. Best Practice & Research Clinical Haematology 19:4, 669-684
CrossRef808
Thomas E. Witzig. (2006) Radioimmunotherapy for B-cell non-Hodgkin lymphoma. Best Practice & Research Clinical Haematology 19:4, 655-668
CrossRef809
E Jantunen. (2006) Autologous stem cell transplantation beyond 60 years of age. Bone Marrow Transplantation 38:11, 715-720
CrossRef810
Nicola Gökbuget, Dieter Hoelzer. (2006) Novel antibody-based therapy for acute lymphoblastic leukaemia. Best Practice & Research Clinical Haematology 19:4, 701-713
CrossRef811
T Ishida, T Ishii, A Inagaki, H Yano, S Kusumoto, M Ri, H Komatsu, S Iida, H Inagaki, R Ueda. (2006) The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma. Leukemia 20:12, 2162-2168
CrossRef812
F. Stenner-Liewen, A. Zippelius, B. C. Pestalozzi, A. Knuth. (2006) Molekular zielgerichtete Therapie. Der Chirurg 77:12, 1118-1125
CrossRef813
K. Namberger, R. Greil. (2006) The Role of Imaging in Malignant Lymphoma: A Critical View on PET Scanning in Current Clinical Practice. Imaging Decisions MRI 10:4, 22-31
CrossRef814
Edgar G. Rizzatti, Adrian Wiestner. (2006) Underlying mechanisms of hematologic malignancies revealed by gene expression profiling. Drug Discovery Today: Disease Mechanisms 3:4, 507-514
CrossRef815
Lydie Cassard, Joël Cohen-Solal, Sophie Camilleri-Broët, Emilie Fournier, Wolf Herman Fridman, Catherine Sautès-Fridman. (2006) Fc gamma receptors and cancer. Springer Seminars in Immunopathology 28:4, 321-328
CrossRef816
Constantinos P Anastassiades, Thomas H Poterucha. (2006) Virchow's node, jaundice, and weight loss—lymphoma mimicking gastrointestinal malignancy. Nature Clinical Practice Gastroenterology & Hepatology 3:11, 645-648
CrossRef817
Brendan C Dickson, Stefano Serra, Runjan Chetty. (2006) Primary gastrointestinal tract lymphoma: diagnosis and management of common neoplasms. Expert Review of Anticancer Therapy 6:11, 1609-1628
CrossRef818
Georg Hess, Thomas Flohr, Karin Kolbe, Sarah Bonn, Martin Schuler, Hans Günter Derigs, Christoph Huber. (2006) Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin’s lymphoma. Annals of Hematology 85:11, 769-779
CrossRef819
Bertrand Coiffier. (2006) Rituximab and CHOP-like chemotherapy in good-prognosis diffuse large-B-cell lymphoma. Nature Clinical Practice Oncology 3:11, 594-595
CrossRef820
Takashi Ishida, Ryuzo Ueda. (2006) CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Science 97:11, 1139-1146
CrossRef821
James O. Armitage. (2006) Any drug that works has a target. Targeted Oncology 1:4, 179-180
CrossRef822
Bertrand Coiffier. (2006) Standard Treatment of Advanced-Stage Diffuse Large B-Cell Lymphoma. Seminars in Hematology 43:4, 213-220
CrossRef823
Neerav N. Shukla, Tanya M. Trippett. (2006) Non-Hodgkin’s lymphoma in children and adolescents. Current Oncology Reports 8:5, 387-394
CrossRef824
Thomas M. Habermann. (2006) Splenectomy, Interferon, and Treatments of Historical Interest in Hairy Cell Leukemia. Hematology/Oncology Clinics of North America 20:5, 1075-1086
CrossRef825
Victor R. Grann, Dawn Hershman, Judith S. Jacobson, Wei-Yann Tsai, Jian Wang, Russell McBride, Nandita Mitra, Michael L. Grossbard, Alfred I. Neugut. (2006) Outcomes and diffusion of doxorubicin-based chemotherapy among elderly patients with aggressive non-Hodgkin lymphoma. Cancer 107:7, 1530-1541
CrossRef826
B. Rehbinder, Ch. Wullstein, W. O. Bechstein, M. Probst, K. Engels, S. Kriener, N. Dobert, W. Schwarz, V. Brixner, D. Steffan, S. Gauer, H. Geiger, I. A. Hauser. (2006) Epstein-Barr Virus-Associated Posttransplant Lymphoproliferative Disorder of Donor Origin after Simultaneous Pancreas?Kidney Transplantation Limited to Pancreas Allograft: A Case Report. American Journal of Transplantation 6:10, 2506-2511
CrossRef827
Maria-Christina Kyrtsonis, Marina P. Siakantaris, Christina Kalpadakis, Maria N. Dimopoulou, Theodoros P. Vassilakopoulos, Flora N. Kontopidou, Christina Antoniou, Penelope Korkolopoulou, Panayiotis Panayiotidis, Gerassimos A. Pangalis. (2006) Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab. European Journal of Haematology 77:4, 300-303
CrossRef828
Thomas P. Miller, Catherine M. Spier, Lisa Rimsza. (2006) Diffuse Aggressive Histologies of Non-Hodgkin Lymphoma: Treatment and Biology of Limited Disease. Seminars in Hematology 43:4, 207-212
CrossRef829
Owen A. O’Connor, Paul Hamlin. (2006) New Drugs for the Treatment of Advanced-Stage Diffuse Large Cell Lymphomas. Seminars in Hematology 43:4, 251-261
CrossRef830
David M Goldenberg. (2006) Epratuzumab in the therapy of oncological and immunological diseases. Expert Review of Anticancer Therapy 6:10, 1341-1353
CrossRef831
Gerhard Held, Joerg Schubert, Marcel Reiser, Michael Pfreundschuh. (2006) Dose-Intensified Treatment of Advanced-Stage Diffuse Large B-Cell Lymphomas. Seminars in Hematology 43:4, 221-229
CrossRef832
Sasha Bernatsky, Rosalind Ramsey-Goldman, Silvy Lachance, Christian A Pineau, Ann E Clarke. (2006) Lymphoma in a patient with systemic lupus erythematosus. Nature Clinical Practice Rheumatology 2:10, 570-574
CrossRef833
Richard I. Fisher. (2006) Treatment of Diffuse Large B-Cell Lymphomas. Seminars in Hematology 43:4, 205-206
CrossRef834
Ambuj Kumar, Heloisa P Soares. (2006) Salvage radiotherapy increases survival in people with residual disease after chemotherapy for advance diffuse large cell lymphoma. Cancer Treatment Reviews 32:6, 487-490
CrossRef835
M. Björkholm, F. Celsing, E. Johansson, . (2006) Sequential multidrug chemotherapy (CHOP-VA-MB) in patients with high-grade non-Hodgkin’s lymphoma—a 20-year follow-up. Annals of Hematology 85:10, 731-733
CrossRef836
Auayporn Nademanee, Stephen J. Forman. (2006) Role of Hematopoietic Stem Cell Transplantation for Advanced-Stage Diffuse Large Cell B-Cell Lymphoma-B. Seminars in Hematology 43:4, 240-250
CrossRef837
Peter R. Holman, Edward D. Ball. 2006. Immunology of Cancer. .
CrossRef838
Miguel H. Bronchud. 2006. Oncology, Molecular. .
CrossRef839
Kathrin Wanner, Susanne Hipp, Madlene Oelsner, Ingo Ringshausen, Christian Bogner, Christian Peschel, Thomas Decker. (2006) Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. British Journal of Haematology 134:5, 475-484
CrossRef840
J Shortt, A Spencer. (2006) Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma. Bone Marrow Transplantation 38:6, 433-436
CrossRef841
Caroline M Behler, Lawrence D Kaplan. (2006) Advances in the management of HIV-related non-Hodgkin lymphoma. Current Opinion in Oncology 18:5, 437-443
CrossRef842
Gerhard Held, Viola Pöschel, Michael Pfreundschuh. (2006) Rituximab for the treatment of diffuse large B-cell lymphomas. Expert Review of Anticancer Therapy 6:8, 1175-1186
CrossRef843
Frank Neumann, Stefani Harmsen, Simona Martin, Ralf Kronenwett, Mustafa Kondakci, Manuel Aivado, Ulrich Germing, Rainer Haas, Guido Kobbe. (2006) Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B-cell non-Hodgkin’s lymphoma. Annals of Hematology 85:8, 530-534
CrossRef844
D Coso, C Sebban, O Boulat, P Biron, J Rey, T Aurran, C Chabannon, L Xerri, B Chetaille, B Esterni, V Ivanov, A M Stoppa, J M Schiano de Collela, J A Gastaut, D Maraninchi, R Bouabdallah. (2006) A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma. Bone Marrow Transplantation 38:3, 217-222
CrossRef845
Hideomi Yamashita, Koji Izutsu, Naoki Nakamura, Kenshiro Shiraishi, Shigeru Chiba, Mineo Kurokawa, Masao Tago, Hiroshi Igaki, Kuni Ohtomo, Keiichi Nakagawa. (2006) Treatment results of chemoradiation therapy for localized aggressive lymphomas: a retrospective 20-year study. Annals of Hematology 85:8, 523-529
CrossRef846
Anna L. Taylor, Kristian M. Bowles, Christopher J. Callaghan, Jenny Z. Wimperis, John W. Grant, Robert E. Marcus, J Andrew Bradley. (2006) Anthracycline-based Chemotherapy as First-line Treatment in Adults with Malignant Posttransplant Lymphoproliferative Disorder after Solid Organ Transplantation. Transplantation 82:3, 375-381
CrossRef847
D K Wilkins, A Mayer. (2006) Development of antibodies for cancer therapy. Expert Opinion on Biological Therapy 6:8, 787-796
CrossRef848
Michael Ellis, Ulla Hedstrom, Chris Frampton, Hussain Alizadeh, Jorgen Kristensen, Fuad V. Shammas, Basel K. al-Ramadi. (2006) Modulation of the systemic inflammatory response by recombinant human interleukin-11: A prospective randomized placebo controlled clinical study in patients with hematological malignancy. Clinical Immunology 120:2, 129-137
CrossRef849
Yoshinori Taeda, Naohiro Ariga, Kayoko Okamura, Naoko Takei, Takuya Komeno, Hamaiti Ueki, Haruo Ohtani. (2006) Primary Breast mucosa-associated lymphoid tissue (malt) lymphoma with high-grade transformation evidenced by prominent lymphoepithelial lesions. Breast Cancer 13:3, 322-327
CrossRef850
Eisuke Shiozawa, Masafumi Takimoto, Reiko Makino, Daisuke Adachi, Bungo Saito, Toshiko Yamochi-Onizuka, Tadanori Yamochi, Junko Shimozuma, Takashi Maeda, Yohko Kohno, Keiichiro Kawakami, Tsuyoshi Nakamaki, Shigeru Tomoyasu, Akira Shiokawa, Hidekazu Ota. (2006) Hypermethylation of CpG islands in p16 as a prognostic factor for diffuse large B-cell lymphoma in a high-risk group. Leukemia Research 30:7, 859-867
CrossRef851
Chee–Kin Hui, Winnie W.W. Cheung, Hai–Ying Zhang, Wing–Yan Au, Yui–Hung Yueng, Anskar Y.H. Leung, Nancy Leung, John M. Luk, Albert K.W. Lie, Yok–Lam Kwong, Raymond Liang, George K.K. Lau. (2006) Kinetics and Risk of De Novo Hepatitis B Infection in HBsAg–Negative Patients Undergoing Cytotoxic Chemotherapy. Gastroenterology 131:1, 59-68
CrossRef852
David J. Flavell, Sarah L. Warnes, Christine J. Bryson, Sarah A. Field, Armorel L. Noss, Graham Packham, Sopsamorn U. Flavell. (2006) The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma. British Journal of Haematology 134:2, 157-170
CrossRef853
Didier Decaudin, Fanny Baran Marszak, J??r??me Couturier, Claire Mathiot, Antoine Martin, Fariba N??mati, Olivier Lantz, James di Santo, Philippe Arnaud, Vincent Bordier, Anne Vincent-Salomon, Marie-France Poupon. (2006) High efficacy of combined rituximab and gemcitabine on Epstein???Barr virus-associated human B-cell lymphoma obtained after Hodgkin??s xenograft in immunodeficient mice. Anti-Cancer Drugs 17:6, 685-695
CrossRef854
N. George Mikhaeel. (2006) Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas. European Journal of Nuclear Medicine and Molecular Imaging 33:S1, 22-26
CrossRef855
Raoul Tibes, Michael J. Keating, Alessandra Ferrajoli, William Wierda, Farhad Ravandi, Guillermo Garcia-Manero, Susan O'Brien, Jorge Cortes, Srdan Verstovsek, Mary L. Browning, Stefan Faderl. (2006) Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer 106:12, 2645-2651
CrossRef856
F K Buadi, I N Micallef, S M Ansell, L F Porrata, A Dispenzieri, M A Elliot, D A Gastineau, M A Gertz, M Q Lacy, M R Litzow, A Tefferi, D J Inwards. (2006) Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplantation 37:11, 1017-1022
CrossRef857
Juliana Pereira, Marcelo Bellesso, Luis Fernando Pracchia, Abrahão Elias Hallack Neto, Beatriz Beitler, Maria Cristina Martins de Almeida Macedo, Lucia Cristina Santos Dias, Pedro Enrique Dorlhiac-Llacer, Frederico Luiz Dulley, Dalton Chamone. (2006) Modified Magrath IVAC regimen as second-line therapy for relapsed or refractory aggressive non-Hodgkin's lymphoma in developing countries: The experience of a single center in Brazil. Leukemia Research 30:6, 681-685
CrossRef858
Nozomi Niitsu, Masataka Okamoto, Sadao Aoki, Hirokazu Okumura, Tadashi Yoshino, Ikuo Miura, Masami Hirano. (2006) Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma. Annals of Hematology 85:6, 374-380
CrossRef859
Parham Khosravi Shahi, Gumersindo Pérez Manga. (2006) Linfoma B difuso de células grandes. Medicina Clínica 127:1, 17-21
CrossRef860
Lars Fischer, Olaf Penack, Chiara Gentilini, Axel Nogai, Arne Muessig, Eckhard Thiel, Lutz Uharek. (2006) The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Experimental Hematology 34:6, 753-759
CrossRef861
Hui Liang, Benyan Luo, Jinpeng Liu. (2006) Non-Hodgkin Lymphoma Presenting with Ophthalmoplegia and Gingival Pain. Journal of Neuro-Ophthalmology 26:2, 153-154
CrossRef862
Daniele Bernardi, Domenico Errante, Umberto Tirelli, Luigi Salvagno, Antonio Bianco, Ian S. Fentiman. (2006) Insight into the treatment of cancer in older patients: Developments in the last decade. Cancer Treatment Reviews 32:4, 277-288
CrossRef863
Élie Azoulay, Benoît Schlemmer. (2006) Diagnostic strategy in cancer patients with acute respiratory failure. Intensive Care Medicine 32:6, 808-822
CrossRef864
K. Rhinow, I. Schirmer, C. Loddenkemper, I. Anagnostopoulos, H. Stein, P. A. Reichart. (2006) Orale Epstein-Barr-Virus-assoziierte diffuse großzellige B-Zell-Lymphome bei HIV-negativen immunsupprimierten Patienten. Mund-, Kiefer- und Gesichtschirurgie 10:3, 155-161
CrossRef865
Bulent Eser, Ismail Sari, Ozlem Canoz, Fevzi Altuntas, Erol Cakmak, Ahmet Ozturk, Metin Ozkan, Ozlem Er, Mustafa Cetin, Ali Unal. (2006) Prognostic significance of Fas (CD95/APO-1) positivity in patients with primary nodal diffuse large B-cell lymphoma. American Journal of Hematology 81:5, 307-314
CrossRef866
Lyndell Lim, Eric B Suhler, Justine R Smith. (2006) Biologic therapies for inflammatory eye disease. Clinical and Experimental Ophthalmology 34:4, 365-374
CrossRef867
Jonathan W Friedberg. (2006) Rituximab for early-stage diffuse large-B-cell lymphoma. The Lancet Oncology 7:5, 357-359
CrossRef868
T. T. BISS, M. R. VELANGI, J. P. HANLEY. (2006) Failure of rituximab to induce immune tolerance in a boy with severe haemophilia A and an alloimmune factor VIII antibody: a case report and review of the literature. Haemophilia 12:3, 280-284
CrossRef869
Lowell Anderson-Reitz. (2006) Dose-dense Chemotherapy for Aggressive Non-Hodgkin Lymphoma. Cancer Nursing 29:3, 198-206
CrossRef870
Michael Pfreundschuh, Lorenz Trümper, Anders Österborg, Ruth Pettengell, Marek Trneny, Kevin Imrie, David Ma, Devinder Gill, Jan Walewski, Pier-Luigi Zinzani, Rolf Stahel, Stein Kvaloy, Ofer Shpilberg, Ulrich Jaeger, Mads Hansen, Tuula Lehtinen, Armando López-Guillermo, Claudia Corrado, Adriana Scheliga, Noel Milpied, Myriam Mendila, Michelle Rashford, Evelyn Kuhnt, Markus Loeffler. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. The Lancet Oncology 7:5, 379-391
CrossRef871
K TAKEI, T YAMAZAKI, U SAWADA, H ISHIZUKA, S AIZAWA. (2006) Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines. Leukemia Research 30:5, 625-631
CrossRef872
Pier Paolo Piccaluga, Giovanni Martinelli, Michele Baccarani. (2006) Advances in the treatment for haematological malignancies. Expert Opinion on Pharmacotherapy 7:6, 721-732
CrossRef873
Rudolf Weiss, Paris Mitrou, Keikawus Arasteh, Dirk Schuermann, Marcus Hentrich, Ulrich Duehrsen, Hinrich Sudeck, Ingo G. H. Schmidt-Wolf, Ioannis Anagnostopoulos, Dieter Huhn. (2006) Acquired immunodeficiency syndrome-related lymphoma. Cancer 106:7, 1560-1568
CrossRef874
Bruce D. Cheson. (2006) Monoclonal Antibody Therapy for B-Cell Malignancies. Seminars in Oncology 33, 2-14
CrossRef875
Barbel Seyfarth, Andreas Josting, Martin Dreyling, Norbert Schmitz. (2006) Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease. British Journal of Haematology 133:1, 3-18
CrossRef876
Deborah A. Thomas, Stefan Faderl, Susan O'Brien, Carlos Bueso-Ramos, Jorge Cortes, Guillermo Garcia-Manero, Francis J. Giles, Srdan Verstovsek, William G. Wierda, Sherry A. Pierce, Jianqin Shan, Mark Brandt, Fredrick B. Hagemeister, Michael J. Keating, Fernando Cabanillas, Hagop Kantarjian. (2006) Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106:7, 1569-1580
CrossRef877
Luis Fayad, Anas Younes. (2006) Novel treatment strategies for aggressive non-Hodgkin’s lymphoma. Expert Opinion on Pharmacotherapy 7:6, 733-748
CrossRef878
B COIFFIER. (2006) Monoclonal antibody as therapy for malignant lymphomas. Comptes Rendus Biologies 329:4, 241-254
CrossRef879
Massimo Federico, Stefano Luminari, Paolo G. Gobbi, Stefano Sacchi, Nicola Renzo, Marco Lombardo, Francesco Merli, Luca Baldini, Caterina Stelitano, Giovanni Partesotti, Giuseppe Polimeno, Antonella Montanini, Caterina Mammi, Maura Brugiatelli. (2006) The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study. European Journal of Haematology 76:3, 217-229
CrossRef880
I Ringshausen, M Oelsner, K Weick, C Bogner, C Peschel, T Decker. (2006) Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL. Leukemia 20:3, 514-520
CrossRef881
Danish Mazhar, Justin Stebbing, Mark Bower. (2006) Non-Hodgkin’s lymphoma and the CNS: prophylaxis and therapy in immunocompetent and HIV-positive individuals. Expert Review of Anticancer Therapy 6:3, 335-341
CrossRef882
Brad Pohlman, John Sweetenham, Roger M Macklis. (2006) Review of clinical radioimmunotherapy. Expert Review of Anticancer Therapy 6:3, 445-461
CrossRef883
Federica Sorá, Nicola Piccirillo, Patrizia Chiusolo, Luca Laurenti, Roberto Marra, Francesco Bartolozzi, Giuseppe Leone, Simona Sica. (2006) Mitoxantrone, carboplatin, cytosine arabinoside, and methylprednisolone followed by autologous peripheral blood stem cell transplantation. Cancer 106:4, 859-866
CrossRef884
E Jantunen, M Itälä, E Juvonen, S Leppä, L Keskinen, K Vasala, K Remes, T Wiklund, E Elonen, T Nousiainen. (2006) Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis. Bone Marrow Transplantation 37:4, 367-372
CrossRef885
Thomas A. Waldmann. (2006) Effective Cancer Therapy Through Immunomodulation*. Annual Review of Medicine 57:1, 65-81
CrossRef886
Winnie Yeo, Philip J. Johnson. (2006) Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43:2, 209-220
CrossRef887
Jean-François Chatal. (2006) Editorial: Radioimmunotherapy, a New Breakthrough in the Treatment of Follicular Non-Hodgkin's Lymphoma: The European Perspective. Cancer Biotherapy & Radiopharmaceuticals 21:1, 1-4
CrossRef888
Niklas Zojer, Klaus Kirchbacher, Michael Vesely, Wolfgang Hübl, Heinz Ludwig. (2006) Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma. Leukemia & Lymphoma 47:6, 1103-1109
CrossRef889
Philippe Solal-Céligny. (2006) Safety of rituximab maintenance therapy in follicular lymphomas. Leukemia Research 30, S16-S21
CrossRef890
F. Zaja, V. Tomadini, A. Zaccaria, M. Lenoci, M. Battista, A. L. Molinari, A. Fabbri, R. Battista, M. G. Cabras, A. Gallamini, R. Fanin. (2006) CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. Leukemia & Lymphoma 47:10, 2174-2180
CrossRef891
Christophe Fruchart, Oumedaly Reman, Nolwenn Le Stang, Dada Musafiri, Stéphane Cheze, Margaret Macro, Odile Switsers, Nicolas Aide, Mélanie Liegard, Xavier Levaltier, Anne-Marie Peny, Michel Leporrier, Stéphane Bardet. (2006) Prognostic value of early 18 fluorodeoxyglucose positron emission tomography and gallium-67 scintigraphy in aggressive lymphoma: a prospective comparative study. Leukemia & Lymphoma 47:12, 2547-2557
CrossRef892
TOMOKI NAOE. (2006) Nihon Naika Gakkai Zasshi 95:3, 534-537
CrossRef893
Peter Mclaughlin. (2006) Late-onset neutropenia following rituximab. Leukemia & Lymphoma 47:6, 965-966
CrossRef894
Arthur P. Rabinowitz, Neil J. Weiner, Bruce S. Tronic, Moshe Fridman, Rebecca F. Liberman, David J. Delgado. (2006) Severe neutropenia in CHOP occurs most frequently in cycle 1: A predictive model. Leukemia & Lymphoma 47:5, 853-858
CrossRef895
Fumi Mizoroki, Yuko Hirose, Masayuki Sano, Haruhiko Fukuda, Kensei Tobinai, Masanobu Nakata, Masafumi Taniwaki, Fumio Kawano, Kimiharu Uozumi, Kenichi Sawada, Shiro Fukuhara, Kaori Nasu, Yoichiro Ohno, Hironobu Toki, Atsushi Togawa, Masahiro Kikuchi, Tomomitsu Hotta, Masanori Shimoyama. (2006) A Phase II Study of VEPA/FEPP Chemotherapy for Aggressive Lymphoma in Elderly Patients: Japan Clinical Oncology Group Study JCOG9203. International Journal of Hematology 83:1, 55-62
CrossRef896
Risto S Cvetkovi??, Caroline M Perry. (2006) Rituximab. Drugs 66:6, 791-820
CrossRef897
Norio Yokose, Yumiko Shioi, Yuich Sugisaki, Yoshiharu Ohaki, Kiyoyuki Ogata, Kazuo Dan. (2006) CD5-positive diffuse large B-cell lymphoma with an unusual phenotype: Cytoplasmic CD20 (+), surface CD20 (−). Leukemia & Lymphoma 47:7, 1415-1417
CrossRef898
Nobert Schmitz, Marita Kloess, Marcel Reiser, Wolfgang E. Berdel, Bernd Metzner, Bernd Dorken, Michael Kneba, Lorenz Trumper, Markus Loeffler, Michael Pfreundschuh, Bertram Glass, . (2006) Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation. Cancer 106:1, 136-145
CrossRef899
Elena Gitelson, Tahseen Al-Saleem, Michael Millenson, Stuart Lessin, Mitchell R. Smith. (2006) Cutaneous B-cell lymphoma responds to rituximab: A report of five cases and a review of the literature. Leukemia & Lymphoma 47:9, 1902-1907
CrossRef900
Krishdeep Singh Chadha, Francisco J. Hernandez-Ilizaliturri, Milind Javle. (2006) Primary Esophageal Lymphoma: Case Series and Review of the Literature. Digestive Diseases and Sciences 51:1, 77-83
CrossRef901
Antonio Gutiérrez, José Rodríguez, Jordi Martínez, Rocío Amezaga, Rafael Ramos, Bernat Galmes, Maria Dolores Bea, Joana Ferrer, Jaume Pons, Antonia Sampol, Miguel Morey, María Antonia Duran, Joan Raurich, Joan Besalduch. (2006) Pathogenic study of anti-CD20 infusion-related severe refractory shock in diffuse large B-cell lymphoma. Leukemia & Lymphoma 47:1, 111-115
CrossRef902
Edgardo S. Santos, Mohamed A. Kharfan-Dabaja, Ernesto Ayala, Luis E. Raez. (2006) Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma. Leukemia & Lymphoma 47:12, 2453-2476
CrossRef903
George Bozas, Dimitra Anagnostou, Anna Tassidou, Lia A. Moulopoulos, Aristotelis Bamias, Meletios A. Dimopoulos. (2006) Extranodal non-Hodgkin's lymphoma presenting as an abdominal wall mass. A case report and review of the literature. Leukemia & Lymphoma 47:2, 329-332
CrossRef904
ITARU MATSUMURA. (2006) Nihon Naika Gakkai Zasshi 95:7, 1375-1381
CrossRef905
Tanin Intragumtornchai, Udomsak Bunworasate, Thanyaphong Na Nakorn, Ponlapat Rojnuckarin. (2006) Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma. Leukemia & Lymphoma 47:7, 1306-1314
CrossRef906
Satoshi Hirai, Hidero Ogino, Shunji Tomita, Hidenobu Ohsaka, Katsushi Hiramatsu, Mitsuru Matsuda, Yoshitake Satomura, Akio Uchiyama, Atsuo Miwa, Yatsugi Noda. (2006) A case of chronic hepatitis C with malignant lymphoma arising from porta hepatical lymph node in follow up period. Kanzo 47:7, 334-340
CrossRef907
Akiyoshi Takami, Tomoe Hayashi, Daisuke Kita, Ryosei Nishimura, Hidesaku Asakura, Shinji Nakao. (2006) Treatment of primary central nervous system lymphoma with induction of complement-dependent cytotoxicity by intraventricular administration of autologous-serum-supplemented rituximab. Cancer Science 97:1, 80-83
CrossRef908
Naoto Tomita, Fumio Kodama, Shigeki Motomura, Hideyuki Koharazawa, Hiroyuki Fujita, Hiroshi Harano, Heiwa Kanamori, Yoshiaki Ishigatsubo. (2006) Prognostic Factors in Diffuse Large Bcell Lymphoma Treated by Riskadopted Therapy. Internal Medicine 45:5, 247-252
CrossRef909
Kristen N. Ganjoo, Caroline S. An, Michael J. Robertson, Leo I. Gordon, Joy A. Sen, Jill Weisenbach, Shuli Li, Edie A. Weller, Attilio Orazi, Sandra J. Horning. (2006) Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis. Leukemia & Lymphoma 47:6, 998-1005
CrossRef910
Markus Raderer, Stefan Wöhrer, Berthold Streubel, Johannes Drach, Ulrich Jäger, Karl Turetschek, Marlene Troch, Andreas Püspök, Christoph C. Zielinski, Andreas Chott. (2006) Activity of Rituximab plus Cyclophosphamide, Doxorubicin/Mitoxantrone, Vincristine and Prednisone in Patients with Relapsed MALT Lymphoma. Oncology 70:6, 411-417
CrossRef911
Chitra Hosing, Rima M. Saliba, Martin Körbling, Sandra Acholonu, John Mcmannis, Paolo Anderlini, Sergio Giralt, Marcos De Lima, Grace-Julia Okoroji, Daniel R. Couriel, Richard Champlin, Issa F. Khouri, Michele L. Donato. (2006) High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma. Leukemia & Lymphoma 47:7, 1290-1294
CrossRef912
(2006) Letters to the Editor. Leukemia & Lymphoma 47:4, 747-775
CrossRef913
Ulrich J. M. Mey, Attilio Olivieri, Katjana S. Orlopp, Christian Rabe, John W. Strehl, Marcus Gorschlueter, Manfred Hensel, Dimitri Flieger, Axel G. Glasmacher, Ingo G. H. Schmidt-Wolf. (2006) DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. Leukemia & Lymphoma 47:12, 2558-2566
CrossRef914
Toshihiko Imamura, Takao Yoshihara, Akira Morimoto, Hiroyuki Ishida, Tohru Sugimoto, Shinsaku Imashuku. (2006) SUCCESSFUL AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION WITH RITUXIMAB ADMINISTRATION FOR PEDIATRIC DIFFUSE LARGE B-CELL LYMPHOMA. Pediatric Hematology-Oncology 23:1, 19-24
CrossRef915
Luigi Rigacci, Luca Nassi, Renato Alterini, Valentina Carrai, Giovanni Longo, Franco Bernardi, Varesco Martini, Alberto Bosi. (2006) Dose-Dense CHOP plus Rituximab (R-CHOP14) for the Treatment of Elderly Patients with High-Risk Diffuse Large B Cell Lymphoma: A Pilot Study. Acta Haematologica 115:1-2, 22-27
CrossRef916
Yuna Lee, Sun Young Kyung, Soo Jin Choi, Soo-Mee Bang, Seong Hwan Jeong, Dong Bok Shin, Jae Hoon Lee. (2006) Two Cases of Interstitial Pneumonitis Caused by Rituximab Therapy. The Korean Journal of Internal Medicine 21:3, 183
CrossRef917
Rodrigo Ruiz-Soto, Guillaume Sergent, Christian Gisselbrecht, Jerome Larghero, Marjan Ertault, Christophe Hennequin, Julien Manson, Eric de Kerviler, Josette Briere, Nicolas Mounier. (2005) Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients. Cancer 104:12, 2735-2742
CrossRef918
Antonio J Grillo-López. (2005) The ODAC Chronicles: Part 7. Tale of two goals. Expert Review of Anticancer Therapy 5:6, 939-941
CrossRef919
Takeshi Hara, Hisashi Tsurumi, Senji Kasahara, Nobuhiro Kanemura, Takeshi Yoshikawa, Naoe Goto, Yasushi Kojima, Toshiki Yamada, Michio Sawada, Takeshi Takahashi, Masami Oyama, Eiichi Tomita, Hisataka Moriwaki. (2005) Low-Dose Granulocyte Colony-Stimulating Factor Overcomes Neutropenia in the Treatment of Non-Hodgkin's Lymphoma with Higher Cost-Effectiveness. International Journal of Hematology 82:5, 430-436
CrossRef920
Joseph M. Tuscano, Shiloh Martin, Kyle Song, Theodore Wun. (2005) B cell reductive therapy in the treatment of autoimmune diseases: A focus on monoclonal antibody treatment of rheumatoid arthritis. Hematology 10:6, 521-527
CrossRef921
Mario B Regazzi, Isabella Iacona, Maria Antonietta Avanzini, Luca Arcaini, Gianpaolo Merlini, Vittorio Perfetti, Francesco Zaja, Michela Montagna, Enrica Morra, Mario Lazzarino. (2005) Pharmacokinetic Behavior of Rituximab. Therapeutic Drug Monitoring 27:6, 785-792
CrossRef922
Mitchell S. Cairo, Elizabeth Raetz, Megan S. Lim, Virginia Davenport, Sherrie L. Perkins. (2005) Childhood and adolescent non-Hodgkin lymphoma: New insights in biology and critical challenges for the future. Pediatric Blood & Cancer 45:6, 753-769
CrossRef923
Mani Mohindru, Amit Verma. (2005) Engineered antibodies act as targeted therapies in cancer treatment. The Indian Journal of Pediatrics 72:11, 943-947
CrossRef924
Michael Darmon, Guillaume Thiery, Magali Ciroldi, Sandra de Miranda, Lionel Galicier, Emmanuel Raffoux, Jean-Roger Le Gall, Beno??t Schlemmer, ??lie Azoulay. (2005) Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy*. Critical Care Medicine 33:11, 2488-2493
CrossRef925
Tawee Tanvetyanon. (2005) Consideration before administering cytotoxic chemotherapy to the critically ill*. Critical Care Medicine 33:11, 2689-2691
CrossRef926
Katie Le, Adrian Lim, Peter Bullpitt, Glenda Wood. (2005) Intravascular B-cell lymphoma diagnosed by skin biopsy. Australasian Journal of Dermatology 46:4, 261-265
CrossRef927
John P. Leonard, Richard R. Furman, Jia Ruan, Morton Coleman. (2005) New developments in immunotherapy for non-Hodgkin’s lymphoma. Current Oncology Reports 7:5, 364-371
CrossRef928
Stamatis-Nick C. Liossis, George C. Tsokos. (2005) Monoclonal antibodies and fusion proteins in medicine. Journal of Allergy and Clinical Immunology 116:4, 721-729
CrossRef929
Eva Kimby. (2005) Tolerability and safety of rituximab (MabThera®). Cancer Treatment Reviews 31:6, 456-473
CrossRef930
Anna L. Taylor, Robert Marcus, J. Andrew Bradley. (2005) Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Critical Reviews in Oncology/Hematology 56:1, 155-167
CrossRef931
Maren Bienert, Ingrid Reisinger, Stefanie Srock, Beatrice I Humplik, Christel Reim, Thomas Kroessin, Norbert Avril, Antonio Pezzutto, Dieter L Munz. (2005) Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin’s lymphoma: initial experience. European Journal of Nuclear Medicine and Molecular Imaging 32:10, 1225-1233
CrossRef932
Richard T. Doocey, Cynthia L. Toze, Joseph M. Connors, Thomas J. Nevill, Randy D. Gascoyne, Michael J. Barnett, Donna L. Forrest, Donna E. Hogge, Julye C. Lavoie, Stephen H. Nantel, John D. Shepherd, Heather J. Sutherland, Nicholas J. Voss, Clayton A. Smith, Kevin W. Song. (2005) Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma*. British Journal of Haematology 131:2, 223-230
CrossRef933
Christophe Fruchart, Yves Denoux, Jacques Chasle, Anne Marie Peny, Véronique Boute, Jean Michel Ollivier, Jean Yves Genot, Jean-Jacques Michels. (2005) High Grade Primary Breast Lymphoma: is it a Different Clinical Entity?. Breast Cancer Research and Treatment 93:3, 191-198
CrossRef934
Andrew McMillan. (2005) Central nervous system-directed preventative therapy in adults with lymphoma. British Journal of Haematology 131:1, 13-21
CrossRef935
Samuel A Jacobs, Kenneth A Foon. (2005) Monoclonal antibody therapy of leukaemias and lymphomas. Expert Opinion on Biological Therapy 5:9, 1225-1243
CrossRef936
Farhad Ravandi, Susan O’Brien. (2005) Infections associated with purine analogs and monoclonal antibodies. Blood Reviews 19:5, 253-273
CrossRef937
J. Pijpe, G. W. van Imhoff, F. K. L. Spijkervet, J. L. N. Roodenburg, G. J. Wolbink, K. Mansour, A. Vissink, C. G. M. Kallenberg, H. Bootsma. (2005) Rituximab treatment in patients with primary Sjögren's syndrome: An open-label phase II study. Arthritis & Rheumatism 52:9, 2740-2750
CrossRef938
Julie Vose, M. Neumann, Mildred Harris. (2005) Update on lymphoma management: Diffuse large B-Cell NHL. Hematology 10:4, 10-14
CrossRef939
Gregory P Adams, Louis M Weiner. (2005) Monoclonal antibody therapy of cancer. Nature Biotechnology 23:9, 1147-1157
CrossRef940
T. Kuittinen, T. Wiklund, K. Remes, E. Elonen, T. Lehtinen, O. Kuittinen, S. Leppa, M. Putkonen, R. Raty, T. Turpeenniemi-Hujanen, T. Nousiainen, E. Jantunen. (2005) Outcome of progressive disease after autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a nation-wide survey. European Journal of Haematology 75:3, 199-205
CrossRef941
Michele Spina, Umberto Tirelli. (2005) Rituximab for HIV-associated lymphoma: weighing the benefits and risks. Current Opinion in Oncology 17:5, 462-465
CrossRef942
Basak Oyan, Yener Koc, Evren Ozdemir, Ayse Kars, Alev Turker, Gulten Tekuzman, Emin Kansu. (2005) Ifosfamide, Idarubicin, and Etoposide in Relapsed/Refractory Hodgkin Disease or Non-Hodgkin Lymphoma: A Salvage Regimen with High Response Rates before Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 11:9, 688-697
CrossRef943
G G Wulf, J Hasenkamp, W Jung, B Chapuy, L Truemper, B Glass. (2005) Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma. Bone Marrow Transplantation 36:3, 271-273
CrossRef944
T SHENKIER. (2005) Unusual Variants of Primary Central Nervous System Lymphoma. Hematology/Oncology Clinics of North America 19:4, 651-664
CrossRef945
Koen Besien, Sonali Smith, Hillard M. Lazarus. (2005) Therapeutic options for patients with hodgkin’s disease and non-hodgkin’s lymphoma who relapse after autologous transplant. Current Treatment Options in Oncology 6:4, 279-287
CrossRef946
Jeanette Doorduijn, Ivonne Buijt, Bronno Holt, Monique Steijaert, Carin Uyl-de Groot, Pieter Sonneveld. (2005) Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy. European Journal of Haematology 75:2, 116-123
CrossRef947
P. T. Daniel, B. Dörken. (2005) Grundlagen der molekularen Diagnostik und Therapie maligner Tumoren. Der Internist 46:8, 835-846
CrossRef948
Peter Borchmann, & Roland Schnell. (2005) The role of pixantrone in the treatment of non-Hodgkin’s lymphoma. Expert Opinion on Investigational Drugs 14:8, 1055-1061
CrossRef949
Lars Møller Pedersen, Tobias Wirenfeldt Klausen, Ulla Høy Davidsen, Hans Erik Johnsen. (2005) Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin’s lymphoma. Annals of Hematology 84:8, 510-516
CrossRef950
Ross Pinkerton. (2005) Continuing challenges in childhood non-Hodgkin's lymphoma. British Journal of Haematology 130:4, 480-488
CrossRef951
C SOUSSAIN, K HOANGXUAN, N DOOLITTLE. (2005) New Treatment Approaches in Primary Central Nervous System Lymphoma. Hematology/Oncology Clinics of North America 19:4, 719-728
CrossRef952
C. Burton, P. Smith, G. Vaughan-Hudson, W. Qian, P. Hoskin, D. Cunningham, B. Hancock, D. Linch. (2005) Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma. British Journal of Haematology 130:4, 536-541
CrossRef953
S. M. Ansell, J. Armitage. (2005) Non-Hodgkin Lymphoma: Diagnosis and Treatment. Mayo Clinic Proceedings 80:8, 1087-1097
CrossRef954
S. Gellrich, J.M. Muche, A. Wilks, K.C. Jasch, C. Voit, T. Fischer, H. Audring, W. Sterry. (2005) Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas - an applicational observation. British Journal of Dermatology 153:1, 167-173
CrossRef955
Bertrand Coiffier. (2005) Current strategies for the treatment of diffuse large B cell lymphoma. Current Opinion in Hematology 12:4, 259-265
CrossRef956
Jennie H. Best, John Hornberger, Stephen J. Proctor, Louis F. Omnes, Fred Jost. (2005) Cost-Effectiveness Analysis of Rituximab Combined with CHOP for Treatment of Diffuse Large B-Cell Lymphoma. Value in Health 8:4, 462-470
CrossRef957
Maryska L.G. Janssen-Heijnen, Dick Johan Spronsen, Valery E.P.P. Lemmens, Saskia Houterman, Kees D.G.W. Verheij, Jan Willem W. Coebergh. (2005) A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International Prognostic Index. British Journal of Haematology 129:5, 597-606
CrossRef958
Bertrand B Coiffier, Catherine Traullé. (2005) Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma. Future Oncology 1:3, 297-306
CrossRef959
Satoshi Ishikura, Kensei Tobinai, Atsushi Ohtsu, Shigeo Nakamura, Tadashi Yoshino, Ichiro Oda, Toshiyuki Takagi, Kiyomi Mera, Yoshikazu Kagami, Kuniaki Itoh, Yoshio Tamaki, Junji Suzumiya, Masafumi Taniwaki, Seiichiro Yamamoto. (2005) Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I-II1, diffuse large B-cell lymphoma of the stomach. Cancer Science 96:6, 349-352
CrossRef960
R TAYLOR. (2005) Use of biological response modifiers to enhance the action of Rituximab. Leukemia Research 29:6, 599-600
CrossRef961
Christian Bjorn Poulsen, Rehannah Borup, Finn Cilius Nielsen, Niels Borregaard, Mads Hansen, Kirsten Gronbaek, Michael Boe Moller, Elisabeth Ralfkiaer. (2005) Microarray-based classification of diffuse large B-cell lymphoma. European Journal of Haematology 74:6, 453-465
CrossRef962
Antonino Musolino, Maria Antonietta Perrone, Maria Michiara, Daniela Delnevo, Vittorio Franciosi, Beatrice Di Blasio, Guido Ceci, Roberta Camisa, Andrea Ardizzoni, Giorgio Cocconi. (2005) Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma. Cancer 103:10, 2109-2117
CrossRef963
Robert M Sharkey, Jack Burton, David M Goldenberg. (2005) Radioimmunotherapy of non-Hodgkin’s lymphoma: a critical appraisal. Expert Review of Clinical Immunology 1:1, 47-62
CrossRef964
Yutaka Tsutsumi, Hiroe Kanamori, Akio Mori, Junji Tanaka, Masahiro Asaka, Masahiro Imamura, Nobuo Masauzi. (2005) Reactivation of hepatitis B virus with rituximab. Expert Opinion on Drug Safety 4:3, 599-608
CrossRef965
Karen W.L. Yee, Susan M. OʼBrien, Francis J. Giles. (2005) Richterʼs Syndrome. The Cancer Journal 11:3, 161-174
CrossRef966
G. Heß. (2005) Immuntherapie maligner Non-Hodgkin-Lymphome. Der Onkologe 11:5, 571-577
CrossRef967
M Ng, J Waters, D Cunningham, I Chau, A Horwich, M Hill, A R Norman, A Wotherspoon, D Catovsky. (2005) Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. British Journal of Cancer 92:8, 1352-1357
CrossRef968
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Ebeling, Sally H.Ellender, Stacey M.Peters, Christine C., Shipp, Margaret A., Aquino, Suzanne L., Harris, Nancy Lee, . (2005) Case 12-2005. New England Journal of Medicine 352:16, 1697-1704
Full Text969
John C. Hornberger, Jennie H. Best. (2005) Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer 103:8, 1644-1651
CrossRef970
Arunee Jetsrisuparb, Surapon Wiangnon, Patcharee Komvilaisak, Churairat Kularbkaew, Wiboonchai Yutanawiboonchai, Emorn Mairieng. (2005) Rituximab Combined With CHOP For Successful Treatment of Aggressive Recurrent, Pediatric B-Cell Large Cell Non-Hodgkin??s Lymphoma. Journal of Pediatric Hematology/Oncology 27:4, 223-226
CrossRef971
S. Ladoire, F. Ghiringhelli, P. Manckoundia, R.O. Casasnovas, E. Solary, J.F. Besancenot, P. Pfitzenmeyer. (2005) Prise en charge des cancers solides et des hémopathies malignes du sujet âgé : l'oncogériatrie, une discipline en devenir. Seconde partie : traitement des cancers solides (partie 2) et des hémopathies malignes du sujet âgé. La Revue de Médecine Interne 26:4, 304-314
CrossRef972
Mayumi Mori, Kiyoshi Kitamura, Michihiko Masuda, Tomomitsu Hotta, Tamotsu Miyazaki, Akira B. Miura, Hideaki Mizoguchi, Akira Shibata, Hidehiko Saito, Tamotsu Matsuda, Toru Masaoka, Mine Harada, Yoshiyuki Niho, Fumimaro Takaku. (2005) Long-term Results of a Multicenter Randomized, Comparative Trial of Modified CHOP versus THP-COP versus THP-COPE Regimens in Elderly Patients with Non-Hodgkin's Lymphoma. International Journal of Hematology 81:3, 246-254
CrossRef973
Binnaz Demirkan, Pinar Balci, Mehmet A. Ozcan, Zuhal Baskan, Ahmet Alacacioglu, Sedat Alpaslan Tuncel, Tulay Canda, Mehmet A. Kocdor, Isil Topcu, Bulent Undar, Mehmet Alakavuklar. (2005) Primary non-hodgkin lymphoma of breast in a patient with rectal carcinoma and magnetic resonance spectroscopic examination. The Breast 14:2, 169-174
CrossRef974
Yukihiro Arai, Jiro Tadokoro, Kinuko Mitani. (2005) Ventricular tachycardia associated with infusion of rituximab in mantle cell lymphoma. American Journal of Hematology 78:4, 317-318
CrossRef975
M. Stern, R. Herrmann. (2005) Overview of monoclonal antibodies in cancer therapy: present and promise. Critical Reviews in Oncology/Hematology 54:1, 11-29
CrossRef976
Michael A. Fridrik, Hubert Hausmaninger, Werner Linkesch, Richard Greil, Otto Krieger, Christian Baldinger, Joerg Klocker, Joerg Pont, Willhelm Oberaigner. (2005) Long-term results of dose density therapy in patients with aggressive lymphoma. Annals of Hematology 84:4, 217-222
CrossRef977
Reyes, Félix, Lepage, Eric, Ganem, Gérard, Molina, Thierry J., Brice, Pauline, Coiffier, Bertrand, Morel, Pierre, Ferme, Christophe, Bosly, Andre, Lederlin, Pierre, Laurent, Guy, Tilly, Hervé, . (2005) ACVBP versus CHOP plus Radiotherapy for Localized Aggressive Lymphoma. New England Journal of Medicine 352:12, 1197-1205
Full Text978
Luigi Rigacci, Valentina Carrai, Luca Nassi, Renato Alterini, Giovanni Longo, Franco Bernardi, Alberto Bosi. (2005) Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma. Cancer 103:5, 970-977
CrossRef979
Corrado Tarella, Alessandro M Gianni. (2005) Bone marrow transplantation for lymphoma CR1. Current Opinion in Oncology 17:2, 99-105
CrossRef980
M. T. Groot, P. J. Lugtenburg, J. Hornberger, P. C. Huijgens, C. A. Uyl-de Groot. (2005) Cost-effectiveness of rituximab (MabTheraR) in diffuse large B-cell lymphoma in the Netherlands. European Journal of Haematology 74:3, 194-202
CrossRef981
Elena Cittera, Chiara Onofri, Maria D’Apolito, Guillaume Cartron, Giovanni Cazzaniga, Leopoldo Zelante, Paolo Paolucci, Andrea Biondi, Martino Introna, Josée Golay. (2005) Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines. Cancer Immunology, Immunotherapy 54:3, 273-286
CrossRef982
Pier Luigi Zinzani. (2005) Lymphoma: Diagnosis, staging, natural history, and treatment strategies. Seminars in Oncology 32, 4-10
CrossRef983
Stephen J. Forman. (2005) Innovations in autologous transplantation for hematologic malignancy. Biology of Blood and Marrow Transplantation 11:2, 28-33
CrossRef984
Robert Marcus. (2005) Use of 90Y-ibritumomab tiuxetan in non-Hodgkin’s lymphoma. Seminars in Oncology 32, 36-43
CrossRef985
David G. Maloney. (2005) Concepts in radiotherapy and immunotherapy: Anti-CD20 mechanisms of action and targets. Seminars in Oncology 32, 19-26
CrossRef986
Carol S. Portlock. (2005) Surgery does not improve survival outcomes in people with primary gastric lymphoma. Cancer Treatment Reviews 31:1, 49-52
CrossRef987
Michael Ellis, Basel al-Ramadi, Ulla Hedström, Chris Frampton, Hussain Alizadeh, Jorgen Kristensen. (2005) Significance of the CC chemokine RANTES in patients with haematological malignancy: results from a prospective observational study. British Journal of Haematology 128:4, 482-489
CrossRef988
J. A. Batsis, F. S. McDonald. (2005) 76-Year-Old Man With Back Pain and Progressive Leg Weakness. Mayo Clinic Proceedings 80:2, 259-262
CrossRef989
Susanne Rödel, Andreas Engert, Volker Diehl, Marcel Reiser. (2005) Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, methotrexate, etoposide and dexamethasone (ACOMED) followed by involved field radiotherapy induces high remission rates and durable long-term survival in patients with aggressive malignant non-Hodgkin's lymphomas: long-term follow-up of a pilot study. Leukemia & Lymphoma 46:12, 1729-1734
CrossRef990
Michael Pfreundschuh. (2005) Management of Diffuse Large B-Cell Lymphoma in Young Patients. American Journal of Cancer 4:6, 349-357
CrossRef991
Francisco J. Hernandez-Ilizaliturri, Venkata Jupudy, Scott Reising, Elizabeth A. Repasky, Myron S. Czuczman. (2005) Concurrent administration of granulocyte colony-stimulating factoror granulocyte-monocyte colony-stimulating factor enhancesthe biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model. Leukemia & Lymphoma 46:12, 1775-1784
CrossRef992
Antonio J Grillo-López. (2005) The ODAC Chronicles: Part 3. The FDA’s philosophy and process for cancer drug evaluation and approval. Expert Review of Anticancer Therapy 5:1, 1-5
CrossRef993
Jeffrey L Halaas, Craig H Moskowitz, Steven Horwitz, Carol Portlock, Ariela Noy, David Straus, Owen A O'Connor, Joachim Yahalom, Andrew D Zelenetz. (2005) R-CHOP-14 in patients with diffuse large B-cell lymphoma: Feasibility and preliminary efficacy. Leukemia & Lymphoma 46:4, 541-547
CrossRef994
Naoki Oyaizu, Yasuji Kozai, Hideki Kodo, Shinji Sunaga, Keiichi Iwabuchi, Masaaki Higashihara, Shigeo Mori. (2005) A Case of Pure Red Cell Aplasia Complicated with Diffuse Large B Cell Lymphoma, T-Cell-Rich/Histiocyte-Rich Variant: Effectiveness of Rituximab and Implications for a Common Immunopathogenic Role of B Lymphocytes. Acta Haematologica 113:3, 194-197
CrossRef995
Asher Chanan-Khan, Beata Holkova, Alec S Goldenberg, Anna Pavlick, Rita Demopoulos, Kenichi Takeshita. (2005) Non-Hodgkin's lymphoma presenting as a breast mass in patients with HIV infection: A report of three cases. Leukemia & Lymphoma 46:8, 1189-1193
CrossRef996
Pier Luigi Zinzani. (2005) Autologous Hematopoietic Stem Cell Transplantation in Non-Hodgkin’s Lymphomas. Acta Haematologica 114:4, 255-259
CrossRef997
Lydia Koulova, Doru Alexandrescu, Janice P. Dutcher, Kevin P. O'Boyle, Saji Eapen, Peter H. Wiernik. (2005) Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): Report of three cases. American Journal of Hematology 78:1, 49-54
CrossRef998
D Wayne Thomas, Roger G Owen, Stephen AN Johnson, Peter Hillmen, John F Seymour, Max M Wolf, Simon AJ Rule. (2005) Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP. Leukemia & Lymphoma 46:4, 549-552
CrossRef999
Ulrich Herrlinger, Agnieszka Korfel, Holger Hebart, Uwe Schlegel, Ludwig Plasswilm, Gerald Illerhaus, J
CrossRef1000
Noriaki Iwahashi, Satoshi Nakatani, Hiroyuki Kakuchi, Masakazu Yamagishi, Kazuki Fukuchi, Yoshio Ishida, Keiji Hirooka, Yukihiro Koretsune, Chisato Ueta, Takuma Shirasaka, Masafumi Kitakaze. (2005) Cardiac Tumor as an Initial Manifestation of Acquired Immunodeficiency Syndrome. Circulation Journal 69:2, 243-245
CrossRef1001
G Visani, B Guiducci, F D'Adamo, A Mele, G Nicolini, G Leopardi, G Sparaventi, S Barulli, L Malerba, A Isidori, M Malagola, PP Piccaluga. (2005) Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma. Leukemia & Lymphoma 46:3, 477-479
CrossRef1002
Bruce D Cheson. (2005) The Role of Radioimmunotherapy with Yttrium-90 Ibritumomab Tiuxetan in the Treatment of Non-Hodgkin Lymphoma. BioDrugs 19:5, 309-322
CrossRef1003
J. M. Vose, B. K. Link, M. L. Grossbard, M. Czuczman, A. Grillo-Lopez, R. I. Fisher. (2005) Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Leukemia & Lymphoma 46:11, 1569-1573
CrossRef1004
C Wenger, M Stern, R Herrmann, CH Rochlitz, M Pless. (2005) Rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non Hodgkin's lymphoma?. Leukemia & Lymphoma 46:1, 71-75
CrossRef1005
Catherine Burton. (2005) A 61-Year-Old Man with Dyspepsia and Weight Loss. PLoS Medicine 2:6, e154
CrossRef1006
Irene Ghobrial, Thomas Habermann, Kay Ristow, Stephen Ansell, William Macon, Suzan Geyer, Christopher McGregor. (2005) Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leukemia & Lymphoma 46:2, 191-196
CrossRef1007
E. Chamorey, R. Gressin, F. Peyrade, J.F. Rossi, G. Lepeu, C. Foussard, J.L. Harrousseau, M. Fabbro, B. Richard, V. Delwail, H. Maisonneuve, J.P. Vilque, A. Thyss. (2005) Prospective Randomized Study Comparing MEMID with a Chop-Like Regimen in Elderly Patients with Aggressive Non-Hodgkin’s Lymphoma. Oncology 69:1, 19-26
CrossRef1008
Masahide KUROKI, Hirotomo SHIBAGUCHI, Motomu KUROKI. (2005) Present Status and Perspectives of Antibody Therapy against Cancer. Japanese Journal of Complementary and Alternative Medicine 2:1, 15-21
CrossRef1009
Bruce A. Chabner, Thomas G. Roberts. (2005) Timeline: Chemotherapy and the war on cancer. Nature Reviews Cancer 5:1, 65-72
CrossRef1010
Stefan W
CrossRef1011
Stefan Woehrer, Michael Hejna, Cathrin Skrabs, Johannes Drach, Christoph C. Zielinski, Ulrich Jaeger, Markus Raderer. (2005) Rituximab, Ara-C, Dexamethasone and Oxaliplatin Is Safe and Active in Heavily Pretreated Patients with Diffuse Large B-Cell Lymphoma. Oncology 69:6, 499-502
CrossRef1012
Toshiaki Hayashi, Teru Hideshima, Masaharu Akiyama, Klaus Podar, Hiroshi Yasui, Noopur Raje, Shaji Kumar, Dharminder Chauhan, Steven P. Treon, Paul Richardson, Kenneth C. Anderson. (2005) Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. British Journal of Haematology 128:2, 192-203
CrossRef1013
C. Buske, M. Dreyling, M. Unterhalt, W. Hiddemann. (2004) Antik
CrossRef1014
Anas Younes. (2004) New treatment strategies for aggressive lymphoma. Seminars in Oncology 31, 10-13
CrossRef1015
Ming-Shen Dai, Tsu-Yi Chao, Woei-Yau Kao, Rong-Yaun Shyu, Tan-Mei Liu. (2004) Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Annals of Hematology 83:12, 769-774
CrossRef1016
Jeyanthi Ramanarayanan, Francisco J. Hernandez-Ilizaliturri, Asher Chanan-Khan, Myron S. Czuczman. (2004) Pro-apoptotic therapy with the oligonucleotide GenasenseTM (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab. British Journal of Haematology 127:5, 519-530
CrossRef1017
Toshitatsu Takao, Yutaka Kobayashi, Junya Kuroda, Atsusi Omoto, Tomoko Nishimura, Yuri Kamitsuji, Etsuko Fukiya, Chie Nakamura, Shinya Kimura, Toshikazu Yoshikawa. (2004) Rituximab is effective for human herpesvirus-8-negative primary effusion lymphoma with CD20 phenotype associated hepatitis C virus-related liver cirrhosis. American Journal of Hematology 77:4, 419-420
CrossRef1018
Michel van Agthoven, Carin A Uyl-de Groot, Pieter Sonneveld, Anton Hagenbeek. (2004) Economic assessment in the management of non-Hodgkin’s lymphoma. Expert Opinion on Pharmacotherapy 5:12, 2529-2548
CrossRef1019
Arjan A van de Loosdrecht, Peter C Huijgens, Gert J Ossenkoppele. (2004) Antibody-targeted therapy: a paradigm of innovative treatment strategies in indolent and aggressive B-cell non-Hodgkin lymphoma. Current Opinion in Hematology 11:6, 419-425
CrossRef1020
Tomohiro Kinoshita, Tomomitsu Hotta, Kensei Tobinai, Tohru Kobayashi, Naoki Ishizuka, Masao Tomonaga, Toshiaki Sai, Youichiro Ohno, Masaharu Kasai, Michinori Ogura, Chikara Mikuni, Hironobu Toki, Masayuki Sano, Yasufumi Masaki, Tomoko Ohtsu, Yoshihiro Matsuno, Takeaki Takenaka, Shigeru Shirakawa, Masanori Shimoyama. (2004) A Randomized Controlled Trial Investigating the Survival Benefit of Dose-Intensified Multidrug Combination Chemotherapy (LSG9) for Intermediate- or High-Grade Non-Hodgkin's Lymphoma: Japan Clinical Oncology Group Study 9002. International Journal of Hematology 80:4, 341-350
CrossRef1021
Axel Glasmacher. (2004) Initial high dose chemotherapy plus autologous stem cell support improves survival outcomes compared with a standard CHOP regimen in people with higher intermediate risk aggressive lymphoma. Cancer Treatment Reviews 30:6, 577-582
CrossRef1022
George P. Canellos. (2004) Lymphoma: Present and future challenges. Seminars in Hematology 41, 26-31
CrossRef1023
Nagahiro Saijo. (2004) What are the reasons for negative phase III trials of molecular-target-based drugs?. Cancer Science 95:10, 772-776
CrossRef1024
Eugen Leo, Lars Scheuer, Ingo G. H. Schmidt-Wolf, Mohammed Kerowgan, Christina Schmitt, Albrecht Leo, Tanja Baumbach, Alwin Kraemer, Ulrich Mey, Axel Benner, Reza Parwaresch, Anthony D. Ho. (2004) Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma. European Journal of Haematology 73:4, 251-257
CrossRef1025
L. Quint. (2004) Anticorps monoclonal anti-CD20 et traitement des maladies auto-immunes. La Revue de Médecine Interne 25:10, 752-754
CrossRef1026
Barry R. Goldspiel. (2004) Chemotherapy Dose Density in Early-Stage Breast Cancer and Non-Hodgkin’s Lymphoma. Pharmacotherapy 24:10, 1347-1357
CrossRef1027
Bungo Saito, Eisuke Shiozawa, Toshiko Yamochi-Onizuka, Daisuke Adachi, Tsuyoshi Nakamaki, Shigeru Tomoyasu, Mitsuhiro Omine, Toshiyuki Mitsuya, Masafumi Takimoto, Hidekazu Ota. (2004) Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression. Pathology International 54:9, 667-674
CrossRef1028
M GASPARETTO. (2004) Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow cytometric high-content screening. Journal of Immunological Methods 292:1-2, 59-71
CrossRef1029
Ariela Noy. (2004) Update in HIV-associated lymphoma. Current Opinion in Oncology 16:5, 450-454
CrossRef1030
Randy D Gascoyne. (2004) Emerging prognostic factors in diffuse large B cell lymphoma. Current Opinion in Oncology 16:5, 436-441
CrossRef1031
Friederike Heuck, Julia Ellermann, Peter Borchmann, Achim Rothe, Hinrich Hansen, Andreas Engert, Elke Pogge von Strandmann. (2004) Combination of the Human Anti-CD30 Antibody 5F11 with Cytostatic Drugs Enhances Its Antitumor Activity against Hodgkin and Anaplastic Large Cell Lymphoma Cell Lines. Journal of Immunotherapy 27:5, 347-353
CrossRef1032
István Takács, N. Erős, I. Bene, F. Bozsó, L. Tordai, Z. Károlyi, G. Radványi, A. Matolcsy. (2004) Successful treatment of relapse of an intravascular B-cell lymphoma with rituximab-CHOP polychemotherapy. Annals of Hematology 83:9, 608-610
CrossRef1033
Yvette L Kasamon, Lode J Swinnen. (2004) Treatment advances in adult Burkitt lymphoma and leukemia. Current Opinion in Oncology 16:5, 429-435
CrossRef1034
Kristie A Blum, Nancy L Bartlett. (2004) 90 Yttrium–ibritumomab tiuxetan: a novel treatment for non-Hodgkin’s lymphoma. Expert Opinion on Biological Therapy 4:8, 1323-1331
CrossRef1035
T WALTER. (2004) Lymphome non hodgkinien primitif du foie chez un patient infect
CrossRef1036
A RUSKONEFOURMESTRAUX. (2004) Les lymphomes gastriques du MALT. La Revue de M
CrossRef1037
(2004) Intensive Therapy for Aggressive Lymphoma. New England Journal of Medicine 351:1, 98-100
Full Text1038
Eric T. Wong, Roy Tishler, Loretta Barron, Julian K. Wu. (2004) Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 101:1, 139-145
CrossRef1039
G. Damaj, A Charbonnier, R. Bouabdallah, N. Vey, D. Coso, A.M. Stoppa, J.A. Gastaut. (2004) Monoclonal antibodies and cytomegalovirus infections. European Journal of Haematology 73:1, 73-74
CrossRef1040
Tetsuya Hamaguchi, Yasuhiro Matsumura, Yukihiro Nakanishi, Kei Muro, Yasuhide Yamada, Yasuhiro Shimada, Kuniaki Shirao, Hisae Niki, Saiko Hosokawa, Toshiaki Tagawa, Tadao Kakizoe. (2004) Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts. Cancer Science 95:7, 608-613
CrossRef1041
K. Tobinai. (2004) Clinical Trials for Malignant Lymphoma in Japan. Japanese Journal of Clinical Oncology 34:7, 369-378
CrossRef1042
Clifford A Hudis, Norbert Schmitz. (2004) Dose-dense chemotherapy in breast cancer and lymphoma. Seminars in Oncology 31, 19-26
CrossRef1043
C DEARDEN. (2004) Non-Hodgkin's lymphoma. Medicine 32:6, 78-84
CrossRef1044
Bryan T Hennessy, Emer O Hanrahan, Peter A Daly. (2004) Non-Hodgkin lymphoma: an update. The Lancet Oncology 5:6, 341-353
CrossRef1045
C LARROCHE, S ZIDI, E MAISSIAT, P FENAUX, R DHOTE. (2004) Un traitement décoiffant qui marche sur un foie pas sain…. La Revue de Médecine Interne 25, S253-S254
CrossRef1046
Marion Harris. (2004) Monoclonal antibodies as therapeutic agents for cancer. The Lancet Oncology 5:5, 292-302
CrossRef1047
Stephen T. Sonis, Linda S. Elting, Dorothy Keefe, Douglas E. Peterson, Mark Schubert, Martin Hauer-Jensen, B. Nebiyou Bekele, Judith Raber-Durlacher, J. Peter Donnelly, Edward B. Rubenstein, . (2004) Perspectives on cancer therapy-induced mucosal injury. Cancer 100:S9, 1995-2025
CrossRef1048
R. J. Jones, W. H. Matsui, B. D. Smith. (2004) Cancer Stem Cells: Are We Missing the Target?. JNCI Journal of the National Cancer Institute 96:8, 583-585
CrossRef1049
Nichola Cooper, Roberto Stasi, Susanna Cunningham-Rundles, Michael A. Feuerstein, John P. Leonard, Sergio Amadori, James B. Bussel. (2004) The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. British Journal of Haematology 125:2, 232-239
CrossRef1050
Eva Kimby, Asgerdur Sverrisdottir, Goran Elinder. (2004) Safety of rituximab therapy during the first trimester of pregnancy: a case history. European Journal of Haematology 72:4, 292-295
CrossRef1051
Milpied, Noel, Deconinck, Eric, Gaillard, Fanny, Delwail, Vincent, Foussard, Charles, Berthou, Christian, Gressin, Remy, Lucas, Virginie, Colombat, Philippe, Harousseau, Jean-Luc, . (2004) Initial Treatment of Aggressive Lymphoma with High-Dose Chemotherapy and Autologous Stem-Cell Support. New England Journal of Medicine 350:13, 1287-1295
Full Text1052
Arjan A. van de Loosdrecht, Peter C. Huijgens, Gert J. Ossenkoppele. (2004) Emerging antibody-targeted therapy in leukemia and lymphoma: current concepts and clinical implications. Anti-Cancer Drugs 15:3, 189-201
CrossRef1053
Montague N. Saulez, John W. Schlipf, Christopher K. Cebra, Sean P. McDonough, Karyn E. Bird. (2004) Use of chemotherapy for treatment of a mixed-cell thoracic lymphoma in a horse. Journal of the American Veterinary Medical Association 224:5, 733-738
CrossRef1054
George J Weiner, Brian K Link. (2004) Monoclonal antibody therapy of B cell lymphoma. Expert Opinion on Biological Therapy 4:3, 375-385
CrossRef1055
William Rastetter, Arturo Molina, Christine A. White. (2004) Rituximab: Expanding Role in Therapy for Lymphomas and Autoimmune Diseases. Annual Review of Medicine 55:1, 477-503
CrossRef1056
Bertrand Coiffier. (2004) Effective Immunochemotherapy For Aggressive Non-Hodgkin’s Lymphoma. Seminars in Oncology 31, 7-11
CrossRef1057
Peter Hillmen. (2004) Advancing Therapy For Chronic Lymphocytic Leukemia–the Role Of Rituximab. Seminars in Oncology 31, 22-26
CrossRef1058
Christian Gisselbrecht, Nicolas Mounier. (2004) Improving Second-Line Therapy in Aggressive Non-Hodgkin’s Lymphoma. Seminars in Oncology 31, 12-16
CrossRef1059
Felix Reyes. (2004) Introduction. Seminars in Oncology 31, 1
CrossRef1060
Glen A Kennedy, Robert Blum, Christopher McCormack, H Miles Prince. (2004) Treatment of primary cutaneous follicular centre lymphoma with rituximab: A report of two cases. Australasian Journal of Dermatology 45:1, 34-37
CrossRef1061
David T. Scadden. (2004) The Malignant Side of Successful Transplantation. American Journal of Transplantation 4:2, 153-154
CrossRef1062
Devinder Singh, Lalit Kumar, Atul Sharma, M Vijayaraghavan, Sanjay Thulkar, N Tandon. (2004) Adrenal Involvement in Non-Hodgkin's Lymphoma: Four Cases and Review of Literature. Leukemia & Lymphoma 45:4, 789-794
CrossRef1063
Lodovico Balducci, Lazzaro Repetto. (2004) Increased risk of myelotoxicity in elderly patients with non-Hodgkin lymphoma. Cancer 100:1, 6-11
CrossRef1064
Margarita Tokar, Boris Rogachev, Itai Levi, Ronit Yerushalmi, Samuel Ariad, David B Geffen. (2004) Rituximab in a Patient with Acute Renal Failure due to B-cell Lymphomatous Infiltration of the Kidneys. Leukemia & Lymphoma 45:4, 819-820
CrossRef1065
V GARYPIDOU, V PERIFANIS, K TZIOMALOS, S THEODORIDOU. (2004) Cardiac Toxicity During Rituximab Administration. Leukemia & Lymphoma 45:1, 203-204
CrossRef1066
Yasutaka Kakinoki, Hiroya Kubota, Yasushi Yamamoto. (2004) CD64 Surface Expression on Neutrophils and Monocytes Is Significantly Up-Regulated after Stimulation with Granulocyte Colony-Stimulating Factor during CHOP Chemotherapy for Patients with Non-Hodgkin’s Lymphoma. International Journal of Hematology 79:1, 55-62
CrossRef1067
Keita UCHINO, Hidekazu SAMESHIMA, Toshihiro MIYAMOTO, Tadafumi IINO, Koji KATO, Hideho HENZAN, Ken-ichi AOKI, Koji NAGAFUJI, Hisashi GONDO, Mine HARADA. (2004) Successful Treatment of Diffuse Large B-cell Lymphoma Following Waldenstroem's Macroglobulinemia with CHOP Chemotherapy Followed by Combination Therapy of CHOP with Rituximab. Internal Medicine 43:2, 131-134
CrossRef1068
Mark J. Ahn, Daniel Dornbusch. (2004) Competency-based benchmarking: Revolutionizing biopharmaceutical product launches. Benchmarking: An International Journal 11:2, 190-202
CrossRef1069
E Jabbour, B Chalhoub, F Suzan, S Aloulou, C Cainap, N Toumi, C Fermé, P Carde, V Ribrag. (2004) Outcome of Elderly Patients with Aggressive Non-Hodgkin's Lymphoma Refractory to or Relapsing after First-line CHOP or CHOP-like Chemotherapy: A Low Probability of Cure. Leukemia & Lymphoma 45:7, 1391-1394
CrossRef1070
ROBERTO BORDONARO, GIUSEPPINA PETRALIA, NUNZIO RESTUCCIA, ANNA MARIA TODARO, DIEGO SERRAINO, DARIO GIUFFRIDA, STEFANO CORDIO, CARMELO GIANNITTO-GIORGIO, PLACIDA SALICE, MARIA URSINO, GIUSEPPE NOVELLO, FRANCESCO MARLETTA, MARIO MANUSIA. (2004) Fludarabine, Mitoxantrone and Dexamethasone as Front-line Therapy in Elderly Patients Affected by Newly-diagnosed, Low-grade Non-Hodgkin's Lymphomas with Unfavorable Prognostic Factors: Results of a Phase II Study. Leukemia & Lymphoma 45:1, 93-100
CrossRef1071
Yutaka Tsutsumi, Takahito Kawamura, Shin Saitoh, Masahiro Yamada, Shinji Obara, Takuya Miura, Hiroe Kanamori, Junji Tanaka, Masahiro Asaka, Masahiro Imamura, Nobuo Masauzi. (2004) Hepatitis B Virus Reactivation in a Case of Non-Hodgkin's Lymphoma Treated with Chemotherapy and Rituximab: Necessity of Prophylaxis for Hepatitis B Virus Reactivation in Rituximab Therapy. Leukemia & Lymphoma 45:3, 627-629
CrossRef1072
Bal Kampalath, Nashwa Abed, Christopher R Chitambar, Peter vanTuinen, Gargi Chakrabarty, Gerald Hanson, R Nagarjun Rao, Vinod B Shidham, Chung-Che Chang. (2004) Mantle Cell Lymphoma in Lymph Nodes with Metastatic Small Cell Carcinoma of Lung: A Diagnostic and Treatment Dilemma. Leukemia & Lymphoma 45:2, 409-414
CrossRef1073
Caroline L Alvares, Estella Matutes, Marie A Scully, John Swansbury, Toon Min, Alicja M Gruszka-Westwood, Shayne Atkinson, Benjamin Hilditch, Ricardo Morilla, Andrew C Wotherspoon, Daniel Catovsky. (2004) Isolated Bone Marrow Involvement in Diffuse Large B Cell Lymphoma: A Report of Three Cases with Review of Morphological, Immunophenotypic and Cytogenetic Findings. Leukemia & Lymphoma 45:4, 769-775
CrossRef1074
Elias Jabbour, Hagop Kantarjian, Jorge Cortes. (2004) Clinical Activity of Farnesyl Transferase Inhibitors in Hematologic Malignancies: Possible Mechanisms of Action. Leukemia & Lymphoma 45:11, 2187-2195
CrossRef1075
Jong Gwang Kim, Sang Kyun Sohn, Dong Hwan Kim, Jin Ho Baek, Tae In Park, Kyu Bo Lee. (2004) Phase II Study of Cyclophosphamide, Epirubicin, Vincristine, Prednisone, and Etoposide (CEOP-E) for Aggressive Non-Hodgkin's Lymphoma. Journal of Korean Medical Science 19:6, 820
CrossRef1076
Keun-Wook Lee, Dae-Young Kim, Tak Yun, Dong-Wan Kim, Tae-You Kim, Sung-Soo Yoon, Dae Seog Heo, Yung-Jue Bang, Seonyang Park, Byoung Kook Kim, Noe Kyeong Kim. (2003) Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients. Cancer 98:12, 2651-2656
CrossRef1077
Gary H. Lyman, David J. Delgado. (2003) Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 98:11, 2402-2409
CrossRef1078
Giorgio Cocconi, Vittorio Franciosi, Anna Dodero, Alessandra Bologna, Giovanna Vasini, Vincenzo De Lisi, Beatrice Di Blasio, Guido Ceci, Roberta Camisa, Stefano Cascinu. (2003) P-CHOP: Cisplatin (P) Added to the Standard CHOP Regimen as First-Line Treatment for Aggressive Non-Hodgkin Lymphoma. American Journal of Clinical Oncology 26:6, 535-542
CrossRef1079
Marie-France Demierre, Youn H Kim, Herschel S Zackheim. (2003) Prognosis, clinical outcomes and quality of life issues in cutaneous T-cell lymphoma. Hematology/Oncology Clinics of North America 17:6, 1485-1507
CrossRef1080
Antonio J Grillo-López. (2003) Rituximab (Rituxan®/MabThera®): the first decade (1993–2003). Expert Review of Anticancer Therapy 3:6, 767-779
CrossRef1081
Francis J. Giles, Julie M. Vose, Kim-Anh Do, Marcella M. Johnson, Taghi Manshouri, Gregory Bociek, Philip J. Bierman, Susan M. O'Brien, Michael J. Keating, Hagop M Kantarjian, James O. Armitage, Maher Albitar. (2003) Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease. British Journal of Haematology 123:5, 850-857
CrossRef1082
Marie-France Demierre, Helmut Kerl, Rein Willemze. (2003) Primary cutaneous B-cell lymphomas: a practical approach. Hematology/Oncology Clinics of North America 17:6, 1333-1350
CrossRef1083
Pier Luigi Zinzani. (2003) Traditional Treatment Approaches in B-cell Non-Hodgkin's Lymphoma. Leukemia & Lymphoma 44:S4, S6-S14
CrossRef1084
A Hagenbeek, A Bischof Delaloye. (2003) Editorial Perspective—Advances in B-Cell Non-Hodgkin's Lymphoma. Leukemia & Lymphoma 44:S4, S1-S4
CrossRef1085
Robert Marcus. (2003) Current Treatment Options in Aggressive Lymphoma. Leukemia & Lymphoma 44:S4, S15-S27
CrossRef1086
Adrian Wiestner, Louis M Staudt. (2003) Towards molecular diagnosis and targeted therapy of lymphoid malignancies. Seminars in Hematology 40:4, 296-307
CrossRef1087
Carol S. Portlock. (2003) Rituximab for lymphocyte-predominant Hodgkin’s disease. Current Oncology Reports 5:5, 358-358
CrossRef1088
Giovanni Martinelli, Daniele Laszlo, Francesco Bertolini, Rocco Pastano, Patrizia Mancuso, Angelica Calleri, Anna Vanazzi, Paola Santoro, Franco Cavalli, Emanuele Zucca. (2003) Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma. British Journal of Haematology 123:2, 271-277
CrossRef1089
K KARAMLOU, D NICHOLS, C NICHOLS. (2003) Intensive care unit outcomes in elderly cancer patients. Critical Care Clinics 19:4, 657-675
CrossRef1090
Li-Yuan Bai, Muh-Hwa Yang, Tzeon-Jye Chiou, Jin-Hwang Liu, Chueh-Chuan Yen, Wei-Shu Wang, Liang-Tsai Hsiao, Ta-Chung Chao, Po-Min Chen. (2003) Non-Hodgkin lymphoma in elderly patients. Cancer 98:6, 1188-1195
CrossRef1091
Jes??s G. Berdeja. (2003) Immunotherapy of lymphoma: update and review of the literature. Current Opinion in Oncology 15:5, 363-370
CrossRef1092
Jérôme Rey, Aude Charbonnier, Jean-Marc Schiano de Colella, Anne-Marie Stoppa, Isabelle Poizot-Martin, Jean-Albert Gastaut, Régis T Costello. (2003) Intensive chemotherapy with rituximab is safe and effective in AIDS non-Hodgkin's lymphoma. AIDS 17:13, 2006-2007
CrossRef1093
Joseph A. Sparano. (2003) Human immunodeficiency virus associated lymphoma. Current Opinion in Oncology 15:5, 372-378
CrossRef1094
P. Sapra, T.M. Allen. (2003) Ligand-targeted liposomal anticancer drugs. Progress in Lipid Research 42:5, 439-462
CrossRef1095
Alessandra Cuttica, Francesco Zallio, Marco Ladetto, Massimo Di Nicola, Daniele Caracciolo, Michele Magni, Carlo Marinone, Maria Dell'Aquila, Michela Rosace, Alessandro Pileri, Mario Boccadoro, Alessandro M. Gianni, Corrado Tarella. (2003) Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting. Cancer 98:5, 983-992
CrossRef1096
Peter Campbell, Robert Marcus. (2003) Monoclonal antibody therapy for lymphoma. Blood Reviews 17:3, 143-152
CrossRef1097
Christiane Querfeld, Joan Guitart, Timothy M. Kuzel, Steven T. Rosen. (2003) Primary cutaneous lymphomas: a review with current treatment options. Blood Reviews 17:3, 131-142
CrossRef1098
Ulrich Jäger. (2003) Innovative strategies in lymphoma therapy. Wiener Klinische Wochenschrift 115:13-14, 462-470
CrossRef1099
Ingo GH Schmidt-Wolf, Jürgen K Rockstroh, Uwe Schlegel, Hendrik Pels, Ulrich Mey, John Strehl, Rudolf Weiss, Dieter Huhn. (2003) Treatment options of AIDS-related lymphoma. Expert Opinion on Pharmacotherapy 4:8, 1331-1343
CrossRef1100
Malik E. Juweid. (2003) Radioimmunotherapy with 131 I-Rituximab: What We Know and What We Don't Know. Cancer Biotherapy & Radiopharmaceuticals 18:4, 489-495
CrossRef1101
Avichai Shimoni, Izhar Hardan, Abraham Avigdor, Moshe Yeshurun, Pia Raanani, Isaac Ben-Bassat, Arnon Nagler. (2003) Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. British Journal of Haematology 122:3, 457-464
CrossRef1102
James K. Liu, Peter Kan, Meic H. Schmidt. (2003) Diffuse large B-cell lymphoma presenting as a sacral tumor. Neurosurgical FOCUS 15:2, 1-5
CrossRef1103
(2003) Interstitial Pneumonitis Related to Rituximab Therapy. New England Journal of Medicine 348:26, 2690-2691
Full Text1104
(2003) Neutropenia in Patients Treated with Rituximab. New England Journal of Medicine 348:26, 2691-2694
Full Text1105
Ke Liu. (2003) The case for cancer immunotherapy. Drug Discovery Today 8:12, 530-531
CrossRef1106
Jacob D Bitran, Leonard Klein, Doreen Link, Jane Kosirog-Glowacki, Cynthia Stewart, David Raack, Pat Sheahan, Josephine Lisowski, Josie Rowen. (2003) High-dose myeloablative therapy and autologous peripheral blood progenitor cell transplantation for elderly patients (greater than 65 years of age) with relapsed large cell lymphoma. Biology of Blood and Marrow Transplantation 9:6, 383-388
CrossRef1107
Christoph von Schilling. (2003) Immunotherapy with anti-CD20 compounds. Seminars in Cancer Biology 13:3, 211-222
CrossRef1108
Kritika Chaiwatanatorn, Newton Lee, Andrew Grigg, Robin Filshie, Frank Firkin. (2003) Delayed-onset neutropenia associated with rituximab therapy. British Journal of Haematology 121:6, 913-918
CrossRef1109
Marcie Tomblyn, Jane N Winter. (2003) Autologous hematopoietic stem cell transplant in first remission in non-Hodgkin’s lymphoma. Expert Review of Anticancer Therapy 3:3, 281-294
CrossRef1110
Toshiaki Hayashi, Steven P. Treon, Teru Hideshima, Yu-Tzu Tai, Masaharu Akiyama, Paul Richardson, Dharminder Chauhan, Iqbal S. Grewal, Kenneth C. Anderson. (2003) Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. British Journal of Haematology 121:4, 592-596
CrossRef1111
Kotaro Shide, Hideho Henzan, Koji Nagafuji, Kenichi Aoki, Toshihiro Miyamoto, Kazuya Shimoda, Yukumasa Kazuyama, Koichi Ohshima, Hisashi Gondo, Mine Harada. (2003) Dynamics of Epstein-Barr virus load in pyothorax-associated lymphoma. Journal of Medical Virology 70:1, 137-140
CrossRef1112
Joud H. Haidar, Ali Shamseddine, Ziad Salem, Yasser Abou Mrad, Michel R. Nasr, Ghazi Zaatari, Ali Bazarbachi. (2003) Loss of CD20 expression in relapsed lymphomas after rituximab therapy. European Journal of Haematology 70:5, 330-332
CrossRef1113
Regis T. Costello, J. Rey, C. Fauriat, J.-A. Gastaut, D. Olive. (2003) New approaches in the immunotherapy of haematological malignancies. European Journal of Haematology 70:5, 333-345
CrossRef1114
Ruth Pettengell, David Linch. (2003) Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkin's lymphoma. British Journal of Haematology 121:1, 44-48
CrossRef1115
Apostolia M. Tsimberidou, Hagop M. Kantarjian, Jorge Cortes, Deborah A. Thomas, Stefan Faderl, Guillermo Garcia-Manero, Srdan Verstovsek, Alessandra Ferrajoli, William Wierda, Yesid Alvarado, Susan M. O'Brien, Maher Albitar, Michael J. Keating, Francis J. Giles. (2003) Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer 97:7, 1711-1720
CrossRef1116
Bertrand Coiffier. (2003) Monoclonal antibodies combined to chemotherapy for the treatment of patients with lymphoma. Blood Reviews 17:1, 25-31
CrossRef1117
Scott R Plotkin, Patrick Y Wen. (2003) Neurologic complications of cancer therapy. Neurologic Clinics 21:1, 279-318
CrossRef1118
Han Myint. (2003) Monoclonal Antibodies: The Good, The Bad, and The Ugly. Journal of Hematotherapy <html_ent glyph="@amp;" ascii="&"/> Stem Cell Research 12:1, 3-6
CrossRef1119
Pierre Quartier, Olivier Tournilhac, Christine Archimbaud, Leila Lazaro, Carine Chaleteix, Pascale Millet, Helene Peigue‐Lafeuille, Stephane Blanche, Alain Fischer, Jean‐Laurent Casanova, Philippe Travade, Marc Tardieu. (2003) Enteroviral Meningoencephalitis after Anti‐CD20 (Rituximab) Treatment. Clinical Infectious Diseases 36:3, e47-e49
CrossRef1120
Bertrand Coiffier. (2003) Immunochemotherapy: The new standard in aggressive non-Hodgkin's lymphoma in the elderly. Seminars in Oncology 30:1, 21-27
CrossRef1121
Emili Montserrat. (2003) Rituximab in chronic lymphocytic leukemia. Seminars in Oncology 30:1, 34-39
CrossRef1122
Wolfgang Hiddemann, Martin Dreyling, Michael Unterhalt. (2003) Rituximab plus chemotherapy in follicular and mantle cell lymphomas. Seminars in Oncology 30:1, 16-20
CrossRef1123
Greg L Plosker, David P Figgitt. (2003) Rituximab. Drugs 63:8, 803-843
CrossRef1124
Thomas S. Davis. (2003) Intravascular Lymphoma Presenting with Cauda Equina Syndrome: Treated with CHOP and Rituxan. Leukemia & Lymphoma 44:5, 887-888
CrossRef1125
T. Schmook, E. Stockfleth, St. Lischner, B. Gahn, E. Christophers, A. Hauschild. (2003) Remarkable remission of a follicular lymphoma treated with rituximab and polychemotherapy (CHOP). Clinical and Experimental Dermatology 28:1, 31-33
CrossRef1126
P. Nygren, R. Larsson. (2003) Overview of the clinical efficacy of investigational anticancer drugs. Journal of Internal Medicine 253:1, 46-75
CrossRef1127
Hans Wildiers, Martin S Highley, Ernst A de Bruijn, Allan T van Oosterom. (2003) Pharmacology of Anticancer Drugs in the Elderly Population. Clinical Pharmacokinetics 42:14, 1213-1242
CrossRef1128
Gabriele Rossi, Marco Zecca, Antonietta Marchi, Piero De Stefano, Luigi Sammarchi, Franco Locatelli. (2003) Modified chop-chemotherapy plus rituximab for diffuse large b-cell lymphoma complicating ataxia-telangiectasia. British Journal of Haematology 120:2, 369-371
CrossRef1129
A. Klepfish, A. Schattner, L. Shvidel, M. Shtalrid, M. Haran, Z. Bentwich, A. Berrebi. (2003) Successful Treatment of Aggressive HIV-associated Non-Hodgkin's Lymphoma with Combination Chemotherapy, Biotherapy with Rituximab and HAART: Presentation of a Therapeutic Option. Leukemia & Lymphoma 44:2, 349-351
CrossRef1130
Gerassimos A. Pangalis, Theodoros P. Vassilakopoulos, Evridiki Michalis, Paraskevi Roussou, Effimia Vrakidou, Panayiotis Repousis, Maria K. Angelopoulou, Marina P. Siakantaris, John Korantzis, Argyrios Symeonidis, Vassiliki Grigorakis, Ekaterini Stefanoudakis, Marina Stamatellou, Konstantinos L. Bourantas, Themis Kalmantis, George Christopoulos, Garyfallia Kokkinis, Ilias Mihalakeas, Antonios Papayiannis. (2003) A Randomized Trial Comparing Intensified CNOP vs. CHOP in Patients with Aggressive Non-Hodgkin's Lymphoma. Leukemia & Lymphoma 44:4, 635-644
CrossRef1131
Greg L Plosker, David P Figgitt. (2003) Spotlight on Rituximab in Non-Hodgkin??s Lymphoma and Chronic Lymphocytic Leukemia1. American Journal of Cancer 2:4, 283-289
CrossRef1132
P. Santoro, G. Martinelli, P.F. Ferrucci, W. Mingrone, E. Cocorocchio, A. Conconi, F.A. Peccatori, K. De Luzio, C. Mazzetta, E. Zucca, F. Cavalli. (2003) ACOD, a Modified CHOP Regimen for Elderly Patients with Aggressive Non-Hodgkin's Lymphoma. Leukemia & Lymphoma 44:5, 801-806
CrossRef1133
E. Jourdan, D. Topart, B. Richard, J. Jourdan, A. Sotto. (2003) Severe Autoimmune Hemolytic Anemia Following Rituximab Therapy in a Patient with a Lymphoproliferative Disorder. Leukemia & Lymphoma 44:5, 889-890
CrossRef1134
Friedemann Honecker, Claus-Henning K??hne, Carsten Bokemeyer. (2003) Colorectal Cancer in the Elderly. Drugs & Aging 20:1, 1-11
CrossRef1135
Andrew Grigg, Philippe Solal-Celigny, Peter Hoskin, Kerry Taylor, Andrew M. (2003) Open-label, Randomized Study of Pegfilgrastim vs. Daily Filgrastim as an Adjunct to Chemotherapy in Elderly Patients with Non-Hodgkin's Lymphoma. Leukemia & Lymphoma 44:9, 1503-1508
CrossRef1136
Michele Spina, Joseph A Sparano, Ulrich Jaeger, Giuseppe Rossi, Umberto Tirelli. (2003) Rituximab and chemotherapy is highly effective in patients with CD20-positive non-Hodgkin's lymphoma and HIV infection. AIDS 17:1, 137-138
CrossRef1137
Giulia Cervetti, Francesco Caracciolo, Nadia Cecconi, Antonio Azzarà, Mario Petrini. (2003) Efficacy and Toxicity of Liposomal Daunorubicin Included in PVABEC Regimen for Aggressive NHL of the Elderly. Leukemia & Lymphoma 44:3, 465-469
CrossRef1138
Catherine Thieblemont, Bertrand Coiffier. (2002) Combination of Chemotherapy and Monoclonal Antibodies for the Treatment of Lymphoma. International Journal of Hematology 76:5, 394-400
CrossRef1139
Josee Golay, Rosanna Gramigna, Valeria Facchinetti, Daniela Capello, Gianluca Gaidano, Martino Introna. (2002) Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab. British Journal of Haematology 119:4, 923-929
CrossRef1140
Antonio J. Grillo-López. (2002) Monoclonal Antibody Therapy for B-Cell Lymphoma. International Journal of Hematology 76:5, 385-393
CrossRef1141
Deborah A Thomas, Jorge Cortes, Hagop M Kantarjian. (2002) New agents in the treatment of acute lymphocytic leukaemia. Best Practice & Research Clinical Haematology 15:4, 771-790
CrossRef1142
Kensei Tobinai. (2002) Monoclonal Antibody Therapy for B-Cell Lymphoma: Clinical Trials of an Anti-CD20 Monoclonal Antibody for B-Cell Lymphoma in Japan. International Journal of Hematology 76:5, 411-419
CrossRef1143
Arthur E Frankel. (2002) Receptor upregulation enhances cell surface receptor targeted therapies. Leukemia Research 26:12, 1069-1071
CrossRef1144
Anand P. Jillella, Paul M. Dainer, Andre M. Kallab, Celalettin Ustun. (2002) Treatment of a patient with end-stage renal disease with Rituximab: Pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis. American Journal of Hematology 71:3, 219-222
CrossRef1145
Glen A. Kennedy, Siok-Keen Tey, Ralph Cobcroft, Paula Marlton, Gavin Cull, Karen Grimmett, Damien Thomson, Devinder Gill. (2002) Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. British Journal of Haematology 119:2, 412-416
CrossRef1146
Antonio J Grillo-López. (2002) Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma. Expert Review of Anticancer Therapy 2:5, 485-493
CrossRef1147
Kensei Tobinai. (2002) Rituximab and other emerging monoclonal antibody therapies for lymphoma. Expert Opinion on Emerging Drugs 7:2, 289-302
CrossRef1148
James M. Foran. (2002) Antibody-based therapy of non-Hodgkin's lymphoma. Best Practice & Research Clinical Haematology 15:3, 449-465
CrossRef1149
Dennis Cooper. (2002) The Rapidly Expanding Role of Rituximab in the Treatment of Aggressive B-Cell Lymphoma. The Cancer Journal 8:5, 364-366
CrossRef1150
Jonathan W. Said. (2002) Large B-cell lymphomas can be stratified and outcome predicted by gene expression profiling. Advances in Anatomic Pathology 9:5, 323-324
CrossRef1151
Ian W. Flinn. (2002) Lymphoma therapy: the challenges ahead. Current Opinion in Oncology 14:5, 473-474
CrossRef1152
P.A. Fields, A.H. Goldstone. (2002) Non-Hodgkin's lymphomas: clinical governance issues. Best Practice & Research Clinical Haematology 15:3, 577-596
CrossRef1153
M. Itala, CH. Geisler, E. Kimby, E. Juvonen, G. Tjonnfjord, K. Karlsson, K. Remes. (2002) Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. European Journal of Haematology 69:3, 129-134
CrossRef1154
(2002) Clinical Trials. Biotechnology Law Report 21:4, 339-351
CrossRef1155
Gerald Jaeger, Peter Neumeister, Ruth Brezinschek, Gerald Hofler, Franz Quehenberger, Werner Linkesch, Heinz Sill. (2002) Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study. European Journal of Haematology 69:1, 21-26
CrossRef1156
Thierry Alcindor, Thomas E. Witzig. (2002) Radioimmunotherapy with Yttrium-90 Ibritumomab tiuxetan for patients with relapsed cd20+ B-Cell non-Hodgkin’s Lymphoma. Current Treatment Options in Oncology 3:4, 275-282
CrossRef1157
Nitin Rohatgi, Renato V. LaRocca, Vanessa Bard, Gopalan Sethuraman, Kenneth A. Foon. (2002) Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas. American Journal of Hematology 70:3, 181-185
CrossRef1158
Richard B. Wilder, Maria A. Rodriguez, L. Jeffrey Medeiros, Susan L. Tucker, Chul S. Ha, Jorge E. Romaguera, Barbara Pro, Mark A. Hess, Fernando Cabanillas, James D. Cox. (2002) International prognostic index-based outcomes for diffuse large B-cell lymphomas. Cancer 94:12, 3083-3088
CrossRef1159
(2002) Rituximab plus CHOP for Diffuse Large-B-Cell Lymphoma. New England Journal of Medicine 346:23, 1830-1831
Full Text1160
Antonio J Grillo-López. (2002) AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients. Expert Review of Anticancer Therapy 2:3, 323-329
CrossRef1161
Myron S. Czuczman. (2002) Immunochemotherapy in indolent non-Hodgkin's lymphoma. Seminars in Oncology 29:2, 11-17
CrossRef1162
Cheson, Bruce D., . (2002) CHOP plus Rituximab — Balancing Facts and Opinion. New England Journal of Medicine 346:4, 280-282
Full Text1163
Tetsuo Yamazaki, Umihiko Sawada, Yoshimasa Kura, Takeyoshi Ito, Yoshitaka Kaneita, Kiyotaka Yasukawa, Takashi Horie. (2002) Dose-intensified CHOP (Double-CHOP) Followed by Consolidation with High-dose Chemotherapy for High and High-intermediate Risk Aggressive Non-Hodgkin's Lymphomas. Leukemia & Lymphoma 43:11, 2117-2123
CrossRef1164
Tomomitsu Hotta. (2002) Anti-CD20 Monoclonal Antibody as a New Treatment Modality for B-Cell Lymphoma. ACTA HISTOCHEMICA ET CYTOCHEMICA 35:4, 275-279
CrossRef1165
Jeff Schriber. (2002) Treatment of Aggressive Non-Hodgkin??s Lymphoma with Chemotherapy in Combination with Filgrastim. Drugs 62:Supplement 1, 33-46
CrossRef1166
Eric Robach, Celalettin Ustun, Andre Kallab, Russel E. Burgess, Anand P. Jillella. (2002) Rituximab Provides Durable Remission in a Patient with Refractory Aggressive Diffuse B-cell Lymphoma Failing Salvage Chemotherapy. Leukemia & Lymphoma 43:11, 2235-2236
CrossRef1167
Kyriaki Dunussi-Joannopoulos. (2002) The Combination of Chemotherapy and Systemic Immunotherapy and the Concept of Cure in Murine Leukemia and Lymphoma. Leukemia & Lymphoma 43:11, 2075-2082
CrossRef1168
C. Tam, H. Turner, R.J. Hicks, J.F. Seymour. (2002) Diffuse Large B-cell Non-Hodgkin's Lymphoma Presenting as Sister Joseph's Nodule. Leukemia & Lymphoma 43:10, 2055-2057
CrossRef
- Letters
